---
document_datetime: 2023-09-21 17:01:55
document_pages: 85
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/folotyn-epar-public-assessment-report_en.pdf
document_name: folotyn-epar-public-assessment-report_en.pdf
version: success
processing_time: 103.0615201
conversion_datetime: 2025-12-30 02:44:32.206706
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
19 April 2012

EMA/453346/2012 Committee for Medicinal Products for Human Use (CHMP)

## Final CHMP assessment report

## Folotyn

International non-proprietary name:

pralatrexate

Procedure No. EMEA/H/C/002096

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................8                                                               |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................         | 8                                                                                                             |
| Information on Paediatric requirements                                                                                     | ....................................................................... 8                                     |
| Information relating to orphan market exclusivity..........................................................                | 8                                                                                                             |
| Applicant's requests for consideration..........................................................................           | 8                                                                                                             |
| Conditional Marketing Authorisation                                                                                        | ............................................................................ 8                                |
| New active Substance status......................................................................................          | 9                                                                                                             |
| Protocol Assistance                                                                                                        | ................................................................................................... 9         |
| Licensing status                                                                                                           | ..................................................................................................... 10      |
| 1.2. Steps taken for the assessment of the product                                                                         | ..................................................... 10                                                      |
| 1.3. Steps taken for the re-examination procedure......................................................                    | 11                                                                                                            |
| 2. Scientific discussion                                                                                                   | ..............................................................................11                              |
| 2.1. Introduction ....................................................................................................     | 11                                                                                                            |
| Problem statement                                                                                                          | ................................................................................................. 11          |
| About the product...................................................................................................       | 12                                                                                                            |
| 2.2. Quality aspects                                                                                                       | ................................................................................................ 12           |
| 2.2.1. Introduction                                                                                                        | ................................................................................................. 12          |
| 2.2.2. Active Substance...........................................................................................         | 12                                                                                                            |
| Manufacture                                                                                                                | .......................................................................................................... 13 |
| Specification                                                                                                              | .......................................................................................................... 13 |
| Stability ................................................................................................................ | 14                                                                                                            |
| 2.2.3. Finished Medicinal Product ..............................................................................           | 14                                                                                                            |
| Pharmaceutical Development ...................................................................................             | 14                                                                                                            |
| Adventitious agents                                                                                                        | ................................................................................................ 15           |
| Manufacture of the product ......................................................................................          | 15                                                                                                            |
| Product specification ...............................................................................................      | 15                                                                                                            |
| Stability of the product............................................................................................       | 15                                                                                                            |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................                          | 16                                                                                                            |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ..................... 16                                                                                      |
| 2.2.6. Recommendation(s) for future quality development............................................                        | 16                                                                                                            |
| 2.3. Non-clinical aspects..........................................................................................        | 16                                                                                                            |
| 2.3.1. Pharmacology...............................................................................................         | 16                                                                                                            |
| Primary pharmacodynamic studies ............................................................................               | 16                                                                                                            |
| Secondary pharmacodynamic studies                                                                                          | ........................................................................ 19                                   |
| Safety pharmacology programme                                                                                              | ............................................................................. 19                              |
| Pharmacodynamic drug interactions                                                                                          | .......................................................................... 20                                 |
| 2.3.2. Pharmacokinetics ..........................................................................................         | 20                                                                                                            |
| Methods of analysis                                                                                                        | ................................................................................................ 20           |
| Absorption.............................................................................................................    | 20                                                                                                            |
| Distribution............................................................................................................   | 21                                                                                                            |
| Metabolism............................................................................................................     | 21                                                                                                            |
| Excretion...............................................................................................................   | 21                                                                                                            |
| Pharmacokinetic drug interactions.............................................................................             | 22                                                                                                            |

<div style=\"page-break-after: always\"></div>

Other pharmacokinetic studies ................................................................................. 22

2.3.3. Toxicology.................................................................................................... 22

Single dose toxicity................................................................................................. 22

Repeat dose toxicity................................................................................................ 22

Genotoxicity .......................................................................................................... 25

Carcinogenicity....................................................................................................... 25

Reproduction Toxicity.............................................................................................. 26

Fertility and early embryonic development ................................................................. 26

Embryo-foetal development ..................................................................................... 26

Prenatal and postnatal development, including maternal function .................................. 26

Studies in which the offspring (juvenile animals) are dosed and/or further evaluated........ 26

Toxicokinetic data................................................................................................... 26

Local Tolerance ...................................................................................................... 27

Other toxicity studies .............................................................................................. 27

Immunotoxicity...................................................................................................... 27

Studies on impurities .............................................................................................. 27

2.3.4. Ecotoxicity/environmental risk assessment........................................................ 28

2.3.5. Discussion on non-clinical aspects.................................................................... 28

2.3.6. Conclusion on non-clinical aspects ................................................................... 32

2.4. Clinical aspects ................................................................................................ 33

2.4.1. Introduction ................................................................................................. 33

GCP...................................................................................................................... 33

2.4.2. Pharmacokinetics .......................................................................................... 34

Absorption............................................................................................................. 34

Distribution............................................................................................................ 34

Elimination ............................................................................................................ 34

Dose proportionality and time dependencies............................................................... 35

Special populations................................................................................................. 36

Pharmacokinetic interaction studies........................................................................... 37

Pharmacokinetics using human biomaterials............................................................... 38

2.4.3. Pharmacodynamics........................................................................................ 38

Mechanism of action ............................................................................................... 38

Primary and Secondary pharmacology ....................................................................... 38

2.4.4. Discussion on clinical pharmacology ................................................................. 39

2.4.5. Conclusions on clinical pharmacology ............................................................... 39

2.5. Clinical efficacy ................................................................................................ 39

2.5.1. Dose response study...................................................................................... 39

2.5.2. Main study ................................................................................................... 40

Methods................................................................................................................ 40

Study Participants .................................................................................................. 40

Treatments............................................................................................................ 41

Objectives ............................................................................................................. 42

Outcomes/endpoints ............................................................................................... 42

Sample size ........................................................................................................... 44

Randomisation ....................................................................................................... 44

Blinding (masking).................................................................................................. 45

<div style=\"page-break-after: always\"></div>

| Statistical methods                                                                                                          | ................................................................................................. 45                    |
|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Results..................................................................................................................    | 46                                                                                                                      |
| Participant flow                                                                                                             | ...................................................................................................... 46               |
| Recruitment...........................................................................................................       | 46                                                                                                                      |
| Conduct of the study...............................................................................................          | 46                                                                                                                      |
| Baseline data                                                                                                                | ......................................................................................................... 47            |
| Numbers analysed                                                                                                             | .................................................................................................. 50                   |
| Outcomes and estimation                                                                                                      | ........................................................................................ 50                             |
| Ancillary analyses...................................................................................................        | 54                                                                                                                      |
| Summary of main study                                                                                                        | .......................................................................................... 58                           |
| Analysis performed across trials (pooled analyses and meta-analysis)............................                             | 59                                                                                                                      |
| Clinical studies in special populations.........................................................................             | 59                                                                                                                      |
| Supportive studies..................................................................................................         | 60                                                                                                                      |
| Proposed confirmatory study....................................................................................              | 61                                                                                                                      |
| 2.5.3. Discussion on clinical efficacy ..........................................................................            | 61                                                                                                                      |
| Design and conduct of clinical studies........................................................................               | 61                                                                                                                      |
| Efficacy data and additional analyses.........................................................................               | 62                                                                                                                      |
| Additional expert consultation                                                                                               | .................................................................................. 62                                   |
| 2.5.4. Conclusions on the clinical efficacy...................................................................               | 63                                                                                                                      |
| 2.6. Clinical safety ..................................................................................................      | 64                                                                                                                      |
| Patient exposure ....................................................................................................        | 64                                                                                                                      |
| Adverse events                                                                                                               | ...................................................................................................... 64               |
| Serious adverse event/deaths/other significant events.................................................                       | 69                                                                                                                      |
| Laboratory findings.................................................................................................         | 71                                                                                                                      |
| Safety in special populations                                                                                                | .................................................................................... 72                                 |
| Safety related to drug-drug interactions and other interactions                                                              | ..................................... 72                                                                                |
| Discontinuation due to adverse events.......................................................................                 | 72                                                                                                                      |
| Post marketing experience.......................................................................................             | 73                                                                                                                      |
| 2.6.1. Discussion on clinical safety ............................................................................            | 73                                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................               | 75                                                                                                                      |
| 2.7. Pharmacovigilance............................................................................................           | 75                                                                                                                      |
| Detailed description of the pharmacovigilance system..................................................                       | 75                                                                                                                      |
| 2.8. User consultation                                                                                                       | ............................................................................................. 75                        |
| 3. Benefit-Risk Balance                                                                                                      | ...........................................................................75                                           |
| Benefits                                                                                                                     | ................................................................................................................ 75     |
| Beneficial effects ....................................................................................................      | 75                                                                                                                      |
| Uncertainty in the knowledge about the beneficial effects .............................................                      | 76                                                                                                                      |
| Risks                                                                                                                        | .................................................................................................................... 76 |
| Unfavourable effects                                                                                                         | ............................................................................................... 76                      |
| Uncertainty in the knowledge about the unfavourable effects                                                                  | ........................................ 77                                                                             |
| Benefit-risk balance                                                                                                         | ................................................................................................ 77                     |
| Importance of favourable and unfavourable effects...................................................... Benefit-risk balance | 77 ................................................................................................ 77                  |
| Discussion on the benefit-risk balance                                                                                       |                                                                                                                         |
| .......................................................................                                                      | 77                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 4.                                                                                                                      | ...............................................................................78 Recommendations                       |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| 5.                                                                                                                      | ........................78 Re-examination of the CHMP opinion of 19 April 2012                                          |
| Detailed grounds for re-examination submitted by the Applicant.................................... 78                   | Detailed grounds for re-examination submitted by the Applicant.................................... 78                   |
| Additional expert consultation .................................................................................. 79    | Additional expert consultation .................................................................................. 79    |
| Overall conclusion on grounds for re-examination ....................................................... 80             | Overall conclusion on grounds for re-examination ....................................................... 80             |
| 6.                                                                                                                      | .......................................81 Recommendations following re-examination                                      |
| REFERENCES ......................................................................................................... 82 | REFERENCES ......................................................................................................... 82 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

µg microgram

AE

adverse event

ADR

adverse drug reaction

ALCL

anaplastic large cell lymphoma

ALK

anaplastic lymphoma kinase

ALT

alanine aminotransferase

ANC

absolute neutrophil count

AST

aspartate aminotransferase

AUC

area under the curve

AUC0- ∞

area under the curve extrapolated to infinity

C10, C19

carbon 10, carbon 19

CHMP

Committee for Medicinal Products for Human Use

CHOP

cyclophosphamide, doxorubicin, vincristine, prednisone

CI

confidence interval

CLL

chronic lymphocytic leukaemia

CLtot

total clearance

Cmax

maximum concentration

COV

coefficient of variation

CT

computed tomography

CR

complete response

CRu

complete response unconfirmed

CTCAE

Common Terminology Criteria for Adverse Events

CYP450

cytochrome P450

DHF

dihydrofolate

DHFR

dihydrofolate reductase

DLBCL

diffuse large B-cell lymphoma

DNA

deoxyribonucleic acid

dTMP

deoxythymidine monophosphate

EMA

European Medicines Agency

EU

European Union

FDA

Food and Drug Administration

FPGS

folylpolyglutamyl synthetase

G-CSF

granulocyte colony stimulating factor

GCP

Good Clinical Practice

GM-CSF

granulocyte/macrophage colony stimulating factor

HR

hazard ratio

HTLV

human T-cell leukaemia virus

ICH

International Conference on Harmonisation

IPI

International Prognostic Index

IWC

International Workshop Criteria

IV

intravenous

LFT

liver function test

m 2

square meter

MALT

mucosa-associated lymphoid tissue

mg

milligram

min

minute

mL

milliliter

mos

months

MTD

maximum tolerated dose

NCI

National Cancer Institute

ND

not determined

NHL

non-Hodgkin's lymphoma

NK

natural killer

NSAID

nonsteroidal anti-inflammatory drug

NSCLC

non-small cell lung cancer

OS

overall survival

PD

progressive disease

PDCO

Paediatric Committee

PET

positron emission tomography

PFS

progression-free survival

<div style=\"page-break-after: always\"></div>

Pgp PK PR PTCL QTc RFC-1 RMP RNA SAE SAP SCT SD SmPC SOC t 1/2 TEN THF T-PLL UE US WBC

P-glycoprotein pharmacokinetic(s) partial response peripheral T-cell lymphoma QT interval corrected for heart rate reduced folate carrier 1 Risk Management Plan ribonucleic acid serious adverse event Statistical Analysis Plan stem cell transplant stable disease Summary of Product Characteristics system organ class terminal elimination half-life toxic epidermal necrolysis tetrahydrofolate T-cell prolymphocytic leukaemia unevaluable United States white blood cell

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Allos  Therapeutics  Ltd  submitted  on  23  November  2010  an  application  for  Marketing Authorisation to the European Medicines Agency (EMA) for Folotyn, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 23 April 2009.

Folotyn was designated as an orphan medicinal product EU/3/07/444 on 13 April 2007. Folotyn was designated as an orphan medicinal product in the following condition: Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).

The  applicant  applied  for  the  following  indication:  treatment  of  adult  patients  with  peripheral  T-cell lymphoma (nodal,  extranodal  and  leukaemic/disseminated)  who  have  progressed  after  at  least  one prior therapy.

## The legal basis for this application refers to:

A - Centralised / Article 8(3) / New active substance.

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application.

The  application  submitted  is  composed  of  administrative  information,  complete  quality  data,  nonclinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or  bibliographic  literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/270/2010 on the agreement of a paediatric investigation plan (PIP).

At  the  time  of  submission  of  the  application,  the  PIP  P/270/2010  was  not  yet  completed  as  some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's requests for consideration

## Conditional Marketing Authorisation

The  applicant  requested  consideration  of  its  application  for  a  Conditional  Marketing  Authorisation  in accordance with Article 14(7) of the above mentioned Regulation based on the following claim(s):

The Applicant outlined that the conditional marketing authorisation would be based on a pivotal singlearm Phase II study (PDX-008), since the lack of approved or well-researched therapies for relapsed or

<div style=\"page-break-after: always\"></div>

refractory PTCL within the EU is suggested to represent a clear unmet medical need. The application included  a  specific  commitment  to  conduct  and  complete  a  Phase  3  confirmatory  study  (see  below) within an agreed timetable.

The Applicant considered that this application for Folotyn 20 mg/ml solution for infusion (pralatrexate) for  the  'Treatment  of  adult  patients  with  peripheral  T-cell  lymphoma  (nodal,  extranodal  and leukaemic/disseminated) who have progressed after at least one prior therapy.' meets both the scope and requirements of Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing  authorisation  for  medicinal  products  use  falling  within  the  scope  of  Regulation  (EC)  No 726/2004 of the European Parliament and of the Council.

The Applicant has provided a document justifying that the medicinal product falls within the scope of the conditional marketing authorisation Regulation (Article 2) and that the requirements for conditional marketing authorisation are fulfilled (Article 4), in particular:

- The risk-benefit balance of the product is positive
- It is likely that the Applicant will be able to provide comprehensive clinical data
- Unmet medical needs will be met

· The benefit to public health of the immediate availability of the product outweighs the risk inherent in the fact that additional data are still required

Initially, the Applicant proposed a study to be provided as a part of fulfilling the conditional approval, i.e.  the  ongoing  Phase  3  multi-centre,  randomised  clinical  trial  (PDX-017)  of  sequential  pralatrexate versus observation in patients with previously undiagnosed PTCL who have not progressed following initial treatment with CHOP-based chemotherapy.

During assessment, the Applicant proposed to perform as a specific obligation a randomised study with pralatrexate versus single-agent systemic treatment of physician's choice. The Applicant considered it unlikely that patients in the post-approval study will be those considered to be eligible for transplant in the  second-line  relapsed  setting  and  suggested  a  choice  of  commercially  available,  single-agent chemotherapeutics and biologicals as comparator.

## New active Substance status

The Applicant requested the active substance pralatrexate contained in the above medicinal product to be considered as a new active substance in itself.

## Protocol Assistance

The Applicant received Protocol Assistance from the CHMP on 5 March 2008. The Protocol Assistance pertained to  clinical  aspects  of  the  dossier,  in  particular  the  potential  registration  under  Exceptional Circumstances of pralatrexate for the treatment of relapsed or refractory PTCL on the basis of a single open-label Phase 2 study. However, the CHMP did not endorse the proposal to base a registration file on a single uncontrolled trial and suggested that a randomised study of pralatrexate in PTCL would provide the most convincing evidence of efficacy and safety. A randomised, controlled, superiority trial design  with  physicians'  choice  as  the  comparator  was  suggested.  The  CHMP  also  considered  that  a control  group  reflecting  clinical  practice  would  enhance  interpretability  of  results  seen  following pralatrexate  administration.  Furthermore,  response  rate  was  not  considered  an  acceptable  primary endpoint  for  a  pivotal  trial  to  support  marketing  authorisation  in  this  condition.  Given  the  high mortality rate expected in this population and the obvious relevance to the patient, OS was considered the preferred primary endpoint.

<div style=\"page-break-after: always\"></div>

## Licensing status

Folotyn has been given a Marketing Authorisation in the United States on 24 September 2009.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur: Tomas Salmonson Co-Rapporteur: Jens Ersbøll

-  The application was received by the EMA on 23 November 2010.
-  The procedure started on 15 December 2010.
-  The Rapporteur's first Assessment Report was circulated to all CHMP members on 7 March 2011. The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  4 March 2011.
-  During the meeting on 14 April 2011, the CHMP agreed on the consolidated List of Questions to be sent  to  the  Applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the  Applicant  on 15 April 2011.
-  The Applicant submitted the responses to the CHMP consolidated List of Questions on 21 July 2011.
-  The Rapporteurs circulated the Joint Assessment Report on the Applicant's responses to the List of Questions to all CHMP members on 2 September 2011.
-  During the CHMP meeting on 22 September 2011, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the Applicant.
-  The  Applicant  submitted  the  responses  to  the  CHMP  List  of  Outstanding  Issues  on  17  October 2011.
-  The Rapporteurs circulated the Joint Assessment Report on the Applicant's responses to the List of Outstanding Issues to all CHMP members on 1 November 2011.
-  During  the  CHMP  meeting  on  16  November  2011,  outstanding  issues  were  addressed  by  the Applicant  during  an  oral  explanation  before  the  CHMP  and  the  CHMP  agreed  on  a  2nd  list  of outstanding issues to be addressed in writing by the Applicant.
-  During  a  meeting  of  a  SAG  on  1  December  2011,  experts  were  convened  to  address  questions raised by the CHMP.
-  The Applicant submitted the responses to the CHMP  2 nd List of Outstanding Issues on 19 December 2011.
-  The Rapporteurs circulated the Joint Assessment Report on the Applicant's responses to the 2 nd List of Outstanding Issues to all CHMP members on 4 January 2012.
-  During the meeting on 19 January 2012, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a conditional Marketing Authorisation to Folotyn.

<div style=\"page-break-after: always\"></div>

## 1.3. Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur: Ian Hudson Co-Rapporteur: Pierre Demolis

-  The Applicant submitted written notice to the EMA on 27 January 2012 to request a re-examination of Folotyn CHMP opinion of 19 January 2012.
-  During  its  meeting  on  16  February  2011,  the  CHMP  appointed  Ian  Hudson  as  Rapporteur  and Pierre Demolis as Co-Rapporteur.
-  The  Applicant  submitted  the  detailed  grounds  for  the  re-examination  on  14  March  2012 (Appendix 2 of Final Opinion). The re-examination procedure started on 15 March 2012.
-  The Rapporteur's Assessment Report was circulated to all CHMP members on 2 April 2012. The Co-Rapporteur's Assessment Report was circulated to all CHMP members on 2 April 2012.
-  During a meeting of the SAG-Oncology on 10 April 2012, experts were convened to consider the grounds for re-examination
-  During  the  CHMP  meeting  on  17  April  2012,  the  detailed  grounds  for  re-examination  were addressed by the Applicant during an oral explanation before the CHMP.
-  During the meeting on 19 April 2012, the CHMP, in the light of the scientific data available and the scientific discussion within the Committee, the CHMP re-examined its initial opinion and in its final opinion  concluded  that  the  application  did  not  satisfy  the  criteria  for  authorisation  and  did  not recommend the granting of the conditional marketing authorisation.

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

Peripheral T cell lymphoma (PTCL) is a very rare condition with an estimated prevalence rate of 0.8 per 10,000 in the European Union.

PTCL  represents  a  heterogeneous  group  of  non-Hodgkin's  lymphomas  that,  with  the  exception  of anaplastic large cell lymphoma (particularly the subtype positive for anaplastic lymphoma kinase), has a  dismal  prognosis.    In  patients  characterized  as  high  risk  by  the  International  Prognostic  Index, 5-year survival has been reported to be as low as 6%.  Several clinical studies have reported a median survival of less than 2 years for patients with T-cell neoplasms and 5-year survival rates of less than 30%.

Because  of  having  an  aggressive  clinical  course  with  poor  outcomes,  PTCL  is  typically  treated  with combination chemotherapy regimens like CHOP and its variants.  The first-line response rates to CHOP chemotherapy  have  been  reported  to  range  between  50%  and  70%.  However,  patients  frequently relapse soon after responding to first-line treatments (Vose et al., 2008).

In  the  case  of  relapsed  or  refractory  PTCL,  there  have  been  relatively  few  studies  of  potential therapeutic  agents.    Agents  tested  have  included  gemcitabine,  deoxycoformycin,  denileukin  diftitox, alemtuzumab, and lenalidomide.  Published reports are, however, difficult to interpret and generalise

<div style=\"page-break-after: always\"></div>

as  few  patients  were  typically  enrolled,  with  various  compositions  of  different  PTCL  entities,  and  no randomised studies are presented.

## About the product

Folotyn  solution  for  infusion  20  mg/ml  contains  pralatrexate,  an  antineoplastic  folate  analogue. Antifolates are anticancer agents used in the treatment of malignancies such as acute lymphoblastic leukaemia, lymphomas, and breast and lung cancer. Pralatrexate is a structural analogue of the widely used antifolate, methotrexate.

Pralatrexate  inhibits  folic  acid  metabolism  by  inhibiting  dihydrofolate  reductase  (DHFR).  It  is  an efficient permeant for reduced folate transporters, including reduced folate carrier 1 (RFC-1) and is an efficient substrate for polyglutamylation by the enzyme folylpolyglutamyl synthetase (FPGS), resulting in extensive internalisation and accumulation within tumour cells. Pralatrexate exerts antifolate activity via  the  inhibition  of  dihydrofolate  reductase  (DHFR),  which  leads  to  depletion  of  intracellular  THF resulting in a disruption of DNA synthesis and subsequent tumour cell death.

In vitro studies in CCRF-CEM leukaemia cells have shown that pralatrexate is 14 times more efficiently transported  into  CCRF-CEM  cells  and  10  times  more  efficiently  polyglutamated  than  methotrexate. These improvements in cellular pharmacokinetics are suggested to lead to improved cytotoxic activity of pralatrexate compared with methotrexate.

The proposed indication for pralatrexate is for  the  treatment  of  adult  patients  with  peripheral  T-cell lymphoma (PTCL) (nodal, other extranodal and leukaemic/disseminated) who have progressed after at least  one  prior  therapy.  The  recommended  dose  of  Folotyn  is  30  mg/m 2 administered  as  an intravenous (IV) infusion over 3-5 minutes, once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity.

Patients  receiving  Folotyn  should  take  low-dose  oral  folic  acid  on  a  daily  basis.  Patients  should  also receive a vitamin B12 intramuscular injection.

Doses may be omitted or reduced based on patient's tolerance. Full blood cell counts and severity of mucositis should be monitored weekly. In addition, serum chemistry tests including renal and hepatic function should be performed regularly.

## 2.2. Quality aspects

## 2.2.1. Introduction

Folotyn is a solution for infusion containing pralatrexate as the active substance. The finished product is  formulated as an aqueous solution containing sodium chloride and pH adjusters in addition to the active substance. Pralatrexate is an antineoplastic folate analogue with a chemical structure similar to methotrexate.

The  excipients  used  in  Folotyn  are  water  (WFI),  tonicity  agent  (sodium  chloride)  and  pH  adjusters (NaOH and HCl).

Folotyn 20 mg/ml solution for infusion is filled into glass vials with chlorobutyl rubber stoppers and crimp seals.

## 2.2.2. Active Substance

Pralatrexate is chemically designated as (2 S )-2-[[4-[(1 RS )-1-[(2,4-diaminopteridin-6-yl)methyl]but-3ynyl]benzoyl]amino]pentanedioic acid and has the following structure

<div style=\"page-break-after: always\"></div>

<!-- image -->

The molecule contains two asymmetric carbon centres (C10) and (C19). The C10 position exists in the RS -configuration (approx. 50:50 ratio) on the link between the two aryl groups. The C19 position is contained in the glutamic acid moiety and predominantly exists in the S -configuration.

Pralatrexate  is  an  off-white  to  yellow  crystalline  material,  soluble  in  aqueous  solutions  at  pH  6.5  or higher  and  practically  insoluble  in  chloroform,  and  ethanol.  It  predominantly  exists  as  a  single polymorph (form A).

## Manufacture

Full information on the active substance pralatrexate is provided in the dossier.

The  active  substance  is  manufactured  by  a  four  step  synthesis  by  the  two  active  substance manufacturers.  The  manufacturing  process  is  described  in  detail  and  critical  steps  and  controls discussed. Rationales are provided for the specifications for the three isolated intermediates and the origin and fate of impurities during the process.

## Specification

The  pralatrexate  active  substance  specification  including  parameters,  analytical  procedures  and acceptance criteria is considered suitable for release of batches of active substance.

The  specification  includes  tests  for  description,  identification  by  Infrared  and  by  High  Performance Liquid  Chromatography  assay,  water  content,  sulphated  ash,  heavy  metals,  clarity  and  colour  of solution, related substances, C10-diastereomers, chiral purity, residual solvents by Gas Chromatography, microbiological content and bacterial endotoxins.

Impurities have been evaluated and found to be acceptable from the point of view of safety.

Satisfactorily  justification  for  the  chosen  parameters  and  related  limits  in  the  active  substance specification  are  presented  in  the  dossier  according  to  relevant  guidelines  (ICH  Q6a  and  Q3A)  and European Pharmacopoeia (Ph. Eur.) standards

The  descriptions  of  the  analytical  methods  are  considered  acceptable  and  their  validations  are performed in accordance with ICH standards and Ph. Eur. requirements.

Batch data from 31 batches are enclosed covering the different manufacturing sites which have been used  during  the  development  of  the  manufacturing  process  and  testing  in  non-clinical  and  clinical studies. Results confirm batch to batch consistency and support uniformity of the quality of the active substance.

<div style=\"page-break-after: always\"></div>

## Stability

Satisfactory  stability  data  on  three  commercial  batches  of  pralatrexate  manufactured  by  one  of  the active substance manufacturers has been provided. Batches were stored in containers simulating the market  packaging  for  24  months  according  to  ICH  conditions  at  long-term  (5°C)  and  6  months  at accelerated conditions (25°C/60%RH).

. The parameters tested were appearance, water content, assay, related substances, chiral purity and C10-diastereomers. As non routine tests bacterial endotoxins and microbial content tests are included in the stability testing plan

Additionally, supportive stability data has been provided on three validation batches for each of the two active substance manufacturers. Three of the batches have been stored  for 12 months at long-term condition  (5°C)  and  6  months  at  accelerated  (25°C/60%RH)  and  the  other  three  batches  from  the other  active  substance  manufacturer  for  3  months  at  both  conditions  and  all  of  them  in  containers simulating those for commercial purposes.

The parameters tested were appearance, water content, assay and related substances. As non routine tests bacterial endotoxins and microbial content are included in the stability testing plan.

Forced  degradation  studies  have  also  been  performed  demonstrating  that  the  most  pronounced degradation was seen at acidic condition.

The photo stability study was performed according to ICH Q1B and demonstrated that pralatrexate is sensitive to light.

The  stability  data  provided  support  the  recommended  retest  period  at  the  proposed  packaging  and storage conditions.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

Pralatrexate is an antineoplastic folate analogue which consists of active substance contained in a nonpyrogenic, sterile, aqueous, isotonic, pH-adjusted solution.

The excipients have remained the same throughout development also in relation to quantities. All meet the corresponding requirement in the Ph. Eur. They have been selected to achieve an aqueous isotonic solution (280-300 mOsm) with a near neutral pH.

No  specific  studies  have  been  performed  concerning  the  compatibility  between  excipients  and  the active substance.  Compatibility is considered self evident and was inferred from the product stability studies.

Compatibility of the active substance with other excipients not included in the formulation has not been assessed, since a simple saline solution was desired and achieved.

Aseptic filtration was selected as the sterilisation method as terminal sterilisation was not considered an  alternative  due  to  the  heat  sensitivity  of  pralatrexate.  The  manufacturing  process  has  remained consistent  throughout  development  with  only  minor  changes  in  relation  to  the  optimisation  and  in relation to process transfer.  The manufacturing process consists of the compounding of bulk solution, filtration and filling of solution and finally capping and labelling. The changes that have been performed are detailed in the dossier.

<div style=\"page-break-after: always\"></div>

The selection of the container closure system was based on being able to contain a sterile parenteral solution intended for intravenous injection, single use and protected from light. Standard packaging materials were chosen.

The compatibility of the product has been assessed with syringes and intravenous physiological sodium chloride  solution.  The  results  demonstrated  compatibility  of  the  finished  medicinal  product  with  the syringes as well as with 0.9% intravenous normal saline solution, the only intended diluent.

## Adventitious agents

All excipients are of non-animal origin except for calcium stearate which is used as a processing aid in the manufacture of the elastomeric closure of the packaging. It is certified by the manufacturer that the  manufacturing  process  is  in  compliance  with  EMEA/410/01  Revision  2  Note  for  Guidance  on Minimizing Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.

## Manufacture of the product

Folotyn 20 mg/ml solution for infusion is manufactured using a conventional aseptic process for sterile aqueous solutions packaged in glass vials that cannot withstand terminal steam sterilisation.

The manufacturing process consists in compounding, filtration, filling into vials and inspection of vials.

The manufacturing formula, flow chart and description of the manufacturing process are presented.

The process has been validated for three batches manufactured to the commercial scale and with the commercial  process.  The  validation  of  the  manufacturing  process  has  been  well  documented  and satisfactory data provided.

## Product specification

Satisfactory specification has  been  presented  for the finished product  and  includes tests for appearance,  identification,  pH,  assay,  related  substances,  volume  in  container,  particulate  matter, osmolality, sterility and bacterial endotoxins.

The proposed test procedures and acceptance criteria comply with the requirements of the Ph. Eur. and current guidelines. Analytical procedures are described and validated.

Batch  analysis  data  are  provided  for  a  substantial  amount  of  batches  (clinical,  site  qualification batches,  stability  batches  and  process  validation  batches).  Data  batches  confirm  consistency  and uniformity of the product indicating that the process is under control.

## Stability of the product

The conditions used in the stability studies are in accordance with the ICH stability guideline (25°C, 25 °C / 60% RH and 40 °C / 75% RH).

The  results  of  the  following  tests  were  submitted:  appearance,  pH,  assay,  related  substances, particulate matter, osmolality, C10-diastereomers, chiral purity, container closure integrity, particulate matter, sterility and bacterial endotoxins.

Analysis of the stability samples has been performed by applying the validated and stability indicating test methods.

Photostability testing confirms that the product is sensitive towards light.

<div style=\"page-break-after: always\"></div>

Based on the stability results provided, the proposed shelf-life and storage conditions are acceptable.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The  new  active  substance  is  an  antineoplastic  folate  analogue  with  a  chemical  structure  similar  to methotrexate.  Information  on  development,  manufacture  and  control  of  the  active  substance  and finished medicinal product has been presented in a satisfactory manner. The results of tests carried out indicate satisfactory consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The  quality  of  this  product  is  considered  to  be  acceptable.  Physicochemical  and  biological  aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. There are no unresolved quality issues.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Pharmacology

## Primary pharmacodynamic studies

## In vitro studies

Studies performed showed that compared to methotrexate, pralatrexate is more effectively taken up by  cancer  cells  through  increased  affinity  for  reduced  folate  transporters  such  as  RFC-1  and  more efficiently polyglutamylated  by  FPGS  (Sirotnak  et  al., 1998).  The  increased  cellular influx of pralatrexate and more effective polyglutamylation of pralatrexate by FPGS translate into more potent in  vitro  anti-cancer  activity  as  compared  to  the  cytotoxic  activity  of  methotrexate  and  edatrexate (Sirotnak et al., 1998; Wang et al., 2003).

In a separate series of studies, Izbicka et al (Izbicka et al., 2009) confirmed the relative biochemical and cellular activities of pralatrexate that differentiate it from methotrexate and expanded the studies to  further  differentiate  pralatrexate's  profile  from  that  of  pemetrexed.  Using  a  cell-free  recombinant human  DHFR  system,  the  approximate  2-fold  difference  in  DHFR  inhibitory  constant  (Ki)  between pralatrexate and methotrexate was confirmed (45 vs 26 nM, respectively). In addition, pralatrexate in a non-polyglutamylated form, was significantly more potent than pemetrexed at inhibiting recombinant human DHFR (Ki &gt; 200 nM). Using the NCI-H460 human NSCLC cell line, it was further demonstrated that pralatrexate was more effectively internalized and polyglutamylated than either methotrexate or pemetrexed.

The increased cellular influx of pralatrexate via the RFC-1 transporter and more effective polyglutamylation  of  pralatrexate  by  FPGS  suggest  that  pralatrexate  may  be  a  more  effective antineoplastic agent  than  other folate analogs. Pralatrexate is significantly  more  potent  than edatrexate or methotrexate in inhibiting in vitro cell growth of a number of human cancer cell lines. The  half  maximum  growth  inhibitory  concentration  (GI50)  of  these  cells  by  pralatrexate  are  about 3-fold  lower  than  those  for  edatrexate  and  at  least  more  than  10-fold  lower  than  those  for methotrexate, despite that edatrexate and methotrexate are marginally more potent DHFR inhibitors.

<div style=\"page-break-after: always\"></div>

Thus, the enhanced in vitro activity of pralatrexate appears to correlate well with its greater cellular uptake and intracellular retention as compared with edatrexate and methotrexate.

In vitro cytotoxicity studies in a panel of 15 human solid tumour cell lines showed that pralatrexate is more  potent  than  methotrexate,  with  pralatrexate  IC50's  on  average  9-fold  lower  compared  with methotrexate (Serova et al., 2009). In addition these studies showed that sensitivity to pralatrexate correlated with higher FPGS  messenger  ribonucleic acid (mRNA)  expression, suggesting that polyglutamylation of pralatrexate is important for its cytotoxic activity.

Pralatrexate was evaluated in the NCI cancer cell panel and showed growth inhibitory activity across a broad spectrum of tumour types. Fifty-three cancer lines from the NCI-60 cell panel were grown in cell culture and treated for 48 hours with different concentrations of pralatrexate (serial ½-log dilutions). At the end of the treatment period the growth of the cancer cells was determined and GI50's were calculated using NCI Developmental Therapeutics Program standard procedures. Of the 53 cancer cell lines tested, 36 cell lines (68%) were highly sensitive to the growth inhibitory effect of pralatrexate with GI50's &lt; 0.1 μ M. Pralatrexate activity of GI50 &lt; 0.1 μ M was observed across a variety of tumour types tested, with leukaemia (4 of 4 tested), colon (7 of 7 tested), and central nervous system (4 of 5 tested) showing the highest frequency of pralatrexate-sensitive cancer cell lines.

Pralatrexate was evaluated for growth inhibitory activity against human tumour cell lines representing head  and  neck  cancer  (HLaC),  breast  cancer  (MDA-MB-231,  MDA-MB-435),  and  NSCLC  (A549, MV522). Growth inhibition was measured in the MTS cell proliferation assay after 3 hours of treatment followed by a 72-hour recovery. Under the experimental conditions, pralatrexate was most active in the  MV522  NSCLC  and  MDA-MB-231  breast  cell  lines  with  half  maximum  inhibitory  concentration (IC50)  values  of  12.8  nM  (MV522)  and  18.0  nM  (MDA-MB-231).  Cytotoxicity  of  pralatrexate  was comparable in HLaC and MDA-MB-435 with IC50 values of 25.8 nM and 24.1 nM, respectively. The A549 lung adenocarcinoma line was slightly less sensitive to pralatrexate (IC50 = 65.1 nM). In a headto-head  comparison  with  conventional  therapeutics,  pralatrexate  was  more  active  than  cisplatin  in every  line  tested  and  superior  to  paclitaxel  in  the  MDA-MB-231  breast  line  and  both  lung  lines. Pralatrexate also demonstrated superior activity versus docetaxel in the MV522 lung cancer line.

Pralatrexate  and  methotrexate  were  evaluated  in  5  human  lymphoma  cell  lines:  RL  (transformed follicular  lymphoma),  HT,  SKI-DLBCL-1  (diffuse  large  B-cell),  Raji  (Burkitt's),  and  Hs445  (Hodgkin's disease) (Wang et al., 2003). After 5 days of continuous in vitro exposure, pralatrexate demonstrated approximately 10-fold greater potency than methotrexate in all cell lines.

To  investigate  the  anti-proliferative  activity  of  pralatrexate  alone  and  in  combination  with  cytidine analogs, pralatrexate combinations with the cytidine analog gemcitabine were studied in a cytotoxicity assay against SKI-DLBCL-1 cells using the standard Trypan Blue Exclusion Assay (Toner et al., 2006). The data support the contention that combinations of a folate analog and a cytidine analog are better than either single agent alone, and that the schedule of the folate analog preceding the cytidine analog is important.

To better understand the potential link between the expression of certain genes involved in folic acid metabolism  and  sensitivity  to  pralatrexate,  the  gene  expression  level  of  a  subset  of  genes  was analyzed in 181 archived lung cancer patient samples that were grouped into 9 categories based on pathology  reports,  including  a  control  group  consisting  of  29  normal  tissue  samples.  Of  7  folate metabolism  genes  analyzed,  5  showed  significant  differential  expression  between  1  or  more  lung cancer groups and the reference normal lung samples.

Pralatrexate was found to be inactive against normal human hepatocytes. Marchi et al, further showed that  pralatrexate  was  not  cytotoxic  against  normal  human  peripheral  blood  mononuclear  cells (PBMC's).

<div style=\"page-break-after: always\"></div>

## In vivo studies

The in vivo anti-tumour activity of pralatrexate was studied in mouse xenograft models (MX-1 mammary carcinoma, LX-1 lung carcinoma, and A549 squamous cell lung cancer). Studies with mammary carcinoma and lung carcinoma showed more complete regressions with pralatrexate than with methotrexate (Sirotnak et al., 1998).

Pralatrexate was compared with docetaxel, paclitaxel, and combinations of pralatrexate with these 2 agents in immune-compromised mice with LX-1 lung tumour cell xenografts. Pralatrexate as a single agent produced a significant reduction in tumour size that was superior to that observed with the other single agent treatments and comparable to that observed with combination therapies.

The schedule-dependent efficacy of pralatrexate was studied in 2 different human tumour xenograft models using 3 different schedules of administration. Pralatrexate was administered by intraperitoneal (IP)  injection  at  its  MTD,  for  each  dose  schedule,  to  mice  engrafted  with  MX-1  (human  breast)  and LX-1  (human  lung)  tumours  (6  mice  per  group).  The  greatest  regression  in  the  2  different  tumour types was obtained with the daily and biweekly schedules, compared with the weekly schedule, which was reproducible in 2 separate experiments. The results indicate some schedule dependence on the ability  of  pralatrexate  to  effect  tumour  growth.  The  schedule  dependence  had  a  greater  effect  than dose per se.

Comparison of pralatrexate to methotrexate, pemetrexed and docetaxel dosed at their respective MTD in  2  NSCLC  cell  tumour  xenograft  models  showed  an  effective  tumour  growth  inhibitory  activity  of pralatrexate compared with these reference agents.

Pralatrexate was compared with cisplatin and carboplatin and combinations with these 2 agents in the JMN human mesothelioma xenograft model (Khokhar et al., 2001). Pralatrexate as a single-agent was more potent than either cisplatin or carboplatin alone.

To further investigate the potential of combining pralatrexate with an EGFR inhibitor, pralatrexate was studied  in  combination  with  cetuximab  in  a  human  squamous  cell  carcinoma  xenograft  in  athymic nu/nu  mice.  In  this  particular  model  pralatrexate  alone  showed  no  significant  activity  whereas cetuximab  as  a  single  agent  showed  good.  The  combination  of  pralatrexate  plus  cetuximab  did  not show improved activity over cetuximab as a single agent.

The in vivo effects of pralatrexate were compared with those of methotrexate in 3 established human NHL xenografts in non-obese, diabetic/severe combined immunodeficient (NOD/SCID) mice (Wang et al.,  2003).  Tumour-bearing  animals were  treated  with  saline  (control)  or  the  MTDs  of  methotrexate (40 mg/kg) or pralatrexate (60 mg/kg) via the IP route twice weekly for 2 weeks. Almost 90% of HT lymphomas treated with pralatrexate completely regressed, whereas those treated with methotrexate had only modest growth delays.

In 2 other xenograft models, treatment with pralatrexate resulted in complete regression rates of 56% (RL)  and  30%  (SKI-DLBCL-1).  No  regressions  and  only  minor  growth  inhibition  were  noted  with methotrexate therapy.

To  investigate  the  anti-proliferative  activity  of  pralatrexate  alone  and  in  combination  with  cytidine analogs, pralatrexate combinations  with  the cytidine analog  gemcitabine  were  studied  in the SKI-DLBCL-1  NHL  xenograft  model.  In  addition,  the  activity of the  standard  combination  of methotrexate/ara-C  was  compared  with  that  of  pralatrexate/gemcitabine  to  determine  if  schedule dependency  of  this  combination  is  important  in  the  treatment  of  lymphoma  (Toner  et  al.,  2006). Cytotoxicity assays using the standard Trypan Blue Exclusion Assay showed that most combinations of pralatrexate  and  gemcitabine  were  superior  to  methotrexate  and  ara-C,  with  the  best  activity  seen when pralatrexate was followed by gemcitabine. Based on these in vitro results, xenograft experiments

<div style=\"page-break-after: always\"></div>

were conducted using one-quarter of  the  MTD  of  pralatrexate  and  gemcitabine  (both  15  mg/kg).  A similar dose reduction for methotrexate and ara-C was not performed given the lower activity in the in vitro  growth  inhibition  assay.  Treatment  with  pralatrexate  alone  showed  better  tumour  growth inhibition than either methotrexate or ara-C alone or in combination. The combination of pralatrexate and  gemcitabine  dosed  each  at  25%  of  their  MTD  was  markedly  more  efficacious  than  any methotrexate-  and/or  ara-C-treated  group.  Although  fewer  complete  remissions  were  noted,  a complete remission was only observed in those animals receiving pralatrexate followed by gemcitabine.

## Secondary pharmacodynamic studies

A study in the rat type-II collagen-induced arthritis model showed a similar efficacy of methotrexate and pralatrexate in inhibiting joint inflammation.

The potential for pralatrexate to bind to secondary targets (receptor screening assay) has not been evaluated.

## Safety pharmacology programme

Safety pharmacology studies performed with pralatrexate are listed below.

Table 1 List of safety pharmacology studies

| Type of Study and Test System                | Study Period   | GLP Compliant   | Study Number   |
|----------------------------------------------|----------------|-----------------|----------------|
| Cardiac safety, isolated dog Purkinje fibers | 2003-2004      | Yes             | PDX-T-04005-D  |
| Cardiac safety, hERG                         | 2003-2005      | No              | PDX-T-05018-H  |
| Cardiovascular and respiratory safety,       | 2006-2007      | Yes             | PDX-T-07036-D  |
| Neurobehavioral, Sprague-Dawley rats         | 2006-2007      | Yes             | PDX-T-07037-R  |

GLP = Good Laboratory Practice, hERG = human ether-a-go-go related gene

The  effect  of  pralatrexate  on  the  hERG  K+  current  was  studied  in  a  hERG-transfected  cell  line (CHO-K1/hERG).  At  the  concentrations  of  0.8,  2,  and  4  mg/ml,  pralatrexate  inhibited  hERG  K+ currents  by  37,  54,  and  54%,  respectively.  At  0.4  mg/ml,  pralatrexate  had  no  effect  on  hERG  K+ currents. The reference compound, E-4031 inhibited hERG K+ currents by 98%.

A  study  was  performed  to  assess  the  effect  of  pralatrexate  on  dog  isolated  Purkinje  fiber  action potential recorded using intracellular microelectrodes. Four Purkinje fibers were isolated from four dogs and perfused with vehicle followed by pralatrexate. Pralatrexate, at target concentrations of 0.4, 0.8, and 2.0 mg/ml (0.34, 0.67 and 1.66 mg/ml, according to the concentration analysis results) did not induce  any  statistically  significant  of  biologically  relevant  (&lt;15%)  changes  in  RMP,  OS,  APA,  V max , APD30, APD60, or APD90 at stimulation frequencies of 1.0 Hz or 0.5 Hz. The positive control agent (dlsotalol) prolonged APD60 and APD90.

A cardiovascular and respiratory function safety assessment study in conscious, telemetryinstrumented, male and female beagle dogs (4/sex/group) showed no effects of pralatrexate dosed IV up  to  and  including  0.7  mg/kg  (the  MTD)  on  respiratory  function  (respiratory  rate,  blood  oxygen saturation, and end tidal CO2), blood pressure (systolic, diastolic, and mean arterial pressure), heart rate,  body  temperature,  electrocardiographic  parameters  (heart  rate,  PR,  QRS,  RR  and  QT/QTc intervals), or mortality.

Electrocardiographic assessments were also performed in a 9-month IV toxicity study in Beagle dogs. Pralatrexate was given to male and female Beagle dogs by slow bolus IV injection at doses of 0.1, 0.3, and 0.7 mg/kg for 2 or 6 cycles (1 cycle consists of 6 weekly doses followed by 1 drug-free week). At interim study days 81-83 one female doses at 0.3 mg/kg had a slightly prolonged PR interval of 0.17 seconds (normal range is 0.06-0.14 seconds). This slight PR  prolongation has no biological

<div style=\"page-break-after: always\"></div>

significance. All other measurements (at predose, study days 81-83, end of study day 282 and after a 4-week recovery period day 309) were within normal limits.

CNS effects were studied in Sprague-Dawley rats. Rats were administered a single dose of 5, 10, or 25 mg/kg  pralatrexate  via  IV  bolus  infusion.  Parameters  evaluated  during  the  study  included  body weight,  body  temperature,  clinical  and  cageside  observations.  In  addition,  rats  were  assigned  for functional  observational  battery  (8/sex/group)  or  locomotor  activity  (8/sex/group)  evaluations  at predose, 5 minutes post-dose, and 24 hours post-dose. Treatment with pralatrexate did not result in any mortality. There were no pralatrexate-related abnormal observations and the body weights were comparable  to  the  control  group.  The  quantitative  and  qualitative  functional  observational  battery observations and the locomotor activity data were comparable to control group at all time points. The body temperature was also comparable at all measured time points.

## Pharmacodynamic drug interactions

Pralatrexate was used in combination with a number of marketed cancer therapeutics in various mouse xenograft models (see section on Primary pharmacodynamics).

## 2.3.2. Pharmacokinetics

Pralatrexate  PK  was  investigated  in  rat  and  dog  using  the  clinical  product,  schedule,  and  route  of administration  in  single-dose  PK  and  GLP-compliant  repeat-dose  TK  studies.  Tissue  distribution  and excretion of pralatrexate were studied in GLP-compliant mass balance studies in rats.  Plasma protein binding and metabolism were studied using human biomaterials.

## Methods of analysis

Analytical methods have been developed and validated for the quantification of the 2 diastereomers, designated  PDX-10a  (S  configuration)  and  PDX-10b  (R configuration)  in  plasma  and  urine  of  rats, dogs, and humans, and in plasma for mice and. Validation assessed parameters of specificity, matrix effect, intrabatch and interbatch precision (relative standard deviation [%RSD]) and accuracy (relative error [%RE]), linearity, and recovery in each matrix.  The lower limit of quantisation (LLOQ) for each diastereomer in all matrices is 0.5 ng/mL and the linear range is 0.5-1,000 ng/mL.

## Absorption

The PK of pralatrexate diastereomers PDX-10a and PDX-10b were characterized following a single IV dose of pralatrexate to male and female rats (12/sex/group). PK analysis of concentration data from plasma and urine samples obtained from these animals showed a biphasic disposition pattern with an initial, rapid decline followed by a more gradual, terminal decline. The volume of distribution at steady state indicated extensive tissue distribution. No significant differences in PK parameters were observed for the two diastereomers. Females exhibited approximately 2-fold higher clearance values.

A single-dose intravenous PK study in Beagle dogs (3/sex/group) showed in general the same pattern as  the  study  in  rats.  There  was  no  gender  difference  in  dogs.  PDX-10b  had  2-fold  higher  clearance values compared with PDX-10a; however, this stereoselectivity diminished with increasing doses.

<div style=\"page-break-after: always\"></div>

Table 2 Summary of PK data

| Study ID      | Species   | Dose (mg/kg \\ mg/m 2 )   | Cmax (ng/ml)       | AUC 0- ∞ (ng/ml •min)   | T 1/2 term (hr)   |
|---------------|-----------|--------------------------|--------------------|-------------------------|-------------------|
| PDX-K-05010-R | Rat       | 5 \\ 30 10 \\ 60 25 \\ 150  | 4,225 9,298 27,275 | 100,807 203,341 597,323 | 4 3 18            |
| PDX-K-05009-D | Dog       | 0.3 \\ 6 1 \\ 20 3 \\ 60    | 458 1,858 4,833    | 31,690 102,177 247,271  | 6 6 15            |
| PDX-008       | Human     | 0.81 \\ 30                | 5,815              | 267,854                 | 12 - 18           |

t 1/2term values are the average for the pralatrexate diastereomers in male and female.

The pralatrexate plasma exposure after single and repeat dose in rat and dog pivotal toxicity studies showed a biphasic disposition with an initial rapid decline followed by a more gradual terminal decline. The  exposure  was  dose  proportional  without  evidence  of  drug  accumulation.  No  apparent  gender difference was noted. Cmax values showed some degree of variability between species; however, due to the initial rapid decline in plasma concentrations, the variability in bolus infusion time (1-2 minutes in animals 3-5 minutes in man) and sampling time immediately following infusion may have contributed to these differences.

## Distribution

Tissue  distribution  of  pralatrexate  over  time  has  not  been  studied;  however,  tissue  distribution  at 168 hours after a single IV  14 C-pralatrexate dose (10 mg/kg) in a mass balance study in rats showed that  the  highest  measurable  content  of  radioactivity  168  hours  post-dose  was  observed  in  the  liver (0.33 vs. 0.24 μ g pralatrexate equivalents/g) and kidneys (0.39 vs. 0.27 μ g pralatrexate equivalents/g) for male vs. female rats, respectively.

The potential of pralatrexate to penetrate the blood-brain barrier was assessed in an in situ rat brain perfusion model. The dose-normalized brain uptake rate of pralatrexate was comparable to that of the low penetration controls, methotrexate and atenolol.

No studies  using  animal  biomaterials  were  performed  with  respect  to  protein  binding.  The  result  of plasma protein  binding  studies  with  pralatrexate  indicate  moderately  high  (67-86%)  human  plasma protein binding. Pralatrexate did not partition into human red blood cells in an in vitro assay.

No placental transfer studies have been performed.

## Metabolism

Metabolism studies of pralatrexate have been performed by incubation with human hepatocytes and human liver microsomes. No significant metabolism was observed in these studies. In addition to the apparent  lack  of  hepatic  metabolism,  no  striking  interspecies  differences  in  PK  parameters  were observed, and therefore, no studies investigating interspecies metabolism differences were performed. No studies on in vivo metabolism have been performed in animals. A human mass balance study with 14 C-pralatrexate is ongoing.

## Excretion

GLP-compliant mass balance studies in rats using  14 C-pralatrexate showed that the primary route of excretion  is  faecal  (44%-66%),  followed  by  urine  (21%-31%)  and  expired  CO2  (6.4%-10%). 70 to 92% of the radioactivity was excreted in the first 24 hours following administration.

<div style=\"page-break-after: always\"></div>

Biliary excretion or enterohepatic circulation was not investigated.

## Pharmacokinetic drug interactions

In competitive binding studies, pralatrexate did not significantly interfere with human plasma protein binding of 6 reference drugs (phenytoin and warfarin [albumin site I], ceftriaxone [albumin site II], digoxin [albumin site III], disopyramide [ α 1-acid glycoprotein and albumin], and propranolol [albumin, α 1-acid  glycoprotein,  and  lipoproteins]),  nor  was  pralatrexate  displaced  to  a  significant  extent  from human  plasma  proteins  by  6  reference  drugs  (phenytoin  and  warfarin  [albumin  site  I],  ibuprofen [albumin site II], digoxin [albumin site III], propranolol [ α 1-acid glycoprotein, albumin,  and lipoproteins], and disopyramide [ α 1-acid glycoprotein and albumin]).

No drug transporter studies were performed in animal model systems. Further, pralatrexate did not significantly  inhibit  or  induce  CYP450  enzymes  or  P-glycoproteins  in  two  human  model  systems  as assessed by bidirectional permeability determination.

## Other pharmacokinetic studies

No other pharmacokinetic studies were performed.

## 2.3.3. Toxicology

## Single dose toxicity

An exploratory IV dose-range finding study in Beagle dogs was performed to determine appropriate doses of pralatrexate for subsequent repeat-dose studies. The lack of a dedicated single-dose toxicity studies was justified in accordance with the current recommendations from EMA (CHMP/SWP/302413/08  and  EMA/CHMP/SWP/81714/2010).  Data  from  the  dose-range  finding  study showed that all dogs developed bloody diarrhoea at day 3, and lethality of a single IV dose 3 mg/kg (60 mg/m 2 ).

## Repeat dose toxicity

Pralatrexate repeat-dose toxicity was evaluated in the rat and dog. Eight- and 14 weeks dose-range finding studies preceded the pivotal 28-week repeat-dose toxicology study in the rat and the pivotal 9-month  study  in  the  dog.  Treatment  included  the  clinical  formulation,  route,  and  schedule  of administration.  The  pivotal  rat  and  dog  repeat-dose  toxicology  studies  were  GLP-compliant  and included toxicokinetic evaluations. The repeat-dose toxicity studies with pralatrexate are summarised in the following table:

Table 3

| Study ID       | Species/Sex/ Number/Group / Duration                                                                                  | Dose (mg/kg) Route                                                          | NOAEL (mg/kg)   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PDX-T- 05013-R | Sprague Dawley rats 5/sex/group 8-week (two 4-week cycles consisting of 3 weekly doses followed by 1 dose- free week) | 0, 25, 50, 75 (0, 150, 300 or 450 mg/m 2 ) IV slow bolus Dosing days: 1, 8, | NA              | Mortality: Males; 1/5 (control), 2/5 (50 mg/kg), and Females; 1/5 (25 mg/kg), 3/5 (50 mg/kg), and 4/5 (75 mg/kg). Pralatrexate-related effects in males included diarrhoea, hunched posture, rough hair coat, and thin appearance at 50 mg/kg. In females, clinical signs of toxicity included thin appearance at 50 and 75 mg/kg, hunched posture and languidness at 25, 50, and 75 mg/kg, and rough hair coat and few |

<div style=\"page-break-after: always\"></div>

|                |                                                                                                                                                                                                                                                    | 15, 29, 36 and 43.                                                                                                                                                            |                  | faeces at 75 mg/kg. Changes in erythrocyte parameters were observed at doses ≥ 25 mg/kg. There was no histopathology evaluation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PDX-T- 07039-R | Sprague Dawley rats 5/sex/group `4 weeks (two 7- week cycles consisting of 6 weekly doses followed by 1 dose- free week)                                                                                                                           | 0, 5, 10, 25 (0, 30, 60 or 150 mg/m 2 ) IV slow bolus Dosing days: 1, 8, 15, 22, 29, 36, 50, 57, 64, 71, 78 and 85                                                            | 25 (150 mg/m 2 ) | No adverse effects were noted in mortality, cageside observations, food consumption, clinical chemistry parameters, or gross pathology. A trend toward lower absolute body weight was noted in the 25 mg/kg females but there was no corresponding effect on food consumption. A significant decrease in testes weight was noted in the 25 mg/kg males. A significant increase in spleen-to-body weight ratio was noted in two of the five 25 mg/kg males. Changes in erythroid parameters consistent with minimal anaemia were observed at doses ≥ 5 mg/kg, but most erythroid parameters returned to normal after the 1-week dose free period, suggesting that the effect was transient and reversible with cessation of treatment. |
| PDX-T- 07034-R | Sprague Dawley rats Interim group (SD 92) 10/sex/group Main group (SD 190) 10/sex/group Recovery group (vehicle and high dose group, SD 211) 5/sex/group 28 weeks (four 7- week cycles consisting of 6 weekly doses followed by 1 dose- free week) | 0, 5, 10, 25 (0, 30, 60 or 150 mg/m 2 ) IV slow bolus Dosing days: 1, 8, 15, 22, 29, 36, 50, 57, 64, 71, 78, 85, 99, 106, 113, 120, 127, 134, 148, 155, 162, 169, 176 and 183 | 5 (30 mg/m 2 )   | See text below the table                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PDX-T- 05015-D | Beagle dogs 2/sex/group 8 weeks (two 4- week cycles consisting of 3 weekly doses followed by 1 dose- free week)                                                                                                                                    | 0, 0.3, 1, 3 (0, 6, 20 or 60 mg/m 2 ) IV slow bolus Dosing days: 1, 8, 15, 29, 36 and 43.                                                                                     | NA               | Mortality: 1 male and 1 female in the 3 mg/kg group. Pralatrexate caused multiple GI effects, including emesis and abnormal faeces at all doses and in both genders. In both genders these GI effects were associated with dehydration at doses ≥ 1 mg/kg and thin appearance at 3 mg/kg. Weight loss and/or lack of weight gain were apparent in all pralatrexate-treated animals. There were no effects on clinical pathology and pathology parameters. There was no histopathology evaluation.                                                                                                                                                                                                                                     |
| PDX-T- 07035-D | Beagle dogs Group 1-3: 2/sex/group Group 4: 3/sex/group from SD 57                                                                                                                                                                                 | 0, 0.1, 0.3, 1.0 (0, 2, 6 or 20 mg/m 2 ) Group 4: 1.0 → 0.7 mg/kg SD                                                                                                          | 0.3 (6 mg/m 2 )  | Mortality: 1 male and 2 females in the 1 mg/kg group. Weekly administration of pralatrexate at 1 mg/kg caused severe toxicity resulting in early terminations. Although tolerated by the animals, a nominal dose of 0.7 mg/kg/week also resulted in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                | 14 weeks (two 7- week cycles consisting of 6 weekly doses followed by 1 dose- free week)                                                                                                                                                | 22 IV slow bolus Dosing days: 1, 8, 15, 22, 29, 36, 50, 57, 64, 71, 78 and 85                        |                 | signs of toxicity. Pralatrexate-related and dose proportional signs of toxicity at this dose included emesis, soft faeces, diarrhoea, and thin appearance. Pralatrexate-related decreases in body weight and food consumption were noted in doses of 1 mg/kg/week. Pralatrexate-related changes in clinical pathology parameters included an increase in absolute reticulocyte count and lowered electrolytes, which was secondary to various signs of gastrointestinal disturbance noted. Pralatrexate- related necropsy findings included reduction in thymic size and weight There was no histopathology evaluation.   |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PDX-T- 07054-D | Beagle dogs Interim group (SD 87) 5/sex/group main group (SD 283) 5/sex/group recovery group (vehicle and high dose group, SD 309) 2/sex/group 9 months (six 7- week cycles consisting of 6 weekly doses followed by 1 dose- free week) | 0, 0.1, 0.3, 0.7 (0, 2, 6 or 14 mg/m 2 ) Group 4: Vitamin B 12 +folic acid from week 4 IV slow bolus | 0.1 (2 mg/m 2 ) | See text below the table                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

A  GLP-compliant  6-month  study  was  performed  in  rats  with  the  clinically  relevant  7-week  cycle (IV dose once weekly for 6 weeks followed by 1 dose-free week). Doses were 0, 5, 10, 25 mg/kg. No adverse  clinical  observations  were  noted.  Three  animals  were  euthanized  moribund  and  three  were found dead, but these events were not considered pralatrexate-related because they were also noted in controls and were associated with procedure injury and isolated incidence.

Mean body weight was lower in males and females dosed at 25 mg/kg. Erythroid parameters were affected in males and females at all pralatrexate doses after 2 and 4 cycles, most notably at 25 mg/kg and  more  pronounced  in  males.    Parameters  included  dose-related  decreases  in  RBC  count, haemoglobin,  and  haematocrit,  with  dose-related  increases  in  mean  corpuscular  volume,  absolute reticulocyte  count,  RBC  distribution  widths,  and  mean  corpuscular  haemoglobin,  and  with  erythroid morphology changes in males.  All hematologic parameters were reversible during the 2-week recovery period.  Higher  spleen  weights  in  male  and  females  and  lower  testes  weights  at  25  mg/kg  were pralatrexate related.

A  GLP-compliant  9-month  study  was  performed  in  dogs  with  the  same  7-week  cycle.  Doses  were 0.1, 0.3  and  0.7  mg/kg.  Due  to  adverse  clinical  signs  (including  death  and  early  termination,  body weight  losses,  and  poor  appetite),  all  0.7  mg/kg  dogs  were  supplemented  with  vitamin  B12 (0.5 mg/animal/week)  and  folic  acid  (5  mg/animal/day)  beginning  during  study  week  4.  Treatment with pralatrexate at 0.7 mg/kg without vitamin B12 or folic acid supplementation resulted in mortality. 1  female  was  found  dead  on  SD  19  and  1  male  and  1  female  were  euthanized  due  to  moribund condition on SD 11 and 19, respectively.  An additional Group 4 male was euthanized moribund on SD 88. Animals administered  pralatrexate  at  doses ≥ 0.3  mg/kg  had  lower  food  consumption,  lower body weight changes and signs associated with GI distress. No abnormal ocular findings were noted

<div style=\"page-break-after: always\"></div>

and there were no pralatrexate-related electrocardiographic changes. Lower RBC counts, haemoglobin concentration, haematocrit, absolute lymphocyte count, and absolute basophil counts were noted in all pralatrexate-treated  groups,  while  slightly  higher  platelet  counts  were  observed  in  male  and  female dogs administered 0.7 mg/kg. Changes in chemistry parameters were considered a result of individual animal variation or reduced food consumption.  Pralatrexate-related findings seen at interim necropsy (SD  87)  were  generally  limited  to  discoloration  of  the  intestinal  tract  (small  and  large  intestine, rectum) and reddened mesenteric lymph nodes in both genders and reddened injection sites in the females;  findings  were  seen  in  all  pralatrexate-dosed  groups.  At  the  terminal  necropsy  (SD 283), darkened and/or reddened duodenum, jejunum, ileum, cecum, colon, and/or rectum were observed in control  animals  as  well  as  dogs  administered  pralatrexate.  There  were  no  pralatrexate-related macroscopic  lesions  at  the  recovery  necropsy  (SD  309).  Microscopic  lesions  in  dogs  found  dead  or euthanized moribound prior to the vitamin B12/folic acid supplementation consisted of hypocellularity of  the  femoral  and  sternal  bone  marrow,  thymic  atrophy,  acinar  atrophy  of  the  mandibular  salivary gland, and necrosis in the intestinal tract. Findings at interim necropsy consisted of epithelial and crypt necrosis  within  the  small  intestine  in  dogs  administered  pralatrexate  at ≥ 0.3 mg/kg.    Findings  at terminal necropsy consisted of villous fusion in the small intestine with infrequent dilation and necrosis of crypt epithelium in dogs administered pralatrexate at ≥ 0.3 mg/kg and thymic atrophy in 3/5 female dogs administered 0.7 mg/kg. There were no pralatrexate-related microscopic lesions after a 4 week recovery period.

## Genotoxicity

Pralatrexate  was  not  mutagenic  in  standard in  vitro and in  vivo mutagenicity  assays  (Ames  Test, CHO cell  chromosome  aberration  assay,  and  mouse  micronucleus  assay).  The  results  from  these genotoxicity studies are further summarized in the table below.

Table 4

| Type of test/study ID/GLP         | Test system                                                      | Concentration range/ Metabolising system                      | Results                                                                                                        |
|-----------------------------------|------------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Gene mutations in bacteria        | Salmonella strains TA98, TA100, TA1535, TA1537, E. coli WP2 uvrA | 5-5,000 µg/plate +/- S9                                       | Negative. No toxicity was observed.                                                                            |
| Gene mutations in mammalian cells | CHO-cells                                                        | 0.125, 0.25, 0.5, 1.0 µg/mL -S9 0.25, 0.5, 1.0, 2.5 µg/mL+ S9 | Negative. Dose-dependent reduction of mitotic index but no inhibition of DNA synthesis at the evaluated doses. |
| Chromosomal aberrations in vivo   | CD-1 Mouse, 5/sex/group micronuclei in bone marrow               | 0.5, 1.0, 2.0, 3.0 mg/kg IP for three consecutive days        | Negative. Reduction of PCE. Mean PDX-10a and PDX-10b plasma exposure was 374 ng/mL following 3 mg/kg IP.       |

PCE: polychromatic erythrocytes

## Carcinogenicity

In accordance with ICH S9, no carcinogenicity studies have been performed with pralatrexate because it is intended to treat patients with serious, life threatening cancer.

<div style=\"page-break-after: always\"></div>

## Reproduction Toxicity

## Fertility and early embryonic development

No fertility and early embryonic development studies were performed with pralatrexate because it is intended to treat patients with serious, life threatening cancer.

## Embryo-foetal development

Embryo-foetal development studies were conducted in rats and rabbits.

The  effects  of  pralatrexate  on  maternal  and/or  foetal  development  were  investigated  after  IV administration  of  pralatrexate  to  pregnant  Sprague-Dawley  rats  from  gestation  day  (GD)  7  through GD 20.  Twenty  five  rats/group  received  pralatrexate  at  0,  0.01,  0.03,  or  0.06 mg/kg/day  (0,  0.06, 0.18, and 0.36 mg/m 2 /day, respectively). Pralatrexate had no effect on maternal, clinical or cage side observations, or gross pathology. At 0.06 mg/kg, pralatrexate caused significant decreases in maternal body weight, body weight changes, and food consumption. At 0.06 mg/kg pralatrexate, there was a significant increase in intra-uterine deaths and post-implantation loss and lower gravid uterine weight. At 0.06 mg/kg, pralatrexate treatment resulted in significantly lower mean litter weight, mean foetal weight, and mean male and female weights per litter, but there was no effect on foetal morphology (external, visceral, skeletal). Pralatrexate had no effect on these parameters at 0.01 or 0.03 mg/kg. The  maternal  NOEL  and  maternal  reproductive  NOEL  were  considered  to  be  0.03 mg/kg/day (0.18 mg/m 2 /day).

The  effects  of  pralatrexate  on  maternal  and/or  foetal  development  were  investigated  after  IV administration  of  pralatrexate  to  pregnant  New  Zealand  White  rabbits  from  GD 8  through  GD 21. Twenty  rabbits/group  received  pralatrexate  at  0,  0.03,  0.1,  or  1  mg/kg/day  (0,  0.36,  1.2,  and 12 mg/m 2 /day,  respectively).  Red  vaginal  discharge  was  noted  during  the  latter  gestational  period (GD 18-26) and 3 animals in the 1 mg/kg/day group were euthanized after signs of aborted litters; no gross  pathology  findings  were  noted  at  necropsy.  There  were  no  significant  differences  in  body weights. At 1 mg/kg, there was a significant increase in number of intra-uterine deaths and percent post-implantation  loss  compared  to  control,  and  mean  gravid  uterine  weights  and  adjusted  body weight change were lower compared to controls. Pralatrexate dosed at 0.03 or 0.1 mg/kg/day had no effect on these parameters. Treatment with pralatrexate had an adverse effect on foetal viability and mean  litter  weight  at  1  mg/kg/day.  There  was  no  effect  on  foetal  morphology  (external,  visceral, skeletal). The maternal NOEL and maternal reproductive NOEL were considered to be 0.1 mg/kg/day (1.2 mg/m 2 /day).

## Prenatal and postnatal development, including maternal function

No  prenatal and postnatal  development  and maternal function studies were performed with pralatrexate because intended to treat patients with serious, life threatening cancer.

## Studies in which the offspring (juvenile animals) are dosed and/or further evaluated

No studies  in  juvenile  animals  were  performed  with  pralatrexate.  The  applied  indication  is  for  adult PTCL patients only.

## Toxicokinetic data

The repeat-dose toxicity studies in rats and dogs included blood sampling for toxicokinetic analysis. The  analysis  included  determination  of  the  individual  diastereomers  PDX-10a  (S  configuration)  and

<div style=\"page-break-after: always\"></div>

PDX-10b (R configuration). The plasma AUC values in the table below are given as the mean value observed for PDX-10a and PDX-10b. For comparison, human data from the phase 2 trial PDX-008 are shown as well. The values are the sums of the two diastereomers.

Table 5

| Study                  | Daily Dose (mg/kg)   | AUC (ng•min/ml)           | Cmax (ng/ml)         |
|------------------------|----------------------|---------------------------|----------------------|
| Rat (Cycle 4/Dose 6)   | 5 10 25              | 355,864 841,482 2,269,911 | 14,884 40,840 64,868 |
| Dog (Cycle 6/Dose 6)   | 0.1 0.3 0.7          | 17,859 44,240 80,369      | 125 316 649          |
| Human (Cycle 2/Dose 6) | 0.81                 | 211,555                   | 4,963                |

## Local Tolerance

Perivenous toxicity of pralatrexate was studied in Sprague-Dawley rats. Five male and 5 female rats were  dosed  40  mg/kg  (240  mg/m 2 )  pralatrexate  (2  ml/kg  dosing  volume)  by  bolus  injection perivascular to the saphenous vein. Animals were observed for 8 days following injection. No systemic toxicities  were  observed  during  this  observation  period.  Therefore,  a  single  perivenous  injection  of pralatrexate at 40 mg/kg did not result in any local irritancy at the injection site in Sprague-Dawley rats.

Dermal tolerance  of  pralatrexate  was  studied  in  Sprague-Dawley  rats.  Five  male  and  5  female  rats were dosed interscapular with 20 mg/kg (120 mg/m 2 ) pralatrexate (1 ml/kg dosing volume) by slow bolus  injection.  Animals  were  observed  for  8  days  following  injection.  No  systemic  toxicities  were observed during this observation period. Minimal oedema and minimal to mild erythema were observed in  both  males  and  females  from  day  4  following  administration  of  a  single  dose  of  pralatrexate. Therefore, intradermal administration of pralatrexate at 20 mg/kg produced minimal to mild irritancy in Sprague-Dawley rats.

## Other toxicity studies

## Immunotoxicity

Pralatrexate is a folate analogue having anti-inflammatory activity, and therefore pralatrexate may be immunosuppressive.  Repeat-dose  toxicity  studies  in  dogs  showed  effects  on  parameters  associated with the immune system, i.e. thymic atrophy and hematologic toxicities, including reduced absolute lymphocyte counts.  No specific studies investigating pralatrexate immunotoxicity were performed.

## Studies on impurities

Three impurities are included in the drug substance specifications  (4-OH-PDX,  10-CBM-PDX, Des-Glu-PDX). These specified impurities were qualified for safety by their exposure in toxicology and clinical studies.

The  only  degradation  product  observed  in  pralatrexate  drug  substance  and  drug  product  that significantly increased over time is 4-OH-PDX. Degradation of pralatrexate to 4-OH-PDX is both timeand temperature-dependent. 4-OH-PDX was found to be significantly less cytotoxic (IC50 ≥ 1.4 µM) against the NCI-H460 lung, and MDA-MB231, MDA-MB435, and SK-BR3 breast cancer cell lines than pralatrexate.  The  toxicity  of  4-OH-PDX  was  evaluated  in  a  six-week  study  where  Beagle  dogs

<div style=\"page-break-after: always\"></div>

(4 dogs/sex/group)  were  treated  IV  once  weekly.  While  renal  toxicity,  ataxia  and  lethargy  were observed in males administered 30 mg/kg, 4-OH-PDX was found to be well-tolerated at doses up to 10 mg/kg (200 mg/m 2 ); mild transient emesis and salivation were the only observed effects at doses of 3 and 10 mg/kg. The NOAEL for 4-OH-PDX in these toxicology studies was 10 mg/kg.

Furthermore, a Multi-Computer Automated Structure Evaluation (MCASE) computational assessment of genetic toxicity potential of starting materials, process materials, intermediates, known and potential impurities,  pralatrexate,  and  degradation  products  was  carried  out.  4-OH-PDX  did  not  exhibit  a consistent positive alert for genotoxic potential across the test battery and can thus be considered nongenotoxic. Of the structures tested, only the starting material IN0222 (2,4-diamino-6-chlormethylpteridine)  exhibited  a  positive  alert  for  genotoxic  potential.  A  bacterial reverse mutation assay (Ames Test) confirmed the positive alert observed in the MCASE analysis. The manufacturing  process  controls  the  residual  IN0222  to  a  level  of  0.00013%  in  pralatrexate  drug substance, which is equivalent to a daily dose of IN0222 of 0.0715 µg/day and is below the threshold of toxicological concern.

## 2.3.4. Ecotoxicity/environmental risk assessment

The  log  P  value  for  pralatrexate  is  0.025,  which  was  determined  experimentally  by  potentiometric titration in dual-phase n-octanol/water (0.15 M KCl) system. This is below the value of 4.5 indicated in the guideline as a trigger for further investigation of persistence, bioaccumulation and toxicity.

Folotyn  is  indicated  for  the  treatment  of  adult  patients  with  relapsed  or  refractory  PTCL  (nodal, extranodal  and  leukaemic/disseminated).  Based  on  the  incidence  of  this  disease  in  the  EU  the maximum number of eligible patients would be 20,295. Based on a refinement of Fpen, the Applicant presented a number for PECsurface water which is below the trigger value for a phase II assessment.

Table 6 Summary of main study results

| Substance (INN/Invented Name): Pralatrexate/Folotyn                 | Substance (INN/Invented Name): Pralatrexate/Folotyn   | Substance (INN/Invented Name): Pralatrexate/Folotyn   | Substance (INN/Invented Name): Pralatrexate/Folotyn   |
|---------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| CAS-number (if available): 146464-95-1                              | CAS-number (if available): 146464-95-1                | CAS-number (if available): 146464-95-1                | CAS-number (if available): 146464-95-1                |
| PBT screening                                                       |                                                       | Result                                                | Conclusion                                            |
| Bioaccumulation potential- log K ow                                 | Draft OECD 122 guideline                              | Log P = 0.025                                         | No PBT Potential                                      |
| Phase I                                                             | Phase I                                               | Phase I                                               | Phase I                                               |
| Calculation                                                         | Value                                                 | Unit                                                  | Conclusion                                            |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.00194 µg/L                                          |  g/L                                                 | < 0.01 threshold                                      |
| Other concerns (e.g. chemical class)                                |                                                       |                                                       | No                                                    |

## 2.3.5. Discussion on non-clinical aspects

Pralatrexate is a folate analogue which inhibits the enzyme dihydrofolate reductase (DHFR) with a Ki of 13.4 pM. DHFR is responsible for the reduction of folate to tetrahydrofolate, which is required for the synthesis  and  catabolism  of  several  amino  acids,  formation  of  creatine  and  choline,  synthesis  of purines, methylation of RNAs, synthesis of deoxythymidine monophosphate (dTMP) and thus synthesis of DNA. DHFR inhibition results in disruption of DNA synthesis which causes necrosis or apoptosis of rapidly dividing cells such as some cancer cells and potentially normal cells of the gastric mucosa and

<div style=\"page-break-after: always\"></div>

bone marrow. It was demonstrated in the human acute lymphoblastic leukaemia cell line CCRF-CEM, that  pralatrexate  is  more  efficiently  transported  into  cancer  cells  than  methotrexate.  Moreover, pralatrexate  is  a  more  effective  folylpolyglutamyl  synthetase  (FPGS)  substrate  than  methotrexate (Sirotnak  et  al.  1998),  which  indicates  that  internalization  and  accumulation  of  polyglutamated pralatrexate within tumour cells is more favourable. The uptake of natural folates into the cell is known to involve several protein carriers, including the reduced folate carrier (RFC), membrane folate binding protein (FBP, also known as folate receptor) and most likely also additional transporter systems yet to be determined.

Currently, there are no non-clinical models for peripheral T-cell lymphoma but pralatrexate was found to  have  growth  inhibitory  activity  in  a  broad  range  of  cancer  cell  lines.  Of  the  56  cancer  cell  lines tested, 39 cell lines (70%) were highly sensitive to the growth inhibitory effect of pralatrexate with 50%  growth  inhibition  concentrations  (GI50)  of  &lt;  0.1 μ M.  The  highest  frequency  of  pralatrexatesensitivity was observed in cancer cell lines of leukaemia (4 of 4 tested), colon (7 of 7 tested), and CNS (5 of 6 tested). In comparative in vitro  studies,  pralatrexate  consistently  exhibited  lower  IC50 values  than  methotrexate  in  the  tumour  cell  lines  tested  (acute  lymphocytic  leukaemia,  breast carcinoma, and non-small cell lung carcinoma cell lines).

Racemic pralatrexate and the individual diastereomers PDX-10a and PDX-10b showed similar cytotoxic activity against the CWR22-RV1 human prostate cancer line.

Pralatrexate  showed higher antitumor activity in  vitro and in  vivo in  mouse  xenograft  models  when compared  to  methotrexate.  This  appears  to  be  due  to  an  increased  cellular  uptake  and  a  higher polyglutamation.  Whether  these  findings  will  translate  to  a  better  antitumor  activity  in  the  clinical setting is not clear. The dose-limiting toxicity (gastrointestinal and haematological toxicity) is directly related  to  its  pharmacology.  It  is  not  clear  why  the  properties  resulting  in  higher  antitumor  activity would  not  result  in  an  equally  stronger  toxicity.  The  Applicant  presented  data  showing  minimal cytotoxicity with normal hepatocytes but these studies were not comparative, and the relevance of the cells  studied  is  questionable.  The  Applicant  also  stated  that  there  is  no  significant  cytotoxicity  to human PBMC, referring to an abstract where there were no data details and there was no comparison to methotrexate.

The  stronger  anti-tumour  activity  in  the  mouse  xenograft  models  cannot  be  translated  directly  to predict  stronger  anti-tumour  activity  in  humans.  The  xenograft  model  is  poorly  adapted  to  answer questions about therapeutic window. The anti-tumour activity is directed against human tumour cells, while toxicity is directed against the mouse tissue. It is clear that there are pronounced differences in the sensitivity to pralatrexate between mice and humans (no toxicity studies were performed in mice, but in the rat the exposure at the MTD was more than 10 times higher than at the MTD in patients). The determination of MTD in the mouse xenograft models is based on bodyweight increase which is of limited  relevance  for  the  human  situation.  The  micronucleus  genotoxicity  study  in  mice  (discussed further below) suggested that haematological toxicity may occur at doses magnitudes lower than those resulting in body weight loss.

It  is  concluded  that  non-clinical  data  have  shown  evidence  of  antitumor  activity  of  pralatrexate  and that there is activity at lower concentrations than with methotrexate. There are no data which would predict a stronger antitumor response in the clinical setting when the two compounds are given at the maximally tolerated dose.

The potential for pralatrexate to bind to secondary targets (receptor screening assay) has not been evaluated.  Considering  the  indication  and  the  serious  adverse  effects  associated  with  pralatrexate treatment, this is acceptable.

<div style=\"page-break-after: always\"></div>

The conducted safety pharmacology studies addressed cardiovascular, respiratory and central nervous system safety. The in  vitro study on cardiovascular safety showed inhibition of hERG but this effect was observed only at concentrations substantially higher than clinical exposure. The in vivo study in dogs showed no cardiovascular effects. Since the dog is very sensitive to the toxicity of pralatrexate, this study was performed at an exposure much lower than the clinical exposure. Toxicokinetics data from  repeat  dose  toxicity  study  at  the  same  dose  (0.7  mg/kg)  showed  a  C max approximately  three times  lower  than  the  clinical  C max (1793  ng/ml  vs.  4963  ng/ml).  While  there  are  no  signals  for cardiovascular effects from the nonclinical studies, the in vivo study provided only limited reassurance concerning cardiac safety, and clinical data are essential.

Pharmacokinetics studies were performed in rats and dogs. The data showed a similar pattern with an initial, rapid declined followed by a more gradual, terminal decline. The volume of distribution at steady state indicated extensive tissue distribution. No significant differences in PK parameters were observed for the two diasteroemers.

Tissue  distribution  of  pralatrexate  over  time  has  not  been  studied.  Tissue  distribution  at  168  hours after a single IV  14 C-pralatrexate dose in a mass balance study in rats showed the highest measurable content  in  liver  and  kidney.  The  potential  of  pralatrexate  to  penetrate  the  blood-brain  barrier  was assessed in an in situ rat brain perfusion model. The uptake rate of pralatrexate was comparable to that  of  methotrexate.  Binding  to  human  plasma  proteins  was  67-86%.v  Placental  transfer  and  milk excretion was not investigated.

Metabolism  studies  have  been  performed  by  incubation  with  human  hepatocytes  and  human  liver microsomes.  No  significant  metabolism  was  observed  in  these  studies.  No  studies  on in  vivo metabolism have been performed in animals. A human mass balance study is ongoing. In vitro studies suggest  limited  metabolism  of  pralatrexate,  and  considering  the  indication  and  the  toxicity  of pralatrexate itself it is agreed that no animal in vivo metabolism studies are required.

In rats, the primary route of excretion was faecal (44-66%), followed by urine (21-31%) and expired CO2 (6.4-10%). 70-92% of pralatrexate-related material was excreted in the first 24 hours following administration. In single-dose PK studies the renal excretion of the parent drug ranged from 3% to 20% in both rats and dogs. In ongoing clinical studies, the percentage of intact pralatrexate excreted in urine is 25-38% (range of the mean for PDX-10a and PDX-10b from studies PDX-007 and PDX-008). Biliary excretion or enterohepatic circulation was not investigated.

In competitive binding studies, pralatrexate did not significantly interfere with human plasma protein binding  of  6  reference  products,  nor  was  pralatrexate  displaced  to  a  significant  extent  from  human plasma proteins by 6 reference products. Further, pralatrexate did not significantly inhibit or induce CYP450 enzymes or P-glycoproteins.

Data from a dose-range finding study showed that a single IV dose 3 mg/kg (60 mg/m 2 ) was lethal to dogs. The dog is considered an appropriate non-clinical model for human anti-folate toxicity since dogs and  humans  have  nearly  identical  serum  folic  acid  and  thymidine  concentrations  (Branda,  1981; Nottebrock and Then, 1977). However, the rat is relatively insensitive to anti-folates since the serum folate and thymidine levels are approximately 8.5 and 16-fold higher than in humans, respectively. The rabbit  is  reported  to  have  a  7-fold  higher  serum  folate  level  than  in  humans,  while  the  thymidine concentration is 2.5-fold of the level in humans (Branda, 1981; Nottebrock and Then, 1977).

Toxicokinetic  analysis  showed  that  in  rat  the  mean  AUC  at  the  NOAEL  (5  mg/kg)  was  close  to  the clinical exposure and at the high dose (25 mg/kg) 10 times clinical exposure; in the dog, exposure at the highest dose (0.7 mg/kg) was only one third of the clinical exposure.

<div style=\"page-break-after: always\"></div>

All  adverse  findings  in  the  repeat-dose  toxicity  studies  appear  to  be  related  to  the  pharmacology  of pralatrexate and were primarily related to reversible gastrointestinal and haematological toxicities. The high sensitivity for pralatrexate of the dog results in exposure far below clinical exposure, while the rat appears to be much less sensitive than humans. Still, the toxicology data give sufficient reassurance that no other toxicity than the pharmacologically mediated toxicity is to be expected.

Pralatrexate  was  negative  in  a  standard  battery  of  genotoxicity  tests.  However,  in  the in  vitro chromosomal  aberration  test,  inhibition  of  mitosis  resulted  in  that  the  test  was  performed  at concentrations far below what is encountered in vivo in clinical use. In the mouse micronucleus study, an initial  range-finding  test  was  performed with doses of 5, 25, 100, 200 and 394 mg/kg IP. These doses  were  tolerated  (based  on  body  weight).  Based  on  these  results  a  micronucleus  assay  was performed  with  doses  of  100,  200  and  394  mg/kg.  However,  with  all  doses  the  frequencies  of polychromatic  erythrocytes  (PCE)  were  too  low  for  evaluation,  suggesting  haematological  toxicity. Following  protocol  amendment,  new  range-finding  tests  were  performed  and  the  final  micronucleus assay was performed at the doses 0.5, 1, 2, and 3 mg/kg. While no toxicokinetics data were generated in  mice,  these  doses  are  unlikely  to  result  in  exposures  exceeding  clinical  exposure.  No  firm conclusions on the genotoxic potential of pralatrexate can be drawn from the studies on chromosomal aberrations in vitro and in vivo . The CHMP noted that other folate analogues were either shown to be negative in the in vitro chromosomal aberration test but positive in the mouse micronucleus assay or stated to be mutagenic in vitro and in vivo . Therefore, based on the pharmacology of pralatrexate as well  as  experience  with  other  folate  analogues  an  increased  risk  for  genotoxicity  from  pralatrexate treatment cannot be excluded. This has been reflected in the proposed SmPC section 5.3.

No  carcinogenicity  studies  have  been  performed  with  pralatrexate  because  it  is  intended  to  treat patients with serious, life threatening cancer.

In studies on embryo-foetal toxicity no significant maternal toxicity in rats and rabbits was recorded at the  applied  high-dose  levels  0.06  and  1.0  mg/kg;  however  the  high  dose  level  of  pralatrexate  was embryo  toxic in both species. Embryo  toxicity was characterized by early resorptions, and post-implantation  loss.  Pralatrexate  did  not  cause  foetal  malformations.  The  maternal/foetal  no observed  effect  level  (NOEL)  was  considered  to  be  0.03  mg/kg/day  (0.18  mg/m 2 /day)  in  rats  and 0.1 mg/kg/day  (1.2 mg/m 2 /day)  in  rabbits.  However,  the  studies  on  embryo-foetal  toxicity  were performed at much lower doses than used in the repeat-dose toxicity studies (maximum dose in rat embryo-foetal toxicity study: 0.6 mg/kg; lowest dose in rat repeat-dose toxicity study: 5 mg/kg). This is understandable since dosing in the embryo-foetal toxicity was daily, while the repeat-dose toxicity study was performed with once weekly dosing. However, this means that exposures in the embryofoetal toxicity were below clinical exposure. No toxicokinetics were performed in the rat embryo-foetal toxicity  study,  but  in  a  dose-range  finding  study,  exposures  at  the  high  dose  2  mg/kg  was Cmax=  212 ng/ml and AUC= 277 ng·h/ml. These values are more than 10 times lower than clinical exposure. In the rabbit, toxicokinetics data from a dose range finding study showed exposures at 1 mg/kg (top dose in the pivotal study) to be Cmax=2560 ng/ml and AUC=2410 ng·h/ml. These values are  approximate  ½  of  the  clinical  exposure.  There  was  no  evidence  for  teratogenicity  in  any  of  the studies  with  pralatrexate.  However,  for  other  folate  analogues  a  teratogenic  potential  has  been reported. The CHMP considered it unlikely that pralatrexate does not share this property and it is likely that pralatrexate is embryotoxic in humans. The risk for teratogenicity is likely to be greater with a less intense  dosing  at  higher  doses  (such  as  the  once  weekly  dosing),  which  is  likely  to  result  in  less embryolethality.

In accordance with ICH S9, pralatrexate has not been studied with respect to effects on fertility and pre- and post-natal development. Due to the genotoxic properties of the related folate analogues, a similar  warning  has  been  included  in  the  proposed  SmPC  section  4.6  to  inform  that  women  of

<div style=\"page-break-after: always\"></div>

childbearing potential must use effective contraception during treatment with pralatrexate. Pralatrexate may have genetically damaging effects. Sexually mature males are advised not father a child  during treatment and up to 6 months thereafter. Barrier contraceptive measures or abstinence are  recommended.  Furthermore,  Folotyn  is  not  recommended  during  pregnancy  and  in  women  of childbearing potential not using contraception and it is contraindicated during breast-feeding.

Perivenous injection of pralatrexate at 40 mg/kg did not result in any local irritancy at the injection site in rats. Intradermal administration at 20 mg/kg produced minimal to mild irritancy in rats.

Nonclinical data on phototoxicity were  not submitted. Pralatrexate absorbs light  at  338  nm (hydrochloric acid conditions) and 372 nm (ammonium acetate conditions). Based on the calculated molar extension coefficients (11939 and 8118 L.mol -1 .cm -1 ),  it  cannot  be  excluded that a phototoxic potential is present. However, a rat distribution study indicated that the distribution of pralatrexate to the skin and eyes is negligible ( ≤ 0.52% of the administered dose). Moreover, the Applicant pointed out that it is not feasible to conduct a 3T3-NRU phototoxicity test due to the cytotoxic properties of pralatrexate.  In  the  mammalian  cell  genotoxicity  assay  the  mitotic  index  was  reduced  from  around 100% at 0.008 µg/ml to 16% at 2.5 µg/ml hence the cytotoxic properties of pralatrexate does not appear  to  preclude  phototoxicity  testing.  Safety  data  are  available  from  689  patients  treated  with pralatrexate.  Only  two  of  the  reported  dermatological  adverse  events  were  considered  related  to treatment. Moreover, the most commonly reported ocular adverse events were reduced visual acuity and eye pain; adverse events which do not appear to be caused by phototoxicity. Hence, based on the clinical safety data, pralatrexate appears to have a low ocular and dermatological phototoxic potential. Considering the relative stability of pralatrexate, the limited and transient distribution of pralatrexate to skin and eyes in rats, the rarity and poor prognosis of the relapsed/refractory PTCL population, the rare  clinical  occurrence  of  mild  AEs  of  phototoxicity  and/or  photosensitivity  related  to  pralatrexate treatment,  and  the  pharmacovigilance  measures  put  in  place  around  dermatologic  reactions,  nonclinical phototoxicity studies with pralatrexate are not warranted.

Pralatrexate is a folate analogue having anti-inflammatory activity, and therefore pralatrexate may be immunosuppressive.  Repeat-dose  toxicity  studies  in  dogs  showed  effects  on  parameters  associated with the immune system, i.e. thymic atrophy and hematologic toxicities, including reduced absolute lymphocyte counts.  No specific studies investigating pralatrexate immunotoxicity were performed. A warning in SmPC section 4.4 reflects that pralatrexate can suppress bone marrow function.

In  studies  on  impurities  the  starting  material  IN0222  (2,4-diamino-6-chlormethylpteridine)  was mutagenic  in  the  bacterial  reverse  mutation  assay.The  manufacturing  process  controls  the  residual starting material to such a level in pralatrexate drug substance, which is equivalent to a daily dose of IN0222 below the threshold of toxicological concern. Hence, the mutagenic property of IN0222 does not cause a safety concern.

Pralatrexate PECsurface water value is below the action limit of 0.01 μ g/L and is not a PBT substance as log Kow does not exceed 4.5.

## 2.3.6. Conclusion on non-clinical aspects

The  non-clinical  data  submitted  are  considered  adequate  to  support  the  marketing  authorisation application. There are no outstanding non-clinical issues.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The  Applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community  were  carried  out  in  accordance  with  the  ethical  standards  of  Directive  2001/20/EC. Furthermore,  the  Applicant  stated  that  the  two  main  studies  included  in  the  PTCL  clinical  study programme of pralatrexate, PDX-02-078 and PDX-008, were conducted according to the principles of Good Clinical Practice (GCP) and the Declaration of Helsinki.

Table 7 - Tabular overview of clinical studies

| Study ID   | Design                                   | Primary Objective                                                          | Study population           | Study population   | Study population   | Study population                                | Primary Endpoint   |
|------------|------------------------------------------|----------------------------------------------------------------------------|----------------------------|--------------------|--------------------|-------------------------------------------------|--------------------|
|            |                                          |                                                                            | Entered/ treated           | Gender M/F         | Median age         | Diagnosis                                       |                    |
| PDX-97-006 | Phase I, Non- randomised, open-label     | Establish weekly i.v. dosage                                               | 35/33                      | 15/18              | 57 yrs (35-77)     | NSCLC                                           |                    |
| PDX-99-053 | Phase II, Non- randomised, open-label    | Determine efficacy in 1st/2nd line                                         | 39/39                      | 13/26              | 57 yrs (40-71)     | Advanced NSCLC                                  | Response rate      |
| PDX-99-083 | Phase I, Non- randomised, open-label     | Dosage and safety in combination with a taxane                             | 51/48                      | 27/21              | 61.5 yrs (37-78)   | Advanced cancers                                |                    |
| PDX-01-014 | Phase I, Non- randomised, open-label     | Establish bi- weekly dose, safety, activity; given with probenicid         | 17/17                      | 8/9                | 57 yrs (33-80)     | Advanced solid tumours                          |                    |
| PDX-01-076 | Phase II, Non- randomised, open-label    | Determine efficacy of Pralatrexate as 1st line therapy                     | 17/16                      | 13/3               | 71. yrs (49-86)    | Unresectable pleural mesothelioma               | Response rate      |
| PDX-02-078 | Phase I/II, Non- randomised, open-label  | Determine efficacy + weekly dosage with vit. B12 and folic acid            | 72/72                      | 44/28              | 56.5 yrs (20-80)   | Relapsed or refractory NHL or Hodgkin lymphoma  |                    |
| PDX-008    | Phase II, Non- randomised, open-label    | Determine efficacy of Pralatrexate with B12 and folic acid supplementation | 115/111                    | 76/35              | 59 yrs (21-85)     | Relapsed or refractory PTCL                     | Response rate      |
| PDX-009    | Phase I/IIa, Non- randomised, open-label | Determine dose, safety and PK of Pralatrexate given with Gemcitabin        | Ongoing 62 treated         |                    |                    | Relapsed or refractory lymphoprol. Malignancies |                    |
| PDX-010    | Phase II, Non- randomised, open-label    | Determine optimal dose with vitamin B12 and folic acid                     | 48 treated at data cut-off |                    |                    | Relapsed or refractory CTCL                     |                    |

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

The  pharmacokinetics  of  pralatrexate  in  plasma  and  urine  was  primarily  evaluated  in  two  Phase  1 studies (PDX 99-083 and PDX-007) and in the pivotal Phase 2 study (PDX-008). In these studies, the individual R- and S-diasteromers at carbon 10 were analysed.

## Absorption

Not  applicable  as  Folotyn  is  an  aqueous  solution  for  IV  administration  that  contains  standard pharmaceutical excipients.

## Distribution

In study PDX-008, the mean Vdss values (CV%) were 105 L (75%) and 37 L (53%) for PDX-10a and PDX-10b, respectively.

In  vitro studies  indicated  moderately  high  plasma  protein  binding  of  pralatrexate  in  human  plasma, about 67% as determined by equilibrium dialysis and about 86% as determined by ultracentrifugation, and that the major binding protein is albumin.  Pralatrexate was found not to partition into red blood cells  to  any  significant  degree.  No  displacement  interactions  were  seen  with  highly  protein  bound reference compounds, which is expected given that pralatrexate is only moderately bound to plasma proteins and is suggested to be a low hepatic-extraction ratio substance.

Based on a study in MDR1-MDCK cells, pralatrexate appeared to be a low-permeability compound that is not a substrate for Pgp.

In  vitro studies  have  demonstrated  that  pralatrexate  is  a  substrate  to  the  uptake  transporters OATP1B1 and OATP1B3, and to the efflux transporters BCRP, MRP2 and MRP3.

## Elimination

Pralatrexate demonstrated a multiphasic decline in plasma concentrations, with a slow terminal phase that is suggested not to substantially contribute to the total exposure or total clearance. The decline of both diastereomers was similar; however, PDX-10b plasma concentrations were about 50-100% higher than  the  PDX-10a  concentrations  at  most  time  points.  The  data  suggested  that  both  pralatrexate diastereomers  have  relatively  low  clearance  values,  moderate  volumes  of  distribution  and  relatively long  terminal  half-lives.  PDX-10b  had  lower  values  for  total  clearance  (CL tot )  and  Vdss,  while  the terminal half-lives were relatively similar for the two diastereomers. After a 30 mg/m 2  dose, the mean CLtot was 417 and 191 ml/min for PDX-10a and PDX-10b, respectively. The mean terminal t1/2 was 18 and 12 hours for PDX-10a and PDX-10b, respectively.

Both pralatrexate diastereomers were excreted unchanged in urine with mean fe values of 31% and 38% for PDX-10a and PDX-10b, respectively. Assuming a fu of ~0.33, the degree of renal clearance indicates that both diastereomers undergo net renal tubular secretion, i.e. via active transport.

The results of the different in vitro metabolism studies all indicated negligible phase I as well as phase II  metabolism  of  pralatrexate.  No  metabolites  have  been  structurally  identified.  It  is  considered unlikely that hepatic metabolism is an important route of elimination for pralatrexate. As there is no mass-balance data yet, extra-hepatic tissue metabolism cannot be completely ruled out. The related compound, methotrexate is, however, reported not to be significantly metabolised, either by hepatic or extra-hepatic mechanisms, but to be primarily excreted unchanged.

<div style=\"page-break-after: always\"></div>

Overall, renal excretion of unchanged substance appeared to account for approximately one third of the total clearance of pralatrexate. The major part of the elimination, on average more than 60%, is therefore  expected  to  be  via  non-renal  routes.  As  there  was  no  significant  hepatic  metabolism  of pralatrexate, the non-renal elimination might be via biliary excretion of unchanged substance and/or extra-hepatic tissue metabolism. There is not yet any human mass-balance data, so the mechanisms for  non-renal  clearance,  or  their  relative  importance,  cannot  be  evaluated.  However,  as  both  renal tubular secretion and, highly likely, biliary excretion of unchanged parent compound are important for the elimination of pralatrexate, renal and hepatic uptake and efflux transporters are expected to be involved to a significant degree. Based on in vitro transport studies, the Applicant suggested that the major  elimination  pathway  for  pralatrexate  may  be  OATP1B1-mediated  sinusoidal  hepatocellular uptake and subsequent MRP2/BCRP-mediated canalicular efflux of pralatrexate, leading to biliary/faecal excretion.

A human mass-balance study is ongoing, but enrolment into the study has been put on hold while a more stable  14 C-pralatrexate is being developed.

Due to the low degree of hepatic metabolism, genetic polymorphism in hepatic metabolising enzymes is  not  an  issue.  On  the  other  hand,  pralatrexate  is  substrate  to  transport  proteins  that  are polymorphically expressed.

For example, the reduced folate carrier protein (RFC-1), responsible for uptake of folates into cells, is polymorphically  expressed,  which  may  lead  to  variation  in  pharmacodynamic  response  as  well  as, possibly, in renal elimination. However, currently available data do not allow for a recommendation of pre-treatment genotyping. The Applicant suggests that as that there are many important components in the pathway, changes in one component may be counteracted by changes in another pathway. For example, the effects of reduced expression of the reduced folate carrier (RFC-1) can be counteracted by increased expression of folylpolyglutamyl synthetase (FPGS) or reduced expression of dihydrofolate reductase (DHFR).

Hepatic  transporters  might  potentially  be  involved  in  the  development  of  pralatrexate-induced hepatotoxicity, although there is yet no data to support this assumption. As a speculative example, MRP2 is a transporter that transports bilirubin out of the hepatocyte and into the bile. In subjects with Dubin-Johnson syndrome (Rotor syndrome) MRP2 is defect or lacking. In these patients, MRP3, which transports  certain  compounds  out  of  the  hepatocyte  into  the  blood,  is  upregulated  and  thereby compensates for the lack of MRP2. Inhibition of MRP3 by pralatrexate in these patients might possibly lead to accumulation of bilirubin in the hepatocytes.

## Dose proportionality and time dependencies

There  was  no  obvious  non-linearity  in  pralatrexate  pharmacokinetics  over  the  studied  dose  range, 30 mg/m 2  to 325 mg/m 2 , although there was a large variability in the data. The pharmacokinetics of pralatrexate did not change significantly over multiple treatment cycles and no relevant accumulation of pralatrexate was observed at once weekly administration.

Pralatrexate pharmacokinetics display high inter-individual variability, with coefficients of variation for pharmacokinetic parameters often exceeding 50%. The variability seemed to be somewhat smaller for the PDX-10b than for the PDX-10a diastereomer. Normalisation of CLtot or Vdss to body weight (BW) or body surface area (BSA) did not improve the population variability.

<div style=\"page-break-after: always\"></div>

## Special populations

##  Impaired renal function

There  was  no  specific  study  of pralatrexate in  patients  with  renal  impairment.  In  the  noncompartmental  co-variate  analysis  including  e.g.  age,  gender,  bodyweight  (BW),  BSA,  CLcrea  and serum creatinine, only age and CLcrea were statistically significant covariates for pralatrexate CLtot. These co-variates accounted for only approximately 10% of the variability in CLtot for PDX-10a and PDX-10b, respectively, and the Applicant considered that a dose reduction is not necessary within the range of CLcrea and age included in the study.

Data in  renal  impairment  is  currently  very  limited,  but  a  specific  study  is  ongoing.  Pharmacokinetic data  from  other  studies  including  patients  with  mild-moderate  impairment  (creatinine  clearance 53-130 ml/min), indicated that total clearance would be approximately 20% lower in a subject with creatinine clearance of 30 ml/min compared with a subject with creatinine clearance of 80 ml/min or above.  At  severe  renal  impairment,  the  non-renal  elimination  might  also  be  affected,  e.g.  due  to inhibition  of  hepatic  transporters  by  urinary  toxins,  and  a  disproportionally  larger  effect  on  total clearance than that predicted from data on CLcrea &gt; 30 ml/min might possibly be expected.

##  Impaired hepatic function

There was no specific study in patients with hepatic impairment. In the non-compartmental co-variate analysis, the laboratory markers Albumin, Bilirubin and Hb were not statistically significant co-variates for pralatrexate clearance. The range of these co-variates was 2.7-4.5 g/dl for albumin, 0.2-1.6 mg/dl for bilirubin and 9.0-15.5 g/dl for Hb. There was no assessment of the hepatic function markers (AST, ALT and TBIL) in the population PK analysis.

Although non-renal mechanisms accounts for the major part of pralatrexate clearance, the lack of a specific study in hepatic impairment is currently acceptable, given that such a study would need to be performed  in  the  target  patient  population,  and  recruitment  would  therefore  likely  be  difficult.  As biliary  excretion  is  likely  an  important  route  of  elimination  for  pralatrexate,  and  hepatic  impairment therefore might be expected to lead to increased exposure, caution is advised in patients with hepatic impairment. A contraindication was not considered appropriate given the proposed indication. Data are currently not sufficient for evaluation of whether patients with pre-existing hepatic impairment have a higher risk of developing hepatotoxicity from pralatrexate treatment (see safety assessment).

##  Gender

The  integrated  non-compartmental  pharmacokinetic  analysis  (n=54)  included  52%  female  and  48% male patients. There was no correlation between gender and pralatrexate clearance in this analysis.

The  population  pharmacokinetic  analysis  (n=154)  included  61%  males  and  39%  females  and  the estimated effect on pralatrexate clearance was small (15% lower clearance in women).

##  Race

The integrated non-compartmental pharmacokinetic analysis (n=54) included 82% White, 15% Black, and 2% Asian patients. One patient (2 %) was of unknown ethnicity.

Covariate analysis did not reveal race as a significant covariate, however, data are not sufficient to draw any conclusions on potential ethnical differences.

<div style=\"page-break-after: always\"></div>

##  Weight

The  patients  included  in  the  integrated  non-compartmental  pharmacokinetic  analysis  (n=54)  had  a weight range of 43 to 127 kg (mean 77 kg). Their creatinine clearance ranged from 53 to 130 ml/min (mean 89 ml/min). The population pharmacokinetic analysis (n=154) included patients up to 85 years.

Weight  or  BSA  were  not  statistically  significant  co-variates  for  pralatrexate  clearance  in  the  noncompartmental analysis.

This analysis does therefore not support dosing based on BSA. Available data might indicate that BSAbased dosing to some extent will add to the overall variability, with higher exposure in larger patients and lower exposure in smaller patients. Differences in BSA would, however, only explain a part of the total  pharmacokinetic  variability.  Potential  overdosing  will  be  handled  by  monitoring  of  side  effects followed by dose reductions/interruptions. In addition, the Applicant presented data demonstrating no or  only  a  weak  relationship  between  BSA  and  effect  of  pralatrexate  on  different  haematological parameters,  which  is  considered  to  reassure  that  BSA-based  dosing  will  not  lead  to  significant underexposure in low-weight patients. There is, however, no or only limited data for BSA extremes.

##  Elderly

The  patients  included  in  the  integrated  non-compartmental  pharmacokinetic  analysis  (n=54)  were within  the  age  range  24-77  years  (mean  60  years).  The  covariate  analysis  revealed  age  as  a statistically significant covariate for pralatrexate clearance. However,  this accounted for only approximately 10% of the observed population variability and the effect was relatively small and is suggested to reflect the decline in renal function with age.

The population PK analysis did not allow for an evaluation of the effect of age.

##  Children

There was no data in children.

## Pharmacokinetic interaction studies

## Effects of pralatrexate on concomitant medications

In  vitro studies  demonstrated  no  relevant  inhibition  by  pralatrexate  of  CYP1A2,  CYP2A6,  CYP2B6 CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.

The  concentrations  in  the in  vitro induction  studies  were  a  bit  too  low  to  completely  rule  out  an induction potential of pralatrexate, however, clinically relevant induction is not expected at intermittent, once weekly administration.

In vitro , pralatrexate was a potent inhibitor of MRP3. The clinical importance of this inhibition is unclear. The Applicant  proposed  warnings  against  concomitant  administration  of  the  known  MRP3  substrates etoposide, tenoposide and methotrexate. MRP3 transports certain substances from the hepatocyte into the blood. Theoretically, inhibition of MRP3 might lead to accumulation of potentially toxic substances in the hepatocyte.

Pralatrexate did not inhibit Pgp, BCRP, OTC2, OAT1 or OAT3 in vitro , and was only a weak inhibitor of OATP1B1 and OATP1B3.

## Effects of concomitant medications on pralatrexate

As  pralatrexate  is  not  subject  to  hepatic  metabolism,  clinically  relevant  effects  of  CYP  inhibitors  or inducers on pralatrexate pharmacokinetics are not expected.

<div style=\"page-break-after: always\"></div>

At combination of pralatrexate with probenecid, tolerability was decreased and the AUC of pralatrexate increased, likely due to inhibition of renal tubular secretion and presumably also by inhibition of cellular efflux.

The  Applicant  also  proposed  warnings  against  concomitant  administration  of  substances  that  affect glomerular  filtration  or  renal  secretion.  As  there  is  no  such  interaction  data  for  pralatrexate,  the Applicant based the proposal on warnings given for the previously approved methotrexate, pemetrexed and raltitrexed, which all have an even higher degree of renal clearance than pralatrexate.

Pralatrexate  is  a  substrate  to  BCRP,  OATP1B1,  MRP2,  MRP3  and  OATP1B3,  with  highest  affinity  for OATP1B3. The Applicant suggested that the risk for a relevant effect on pralatrexate pharmacokinetics by an inhibitor of one of these transporters may be low as pralatrexate is a substrate for a number of different transporters. However, as the transporters have different functions and are part of a chain of event (e.g. uptake-efflux) it is not evident that inhibition of one transporter may be compensated by another  transporter.  Nevertheless,  it  is  agreed  that  current  knowledge  is  not  sufficient  to  include specific  warnings  regarding  transport  inhibition,  except  for  the  warnings  against  probenecid  and substances that are known to affect renal secretion.

## Pharmacokinetics using human biomaterials

Not applicable.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Pralatrexate  is  a  new  anti-neoplastic  folate  analogue  that in  vitro was  shown  to  be  more  efficiently transported into the cells and more efficiently polyglutamated than methotrexate.

Pralatrexate has high affinity for the reduced folate carrier 1 protein and is an efficient substrate for polyglutamation by the enzyme folylpolyglutamyl synthetase, resulting in extensive internalization and accumulation  within  tumour  cells.    Pralatrexate  exerts  antifolate  activity  via  the  inhibition  of  the enzyme  dihydrofolate  reductase  (DHFR)  in  the  folic  acid  metabolic  pathway.    Folate  undergoes reduction  to  dihydrofolate,  which  in  turn  is  then  reduced  to  tetrahydrofolate  (THF)  by  the  action  of DHFR.  THF is required for the synthesis and catabolism of several amino acids, formation of creatine and choline, synthesis of purines, methylation of RNA, and synthesis of deoxythymidine monophosphate and thus synthesis of DNA.  The inhibition of the metabolic pathways thus provides the basis for the cytotoxic activity of antifolate agents such as pralatrexate.

## Primary and Secondary pharmacology

No specific studies on primary pharmacology in humans were performed in addition to the in vitro PD studies discussed in section 2.3.2.

Cardiovascular  safety  assessment  in  in-vitro  studies  showed  that  pralatrexate  does  not  inhibit  the human ether-a-go-go-related gene (hERG) or affect dog Purkinje fiber action potential at concentrations well above the clinically observed Cmax.  A QTc assessment was completed in a subgroup of 14 evaluable NSCLC patients in PDX-007.  Patients were treated with pralatrexate doses of 190 or 230 mg/m 2  administered IV over 3 - 5 minutes or over 60 minutes. 12-lead electrocardiograms (ECGs) were performed at screening, at baseline (just prior to pralatrexate injection), at the end of infusion,  and  1,  3  and  6 hours  post-infusion  in  conjunction  with  pralatrexate  plasma  PK  collections. Pralatrexate demonstrated only a minimal impact on cardiac repolarisation with no patient exhibiting a

<div style=\"page-break-after: always\"></div>

QTc interval  500 msec.  There was no correlation observed between either maximum or mean QTc changes  post-injection  with  pralatrexate  exposures  (Cmax  or  AUC ∞ ).    The  mean  Cmax  and  AUC ∞ values  observed  in  patients  dosed  at  190  mg/m 2 were  approximately  5-fold  higher  than  the  mean values  observed  in  PDX-008;  these  findings  suggest  that  pralatrexate  is  unlikely  to  markedly  delay cardiac repolarisation in PTCL patients treated with pralatrexate doses ≤ 30 mg/m 2 .

## 2.4.4. Discussion on clinical pharmacology

The pharmacokinetic profile in plasma and urine of the two pralatrexate diastereomers is considered sufficiently studied in the target population, at the proposed clinical dose of 30 mg/m 2 .

Protein binding, distribution to blood cells, permeability over Pgp-expressing cells, substrate specificity/inhibition potential for certain transport  proteins  and  hepatic  metabolism  has  been thoroughly investigated in vitro . No hepatic metabolism was observed. As it has not yet been possible to finalise the mass-balance study due to instability of the radiolabel, there is still some uncertainty regarding  the  non-renal  metabolism  pathways,  which  account  for  about  2/3  of  the  total  clearance. Based  on in  vitro transport  studies,  the  Applicant  suggests  that  the  major  elimination  pathway  for pralatrexate may be OATP1B1-mediated sinusoidal hepatocellular uptake and subsequent MRP2/BCRPmediated canalicular efflux of pralatrexate, leading to biliary/faecal excretion.

There is  no  specific  data  in  patients  with  organ  impairment.  A  study  in  renally  impaired  patients  is planned. Some patients with mild to moderate renal impairment (CLcrea &gt; 50 ml/min) were included in  the  pharmacokinetic  studies,  but  for  severe  renal  impairment  and  for  hepatic  impairment, recommendations will presently need to be based on theoretical considerations.

In  vitro inhibition  studies  demonstrated  no  potential  or  pralatrexate  to  inhibit  CYP450  metabolising enzymes.  Pralatrexate  was,  however,  a  potent  inhibitor  of  the  efflux  transporter  MRP3.  The  clinical relevance of such inhibition is currently unclear.

Probenecid decreased clearance as well as tolerability of pralatrexate, likely by effecting renal secretion and possibly tissue distribution. Pralatrexate may interact also with other substances that are actively secreted or known to inhibit active renal secretion.

## 2.4.5. Conclusions on clinical pharmacology

At present, the in vivo data on pralatrexate pharmacokinetics are considered sufficient. The data from the ongoing mass-balance study and renal impairment study should be submitted when available.

Also  the  provided in  vitro data  on  metabolism,  transport  proteins  and  CYP  inhibition  are  considered sufficient, although the clinical implications of the transporter data are yet largely unknown.

In vitro studies in leukaemia cells have shown that pralatrexate is more efficiently transported into the cells and  more  efficiently polyglutamated  than methotrexate. These  improvements  in  cellular pharmacokinetics are suggested to lead to improved cytotoxic activity of pralatrexate compared with methotrexate. Whether toxicity is similarly affected is unknown.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study

No formal dose-response studies were reported.  See Supportive Studies for a description of phase I-II studies.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study

PDX-008: A  Multi-center,  Phase  2,  Open-label  Study  of  (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.

## Methods

## Study Participants

## Inclusion criteria, selected

1. Patient  recruited  into  the  study  had  histologically/cytologically  confirmed  PTCL,  using  the  Revised European American Lymphoma (REAL) WHO disease classification:
2.  T/NK-cell leukaemia/lymphoma
3.  Adult T-cell lymphoma/leukaemia (human T-cell leukaemia virus [HTLV] 1+)
4.  Angioimmunoblastic T-cell lymphoma
5.  Blastic NK lymphoma (with skin, lymph node, or visceral involvement)
6.  Anaplastic large cell lymphoma (ALCL), primary systemic type
7.  PTCL - unspecified
8.  T/NK-cell lymphoma - nasal
9.  Enteropathy-type intestinal lymphoma
10.  Hepatosplenic T-cell lymphoma
11.  Extranodal peripheral T/NK-cell lymphoma - unspecified
12.  Subcutaneous panniculitis T-cell lymphoma
13.  Transformed mycosis fungoides
2. Patient  had  documented  PD  after  at  least  1  prior  treatment.  Patients  may  not  have received  an experimental drug or biologic as their only prior therapy. Patient must have had clear PD after the last treatment received. Patient had at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL.
3. ECOG performance status ≤ 2.
4. At least 18 years of age.
5. Adequate  haematological,  hepatic,  and  renal  function  as  defined  by:  absolute neutrophil  count (ANC) ≥ 1000/ μ L, platelet count ≥ 100,000/ μ L (at both screening and within 3 days prior to dosing on  cycle  1,  day  1),  total  bilirubin ≤ 1.5  mg/dL, aspartate  aminotransferase  (AST)  and  alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), (AST/ALT &lt; 5 × ULN if documented hepatic involvement with lymphoma), creatinine ≤ 1.5 mg/dL (if the patient's creatinine was &gt; 1.5 mg/dL, then the calculated creatinine clearance must have been ≥ 50 mL/minute).

## Exclusion criteria, selected

## 1. Patient had:

-  Precursor T/NK neoplasms, with the exception of blastic NK lymphoma

<div style=\"page-break-after: always\"></div>

-  T-cell prolymphocytic leukaemia (T-PLL)
-  T-cell large granular lymphocytic leukaemia
-  Mycosis fungoides, other than transformed mycosis fungoides
-  Sézary syndrome
-  Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
2. Congestive heart failure Class III/IV according to the NYHA Guidelines.
3. Uncontrolled hypertension.
4. Human  immunodeficiency  virus  (HIV)-positive  diagnosis  and  was  receiving  combination  antiretroviral therapy.
5. Patient had, or had history of, brain metastases or central nervous system (CNS) disease.
6. Patient had undergone an allogeneic SCT.
7. Patient had relapsed less than 75 days from time of an autologous SCT.
8. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas  or  mitomycin  C)  prior  to  study  treatment  or  planned  use  during  the  course  of  the study.
9. Receipt  of  corticosteroids  within  7  days  of  study  treatment,  unless  patient  had  been  taking  a continuous dose of no more than 10 mg/day of prednisone for at least 1 month.
10. Previous exposure to pralatrexate.

## Treatments

## Pralatrexate administration

One  cycle  of  pralatrexate  therapy  was  7  weeks  in  duration  and  consisted  of  6  weekly  doses  of pralatrexate  IV  push  over  3-5  minutes,  followed  by  1  week  of  rest.  The  dose  of  pralatrexate was 30 mg/m 2 /week.

Dose reduction to 20 mg/m 2 due to toxicity was allowed per protocol-defined criteria for haematological  toxicities,  mucosal  inflammation,  and  other  treatment-related  non-haematological toxicities.  No  further  dose  reductions  were  allowed.  If  the  patient  developed  an  AE  indicating intolerance  of  this  lower  dose  of  20 mg/m 2 /week,  the  patient  was  to  be  discontinued  from  study treatment. Re-escalation of the pralatrexate dose once a dose reduction occurred was not allowed.

## Vitamin administration

Vitamin supplementation began after a patient's blood has been collected for MMA and Hcy analysis at screening based on the following:

-  If the patient's MMA level was &gt; 200 nmol/L and/or Hcy was &gt; 10 μ mol/L at screening, vitamin supplementation  was  initiated  at  least  10  days  prior  to  pralatrexate  administration on  cycle  1, dose 1.
-  If, however, MMA and Hcy results were within normal range, pralatrexate dosing could be started immediately (it was not necessary to wait 10 days).

Vitamin supplementation consisted of vitamin B12 1 mg intramuscular (IM) every (q) 8-10 weeks, and folic  acid  1.0-1.25 mg, orally (po) every day (qd). Once pralatrexate was permanently discontinued,

<div style=\"page-break-after: always\"></div>

vitamin supplementation continued at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.

## Therapies not permitted

While on treatment with pralatrexate, steroids were not allowed for prophylaxis or treatment. Any form of  additional  therapy  for  T-cell  lymphoma  was  not  permitted  during  treatment  with pralatrexate, including radiation therapy, other cytotoxic agents, biologic, or immune response modifiers.

## Duration of therapy

Patients were treated with pralatrexate (6 weeks of treatment followed by 1 week of rest) for up to 24 months or until at least 1 of several pre-determined study treatment discontinuation criteria were met. Criteria for study treatment discontinuation were:

-  Development of PD
-  Initiation of radiotherapy or systemic chemo/biologic therapy for T-cell lymphoma
-  Development of an AE indicating intolerance of the lowest study dose allowed (20 mg/m 2 /week)
-  Omission of 3 sequential doses of pralatrexate due to a treatment-related AE
-  Development of an AE, intercurrent illness, condition, or procedural complication
-  that may interfere with the patient's participation
-  Withdrawal of consent
-  Death of patient
-  Investigator decision
-  Sponsor decision
-  Treatment with pralatrexate for 24 months

## Objectives

The primary objective was to determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL.

Secondary objectives were to determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL as well as to determine the PK  profile of pralatrexate when  administered  with vitamin B12  and  folic acid supplementation.

## Outcomes/endpoints

The primary efficacy endpoint in PDX-008 was response rate defined as the number of responders (CR + CRu + PR) divided by the number of evaluable patients.

The Secondary efficacy variables were:

-  Duration  of  response;  defined  as  the  number  of  days  between  the  date  of  first  tumour response assessment of objective response (including CR, CRu, and PR) to the time of the first tumour response assessment of PD or death due to any cause

<div style=\"page-break-after: always\"></div>

-  PFS; number of days from study day 1 to the date of PD per central radiology review or death, regardless of cause
-  OS; number of days from study day 1 to death

Exploratory analyses included:

-  Evaluation of the correlation between response rate and survival.
-  A retrospective analysis comparing the investigators' assessment of response rate and PFS with the same endpoints for the immediate prior therapy for patients entered into the study.
-  Exploration of the effect of pralatrexate on progressive resistance to consecutive prior treatments.

## Response assessment

Response was assessed on the basis of clinical, radiological, and pathological criteria. Response was assessed  by  independent  central  review  according  to  IWC  and  by  the treating  investigator.  Central review assessors were blinded to the response assessments by the treating investigator. The primary analysis was based on response assessed by central review.

As  the  IWC  (Cheson  et  al.,  1999)  did  not  address  incorporation  of  cutaneous  disease  into  the assessment  of  response,  the charter  used  by  the  independent  central  review  established  rules for incorporation of the cutaneous disease into response assessments. Positron-emission tomography (PET) scans  were  also  collected  throughout  the  study  at  the  baseline  and  response  assessment visits for the purpose of an exploratory analysis.

The following procedures/tests were performed for evaluation of response:

1. Radiographic imaging (using same imaging technique as screening):
2.  CT of chest, neck, abdomen, and pelvis
3.  Other  imaging  techniques  documenting  disease  site(s)  other  than  chest,  neck,  abdomen,  or pelvis, if applicable.
4.  Exploratory: Whole body PET (Note: PET imaging was not necessary if PD according to the IWC documented by clinical examination, CT or other imaging technique)
2. Physical examination to assess liver, spleen, lymph nodes, and skin (included medical photography with ruler measurements for documentation of any skin lesions).
3. LDH level determination.
4. If the patient's screening bone marrow biopsy/aspirate results were positive or indeterminate and the patient had a confirmed CR, a repeat bone marrow biopsy and aspirate assessment was to be performed. Prior to Amendment 4 (04 Oct 2006) of the protocol, if a patient's screening bone marrow biopsy/aspirate results were positive or indeterminate and the patient had a confirmed CR by imaging, a repeat bone marrow biopsy and aspirate assessment by flow cytometry were required per the protocol. Effective with Amendment 4, the bone marrow flow cytometry assessment was no longer required. If bone marrow aspirate flow cytometry was performed, results were to be sent to the central pathology reviewer. Once a patient's bone marrow was negative for lymphoma, the bone marrow biopsy was only repeated when clinically indicated unless it was the patient's only site of disease.
5. A tumour biopsy could be performed if needed to confirm a response evaluation.

<div style=\"page-break-after: always\"></div>

6. If peripheral blood flow cytometry was performed, results were to be sent to the central pathology reviewer.

## On-study assessments

Evaluation  of  response  was  to  be  performed  within  7  days  prior  to  the  projected  first  dose  of the second  cycle  and  then  within  7  days  prior  to  the  projected  first  dose  of  every  even numbered subsequent cycle (i.e. prior to cycles 4, 6, 8, etc), see overview below.

Figure 1

<!-- image -->

## Post-treatment follow-up

All patients who received at least 1 dose of pralatrexate were to attend routine follow-up visits every 3 months  (±  2  weeks)  after  the  safety  follow-up  visit  (to  occur  35  ±  5  days  after the  last  dose  of pralatrexate) until PD was determined or subsequent treatment for T-cell lymphoma was initiated. The frequency  of  response  assessments  for  those  patients  who  sustained  a  CR  for  at  least 1  year  was based on the institution's standard of care and was no longer required every 3 months. Once PD was documented or subsequent treatment for T-cell lymphoma was initiated, routine follow-up visits were no longer required. Patients were followed for survival and subsequent treatment for T-cell lymphoma every 6 months for a total duration of 2 years after the first dose of pralatrexate.

## Sample size

A 2-stage Simon design was employed for this study. A minimum of 100 patients were to be recruited based on a null hypothesis of a true response rate of 15% and an alternative hypothesis of a true response  rate  of  27%.  Given  response  rates  p0  and  p1  of  15%  and  27%  respectively  and  error probabilities, α and 1β , of 2.2% and 84.3% at least 4 out of 35 patients had to experience a response in Stage 1 for the trial to proceed to Stage 2. In Stage 2, 65 additional patients were to be enrolled where at least 23 out of the total 100 patients had to show response in order to exclude 15% with a 95% confidence interval for the response rate. Since the above properties are not explicitly stated in the Simon paper, they were derived using equation (1) under the 'Optimal Two-Stage Designs' section of the Simon reference.

The levels of response rates p0 and p1 were chosen based on the assumption that a response rate of 20% was considered  a  good  indicator  of  activity  with  any  new  treatment  in  the  patient  population comprised in the current protocol.

## Randomisation

## Not applicable

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

Not applicable

## Statistical methods

Analyses of primary and secondary efficacy endpoints were based on all evaluable patients. A patient was considered evaluable if he/she received at least 1 dose of pralatrexate and had the diagnosis of eligible  PTCL  histopathological  subtype  confirmed  by  central  pathology  review.  The  presentation  of safety endpoints were based on all enrolled patients who received at least 1 dose of pralatrexate.

Response rate was estimated using response data received from central review with a 95% confidence interval  calculated  using  the  binomial  density  function.  Response  rate  based  on  investigators' assessments were also to be reported.

Duration of response was measured from the first day of documented response to disease progression or  death.  Patients  receiving  subsequent  therapy  (including  transplant)  before  documentation  of  PD were censored. In addition to duration of response, duration of treatment for responding patients was to be presented.

PFS and OS were estimated using the Kaplan-Meier product-limit estimator.

Patients who  were  alive  without  a  disease  response  assessment  of  PD  were  censored  at  the  last disease assessment date or the date of first dose, whichever was later. Date of progression was not to be imputed for patients with missing tumour assessment(s) during treatment before an assessment of PD. These patients were considered as having PD on the date of the actual assessment of PD or they were censored at the date of their last assessment (at which there was no progression) or study day 1, whichever  occurred  later.  Patients  who  withdraw  consent  to  participate  in  the  study prior to progression were censored at the date of their last disease assessment (or study day 1, whichever was later). Patients who withdraw from treatment prior to progression without withdrawing consent were followed for disease status and survival whenever possible. These patients were censored at their last tumour assessment or initiation of subsequent anti-cancer therapy, whichever came first, if they had not  progressed  by  that  time.  Patients  who  did  not  have response  assessments  after  baseline  were censored at study day 1.

Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last  contact.  Patients  who  withdraw  consent  to  participate  in  the  study,  including  consent  to  be followed,  were  censored  on  the  date  of  withdrawal.  Patients  who  withdraw  from  treatment  without withdrawing consent were to be followed for survival status.

Additional efficacy analyses not described in the Statistical Analysis Plan were performed regarding the relationship between response and survival. Two main approaches were employed; a Cox model with a time-dependent covariate indicating each patient's responder status over time and a method referred to as 'the landmark method'. In the latter a time-point (landmark) was chosen post enrolment and all patients who were alive at that time-point were categorized as either responders or non-responders and responder status was included as a binary covariate in a Cox model.

In addition, in order to explore a hypothesis of progressive resistance with the objective to establish clinical benefit, retrospective analyses were performed where patients' response rates and PFS to prior therapies were analysed using patients as their own control.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

## Recruitment

Patients  were  enrolled  between  24  August  2006  and  14  April  2008  across  25  study  centres  (out  of 35 activated);  15  centres  enrolled  80  patients  in  US,  8 centres  enrolled  26  patients  in  Europe,  and 2 centres enrolled 9 patients in Canada. The database cut-off was performed on 17 August 2009.

The DMC reviewed data tables on 21 September 2007 for the first 35 treated patients. The threshold for response rate for Stage 1 of the trial (at least 4 out of 35 patients responding) had been exceeded and the DMC recommended that the trial should continue as planned.

## Conduct of the study

Six amendments  were  made  to  the  initial study protocol.  Only  one  of  these  amendments, amendment 6, was made after the first patient inclusion. This amendment was made to allow patients to  continue  treatment  with  pralatrexate  beyond  24 months  after  their  initial  dose  if  they  were

<div style=\"page-break-after: always\"></div>

experiencing clinical benefit per the investigator's judgment. In amendment 5 amongst other changes the eligibility criterion regarding platelets was increased from 50,000/µL to 100,000/µL.

Two  different  protocol  deviations  occurred:  Receipt  of  a  prohibited  concomitant  medication  per  the protocol  (no=6,  all  due  to  corticosteroid  therapy),  and  failure  to  adhere  to  protocol-specified  dose modification rules (no=17).

## Baseline data

The majority of patients were male, white and ≥ 65 years old. The median age was 59 years. A male predominance has been described in PTCL.

## Table 8 Patient demographics

<!-- image -->

| Parameter         | Value     | Efficacy Analysis Set (N =109)   |
|-------------------|-----------|----------------------------------|
| Gender n (%)      | Male      | 74 (68)                          |
|                   | Female    | 35 (32)                          |
| Race n (%)        | White     | 79 (72)                          |
|                   | Black     | 13 (12)                          |
|                   | Asian     | 6 (6)                            |
|                   | Hispanic  | 9 (8)                            |
|                   | Other     | 1 (<1)                           |
|                   | Unknown   | 1 (<1)                           |
| Age (years) n (%) | <65       | 70 (64)                          |
|                   | ≥65       | 39 (36)                          |
|                   | Median    | 59.0                             |
|                   | Mean      | 57.9                             |
|                   | Std Dev   | 14                               |
|                   | Min - Max | 21-85                            |
|                   | N Missing | 0                                |

PTCL-unspecified was the most common entity enrolled, representing more than half of the patients, followed by ALCL, primary systemic type.

Table 9 Histopathology per central review; efficacy analysis set

|                                                                       | (N=109)   | (N=109)   |
|-----------------------------------------------------------------------|-----------|-----------|
|                                                                       | n         | (%)       |
| PTCL-unspecified                                                      | 59        | (54)      |
| Anaplastic large cell lymphoma,primarysystemictype                    | 17        | (16)      |
| AngioimmunoblasticT-celllymphoma                                      | 13        | (12)      |
| Transformed mycosis 6fungoides                                        | 12        | (11)      |
| BlasticNK lymphoma a (with skin, lymph node, or visceral involvement) | 4         | (4)       |
| T/NK-cell lymphoma-nasal                                              | 2         | (2)       |
| Extranodal peripheral T/NK-cell lymphoma unspecified                  | 1         | (<1)      |
| Adult T-cell leukemia/lymphoma (HTLV 1+)                              | 1         | (<1)      |

<div style=\"page-break-after: always\"></div>

Median number of prior systemic regimens was 3, with almost 1/3 of patients having received 4 or more regimens. Twenty-four percent of patients had not responded (CR/PR) to any previous therapy and 64% of patients did not respond to the most recent prior therapy. Thus, a heavily pre-treated population with a high fraction of resistant patients was recruited to the study.

Table 10 Disease characteristics; efficacy analysis set

<!-- image -->

|                                                  |           | (N=109)   | (N=109)   |
|--------------------------------------------------|-----------|-----------|-----------|
|                                                  |           | n         | (%)       |
| Months SinceInitial Diagnosis                    | Median    | 15.4      |           |
|                                                  | Mean      | 30.3      |           |
|                                                  | Std Dev   | 43.1      |           |
|                                                  | Min - Max |           | 0.8-322.3 |
|                                                  | N Missing | 0         |           |
| DaysSince Most RecentProgression                 | Median    | 32        |           |
|                                                  | Mean      | 58        |           |
|                                                  | Std Dev   | 169       |           |
|                                                  | Min - Max |           | 2 -1736   |
|                                                  | N Missing | 3         |           |
| Number of Prior Regimens n (%)                   | 1         | 18        | (17)      |
|                                                  | 2         | 26        | (24)      |
|                                                  | 3         | 23        | (21)      |
|                                                  | 4         | 16        | (15)      |
|                                                  | >=5       | 26        | (24)      |
|                                                  | Median    | 3.0       |           |
|                                                  | Min - Max | 1         | 12        |
| Number of Prior Systemic Regimens n (%)          | 1         | 23        | (21)      |
|                                                  | 2         | 29        | (27)      |
|                                                  | 3         | 23        | (21)      |
|                                                  | 4         | 14        | (13)      |
|                                                  | >=5       | 20        | (18)      |
|                                                  | Median    | 3.0       |           |
|                                                  | Min - Max | 1         | 11        |
| Best Response toAnyPrior Regimen                 | CR        | 48        | (44)      |
|                                                  | PR        | 35        | (32)      |
|                                                  | SD        | 9         | (8)       |
|                                                  | PD        | 12        | (11)      |
|                                                  | NA        | 5         | (5)       |
| ResponsetoMostRecentPriorRegimen                 | CR        | 20        | (18)      |
|                                                  | PR        | 20        | (18)      |
|                                                  | SD        | 14        | (13)      |
|                                                  | PD        | 43        | (39)      |
|                                                  | NA        | 12        | (11)      |
| BaselineECOGPS                                   | 0         | 42        | (39)      |
|                                                  | 1         | 49        | (45)      |
|                                                  | 2         | 18        |           |
| BaselineCutaneous InvolvementperCentralReview[1] | No        | Yes 35 74 |           |

Seventy-eight  patients  (70%)  had  previously  received  CHOP,  which  was  the  most  common  prior therapy.  Twenty-five  patients  received  CHOP  as  the  most  recent  prior  therapy,  10  of  these  without evidence of response. Eighteen patients had undergone ABMT before study entry, whereof 9 as the most recent therapy; 4 of these with no evidence of response.

<div style=\"page-break-after: always\"></div>

Table 11 Prior therapy for peripheral T-cell lymphoma

<!-- image -->

| Prior Therapy for PTCL                           | Safety Analysis Set (N = 111) n (%)   |
|--------------------------------------------------|---------------------------------------|
| Local Therapy                                    |                                       |
| Radiation therapy                                | 25 (23)                               |
| Photopheresis                                    | 10 (9)                                |
| Topical nitrogen mustard                         | 4 (4)                                 |
| Systemic Therapy                                 |                                       |
| CHOP                                             | 78 (70)                               |
| Platinum-containing multi-agent chemotherapy     | 45 (41)                               |
| Non platinum-containing multi-agent chemotherapy | 43 (39)                               |
| Single-agent chemotherapy                        | 36 (32)                               |
| Autologous stem cell transplant                  | 18 (16)                               |
| Bexarotene                                       | 15 (14)                               |
| Other                                            | 13 (12)                               |
| Steroids alone                                   | 8 (7)                                 |
| HyperCVAD                                        | 8 (7)                                 |
| Denileukin diftitox                              | 7 (6)                                 |
| Systemic investigational agents                  | 7 (6)                                 |

Table 12 Most recent prior therapy for peripheral T-cell lymphoma

| Most Recent Prior Therapy for PTCL               | Safety Analysis Set (N =111) n (%)   |
|--------------------------------------------------|--------------------------------------|
| Local Therapy                                    |                                      |
| Radiation therapy                                | 6 (5)                                |
| Topical nitrogen mustard                         | 1 (<1)                               |
| Systemic Therapy                                 |                                      |
| CHOP                                             | 25 (23)                              |
| Non platinum-containing multi-agent chemotherapy | 21 (19)                              |
| Single-agent chemotherapy                        | 20 (18)                              |
| Platinum-containing multi-agent chemotherapy     | 20 (18)                              |
| Autologous stem cell transplant                  | 9 (8)                                |
| Bexarotene                                       | 8 (7)                                |
| Denileukin diftitox                              | 2 (2)                                |
| HyperCVAD                                        | 2 (2)                                |
| Other                                            | 2 (2)                                |
| Systemic investigational agents                  | 2 (2)                                |
| Steroids alone                                   | 一 (<1)                               |

<div style=\"page-break-after: always\"></div>

Table 13 Most recent prior therapy - with no evidence of response

|                                                  | Safety Analysis Set - No Evidence of Response (N=70) n (%)   |
|--------------------------------------------------|--------------------------------------------------------------|
| Local Therapy                                    |                                                              |
| Radiation Therapy                                | 4 (6)                                                        |
| Topical nitrogen mustard                         | (1)                                                          |
| Systemic Therapy                                 |                                                              |
| Single agent chemotherapy                        | 17 (24)                                                      |
| Platinum-containing multi-agent chemotherapy     | 13 (19)                                                      |
| Non platinum-containing multi-agent chemotherapy | 11 (16)                                                      |
| CHOP                                             | 10 (14)                                                      |
| Bexarotene                                       | 7 (10)                                                       |
| Autologous stem cell transplant                  | 4 (6)                                                        |
| Systemic investigational agents                  | 2 (3)                                                        |
| Steroids alone                                   | 1 (1)                                                        |
| HyperCVAD                                        | 1 (1)                                                        |
| Other                                            | (1)                                                          |

## Numbers analysed

109 patients were evaluable for the efficacy analyses, 111 patient for the safety analysis.

## Outcomes and estimation

- Primary endpoint, primary analysis with supportive analyses

## Table 14 Summary of best response

| Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   | Efficacy Analysis Set (N = 109)   |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                   | Central review of IWC             | Central review of IWC             | Central review of IWC             | Local Investigator Review         | Local Investigator Review         | Local Investigator Review         |
|                                   | n                                 | (%)                               | (95% CI)                          | n                                 | (%)                               | (95% CI)                          |
| CR+CRu+PR                         | 32                                | (29)                              | (21, 39)                          | 43                                | (39)                              | (30, 49)                          |
| CR                                | 11                                | (10)                              |                                   | 17                                | (16)                              |                                   |
| Cru                               | 1                                 | (1)                               |                                   | 3                                 | (3)                               |                                   |
| PR                                | 20                                | (18)                              |                                   | 23                                | (21)                              |                                   |
| SD                                | 21                                | (19)                              |                                   | 21                                | (19)                              |                                   |
| PD                                | 40                                | (37)                              |                                   | 40                                | (37)                              |                                   |
| UE                                | 2                                 | (2)                               |                                   | -                                 | -                                 |                                   |
| Missing: off-treatment in cycle 1 | 14                                | (13)                              |                                   | 5                                 | (5)                               |                                   |

IWC = International Workshop Criteria

CI = confidence interval

CR = complete response

CRu = complete response unconfirmed

SD = stable disease

PR = partial response

PD = progressive disease

UE = unevaluable (insufficient materials for central review)

<div style=\"page-break-after: always\"></div>

According to the primary analysis, independent central review using IWC, 32 patients responded to the treatment  corresponding  to  an  overall  response  rate  of  29%  with  95%  CI  21-39%;  11,  1,  and 20 patients reached CR, CRu, and PR, respectively. In the local investigator review, substantially more patients reached CR/CRu and overall 43 patients (39%) were judged as responders. The response rate according to IWC+PET was 26% (n=28) with 15 patients reaching CR.

Seventeen  patients  (25%)  of  the  69  patients  in  the  overall  efficacy  analysis  set  that  did  not  have evidence of response to their most recent prior therapy were stated to respond to pralatrexate per central review. Of the 26 patients in the efficacy analysis set that did not have evidence of response to any prior therapy, 5 patients (19%) responded to pralatrexate.

Response to pralatrexate was of relatively rapid onset, with 20 patients (63% of responders) observed to respond within 1 cycle of treatment as assessed by central review.

Table 15 Waterfall-chart showing the maximum change from baseline in the sum of the products of the greatest diameter (SPD)

<!-- image -->

Notable findings in the subset analyses include a slightly higher response rate in patients ≥ 65 years old than in younger patients, a slightly better response rate in methotrexate-naive patients, a lower response  rate  in  patients  diagnosed  with  angioimmunoblastic  T-cell  lymphoma  as  compared  to  the other entities included in the study, and, perhaps surprisingly, a slightly lower response rate in patients recruited at European centres as compared to North American centres (21% vs. 32%). However, the numbers  of  patients  in  the  subgroups  are  generally  low,  and  the  results  therefore  have  to  be interpreted with caution.

<div style=\"page-break-after: always\"></div>

Table 16 Response rate by subsets per central assessment, efficacy analysis set (selected)

|                                       |                                   | Subset Incidence   | Subset Incidence   |            | Resp.   |          |
|---------------------------------------|-----------------------------------|--------------------|--------------------|------------|---------|----------|
|                                       |                                   | N                  | (%)                | Responders | Rate(%) | (95% CI) |
| Overall                               |                                   | 109                | (100)              | 32         | (29)    | (21，39)  |
| Age                                   | Age<65                            | 70                 | (64)               | 19         | (27)    | (17，39)  |
|                                       | Age >=65                          | 39                 | (36)               | 13         | (33)    | (19,50)  |
| PriorSystemic TherapyforPTCL          | 1 Regimen                         | 23                 | (21)               | 8          | (35)    | (16,57)  |
|                                       | 2 Regimens                        | 29                 | (27)               | 7          | (24)    | (10，44)  |
|                                       | >2 Regimens                       | 57                 | (52)               | 17         | (30)    | (18，43)  |
| Histology                             | PTCL Unspecified                  | 59                 | (54)               | 19         | (32)    | (21，46)  |
|                                       | Angioimmunobl Tcl                 | 13                 | (12)               | 1          | (8)     | (0，36)   |
|                                       | Anaplastic LCL                    | 17                 | (16)               | 6          | (35)    | (14，62)  |
|                                       | Transformed MF                    | 12                 | (11)               | 3          | (25)    | (5，57)   |
|                                       | Other                             | 8                  | (7)                | 3          | (38)    | (9，76)   |
| Best Response to Prior Therapy        | CR or PR                          | 83                 | (76)               | 27         | (33)    | (23，44)  |
|                                       | SDorPDorUnknown                   | 26                 | (24)               | 5          | (19)    | (7，39)   |
| BestResponsetoMostRecentPrior Therapy | CR/PR                             | 40                 | (37)               | 15         | (38)    | (23，54)  |
|                                       | SD/PD                             | 57                 | (52)               | 14         | (25)    | (14, 38) |
|                                       | NA                                | 12                 | (11)               | 3          | (25)    | (5，57)   |
| Selected Prior SystemicTherapyforPTCL | 1 prior regimen-prior CHOP        | 15                 | (14)               | 7          | (47)    | (21，73)  |
|                                       | 1 prior regimen -no prior CHOP    | 8                  | (7)                | 1          | (12)    | (0，53)   |
|                                       | >1 prior regimens-prior CHoP      | 61                 | (56)               | 15         | (25)    | (14, 37) |
|                                       | >1 prior regimens - no prior CHOP | 25                 | (23)               | 9          | (36)    | (18, 57) |
| Prior Methotrexate                    | Yes                               | 21                 | (19)               | 5          | (24)    | (8，47)   |
|                                       | No                                | 88                 | (81)               | 27         | (31)    | (21，41)  |
| Prior Transplant                      | Yes                               | 18                 | (17)               | 6          | (33)    | (13,59)  |
|                                       | No                                | 91                 | (83)               | 26         | (29)    | (20，39)  |
| Global Region                         | North America                     | 85                 | (78)               | 27         | (32)    | (22，43)  |
|                                       | Europe                            | 24                 | (22)               | 5          | (21)    | (7，42)   |

## · Secondary endpoints with supportive analyses

## o Duration of response

The median duration of response assessed by IWC, based on 32 responding patients with 16 events, was 306 days (95% CI, 103-not estimable). Fourteen of the 32 responding patients had a duration of response in excess of 6 months. The 6-month and 12-month Kaplan-Meier estimates for duration of response  were  60%  and  45%,  respectively. The  calculation  was  based  on  16  patients  with  event dates (14 PD, 2 death) and censored end dates for the remaining 16 responding patients.

Table 17 Duration of response per central review; efficacy analysis set

<!-- image -->

<div style=\"page-break-after: always\"></div>

The  criterion  used  for  response  was  evidence  of  CR,  CRu,  or  PR  at  one  occasion.  In  16  of  the  32 responding  patients,  the  response  was  confirmed  at  the  next  consecutive  scheduled  response assessment,  corresponding  to  a  confirmed  response  lasting  at  least ≥ 14  weeks;  in  3  patients,  the response  was  confirmed  at  unscheduled  assessments  less  than  14  weeks  later.  The  remaining  13 responders were either progressing or censored before the next consecutive scheduled assessment, meaning  they  did  not  have  a  confirmed  response  and  a  duration  of  response  &lt;14  weeks.  If  these figures  are  used  in  a  conservative  calculation  of  response  rate,  taking  into  account  only  responders with  a  confirmed  duration ≥ 14  weeks,  the  response  rate  would  be  16/109  patients  (15%).  Among these 16 patients with a confirmed duration ≥ 14 weeks, only 5 experienced events (4 PR, 1 death), the remaining being censored.

The median duration of response assessed by IWC plus PET based on 28 responding patients was 386 days  (95%  CI,  191-not  estimable).  The 6-month  and  12-month  estimates  were  71%  and  57%, respectively. Median  duration  of  response  per  local  investigator  was  246  days  (95%  CI,  154-379), based on 43 responders with 25 events. The 6-month and 12-month estimates were 59% and 39%, respectively.

Sensitivity  analyses  were  conducted  to  investigate  the  robustness  of  the  Kaplan-Meier estimates  for duration  of  response.  These  analyses  compared  the  duration  of  response:  1)  per the  protocol specification; 2) if patients were censored for transplant at the time of last contact (rather than at time of transplant); 3) based on response assessment by independent central review using IWC + PET; and 4) based on response assessment by the investigator.

Table 18 Duration of response - sensitivity analyses

| Analysis                                                                     | No. Responders/Events   |   Median (months) | 6-Month Estimate   |
|------------------------------------------------------------------------------|-------------------------|-------------------|--------------------|
| Per protocol/statistical analysis plan                                       | 32/16                   |              10.1 | 60%                |
| Censortransplant atlast contacta                                             | 32/16                   |              13.1 | 62%                |
| Per protocol/statistical analysis plan - using IWC + PET response assessment | 28/11                   |              12.7 | 71%                |
| Perinvestigatorresponse assessment                                           | 43/25                   |               8.1 | 59%                |

## o Progression-free survival

Seventy patients (64%) had an event of either PD (n = 63, 58%) or death (n = 7, 6%) that was used to calculate their PFS.

Thirty-nine  patients  (36%)  in  the  efficacy  analysis population  were  censored  for  PFS  (based  on response assessed by central review using IWC) because they had not yet progressed at the time of the data cut-off date (n = 5, 5%) or they received anti-cancer therapy before PD was assessed (n = 26,  24%),  and  4  patients  (4%) terminated  study  follow-up  for  response.  Four  patients  (4%)  were censored due to transplant.

The median PFS based on response assessed by IWC was 106 days (95% CI, 51-146) with a range of 1-726 days.

<div style=\"page-break-after: always\"></div>

Table 19 Progression-free survival per central review (IWC)

<!-- image -->

The median PFS based on response assessed by IWC plus PET was 141 days (95% CI, 79-243) or 4.6 months, with a range of 1-726 days. The median PFS based on response assessed by local investigator was 121 days (95% CI, 77-148 days) or 4.0 months, with a range of 1-726 days.

## o Overall survival

Forty-seven patients (43%) were censored for OS because they were still alive at the time of the data cut-off date.

The median OS for the efficacy analysis set was 14.5 months (95% CI, 10.6- 22.5), with a range of 1.0-24.1 months.

- o Updated PDX-008 Response and Survival Data

Since  the  cut-off  of  17  August  2009,  several  PDX-008 investigational  sites  have  provided  additional survival data (n = 17) and/or response data (n = 7) for patients who were censored for one or more efficacy endpoint in the original analysis.

Table 20 Survival Rates following pralatrexate initiation

|                       | 1 year (%)       | 2 year's (%)     | 3 year's (%)     | 1 year's (%)     |
|-----------------------|------------------|------------------|------------------|------------------|
| Original PDX-008 Data | 55.3 (45.2-64.3) | 33.7 (23.3-44.5) |                  |                  |
| Updated PDX-008 Data  | 56.0 (46.1-64.9) | 34.8 (25.8-43.9) | 28.5 (19.1-38.6) | 24.9 (15.0-36.2) |

## Ancillary analyses

- Comparison of PFS and response rate with previous treatments of PTCL

It  was  hypothesised  that  the  response  rates  and  PFS  would  be  lower  with  each  subsequent line  of therapy  (hypothesis  #1).  Analyses  were  conducted  on  those  patients  who  received  at least  3  prior therapies. PFS and response rate of third prior therapy (-3) were compared with those of the second prior therapy (-2), PFS and response rate of second prior therapy (-2) were compared with those last line of therapy (-1) prior to pralatrexate, and PFS and response rate of last line of therapy (-1) were compared with pralatrexate therapy for these patients. These analyses utilised investigator assessment of PFS, and response since central review of tumour assessments on prior therapies was not available.

<div style=\"page-break-after: always\"></div>

It  was  further  hypothesised  (hypothesis  #2)  that  if  progressive  resistance  was  demonstrated, then pralatrexate may reverse or slow this trend, consistent with a clinical benefit for the drug. Therefore, an analysis was conducted on all patients comparing PFS and response rate of last line of therapy with those of pralatrexate therapy.

Table 21 Comparison of median progression-free survival with previous treatments of PTCL: Patients with ≥ 2 previous treatments

| Prior Systemic Treatment   | Comparison      | N   | Progression-free Survival   | Progression-free Survival   | Response Rate   |
|----------------------------|-----------------|-----|-----------------------------|-----------------------------|-----------------|
|                            |                 |     | Median (Days)95% CI         | HazardRatio 95% CI          |                 |
| Pralatrexate               |                 | 86  | 119.00 (77.00,146.00)       |                             | 40              |
| -1                         | 1vspralatrexate | 86  | 89.50 (72.00,123.00)        | 1.201 (0.868, 1.661)        | 29              |
| -2                         | -2 vs -1        | 86  | 144.00 (91.00, 188.00)      | 0.785 (0.579, 1.063)        | 38              |

Table 22 Comparison of median progression-free survival and response rate between pralatrexate and the immediate prior treatment

| Prior Systemic Treatment   | Comparison N        | Progression-free Survival   | Progression-free Survival   | Response Rate   |
|----------------------------|---------------------|-----------------------------|-----------------------------|-----------------|
|                            |                     | Median (Days ) 95% CI       | HazardRatio 95% CI          |                 |
| Pralatrexate               | 109                 | 121.00 (77.00, 148.00)      |                             | 39              |
| -1                         | 1vspralatrexate 109 | 114.00 (89.00,151.00)       | 1.051 (0.785, 1.407)        | 38              |

The  retrospective  analyses  presented  indicate  that  pralatrexate  induces  longer  PFS  and,  in  certain analyses, higher response rate than the previous lymphoma treatment(s).

## · Additional intra-individual PFS analyses

The  Applicant  has  undertaken  further  analyses  to  evaluate the  impact  of  an  objective  response  to pralatrexate  on  patient  outcomes.  In  order  to determine  whether  patients  who  responded  to pralatrexate  on  PDX-008  were  more  likely  to respond  due  to  a  superior  disease  prognosis  at  study entry, a retrospective analysis was conducted comparing the PFS of the pralatrexate responders with the PFS of the same patients' most recent prior therapies.

<div style=\"page-break-after: always\"></div>

Figure 2 Comparison of PFS for pralatrexate responders by central review on PDX-008 vs. most recent prior therapy

<!-- image -->

- PFS and OS According to Best Response to Pralatrexate
- PFS on pralatrexate compared to TTP on prior therapy

Table 23

|                                     | Outcome to Pralatrexate Therapy   | Outcome to Pralatrexate Therapy   | Outcome to Pralatrexate Therapy   |
|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                     | Response (n = 32)                 | Progressive Disease (n = 40)      | Stable Disease (n = 21)           |
| Median OS                           | 711                               | 275                               | 517                               |
| Median PFS                          | 438                               | 43                                | 143                               |
| Difference (Median OS - Median PFS) | 273                               | 232                               | 374                               |

Table 24 Comparison of Median PFS* and Response Rates between Pralatrexate and the Immediate Prior Systemic Regimens for Patients with At Least 2** Prior Systemic Regimens

| Regimen                                 | Prior Systemic   |   N |   PFS Median (days) |   HR | Response Rate   |
|-----------------------------------------|------------------|-----|---------------------|------|-----------------|
| Overall                                 | Pralatrexate     |  86 |               119   | 1.2  | 40%             |
| Overall                                 | -1               |  86 |                89.5 | 1.2  | 29%             |
| Single-agent Chemotherapy               | Pralatrexate     |  18 |                68.5 | 1.25 | 44%             |
| Single-agent Chemotherapy               | -1               |  18 |                81.5 | 1.25 | 11%             |
| CHOP                                    | Pralatrexate     |  15 |                97   | 0.92 | 33%             |
| CHOP                                    | -1               |  15 |               114   | 0.92 | 40%             |
| Bexarotene/Denileukin diftitox          | Pralatrexate     |   9 |               178   | 1.36 | 67%             |
| Bexarotene/Denileukin diftitox          | -1               |   9 |                56   | 1.36 | 33%             |
| Platinum-based Multi-agent Chemotherapy | Pralatrexate     |  16 |                77   | 1.29 | 25%             |
| Platinum-based Multi-agent Chemotherapy | -1               |  16 |                62   | 1.29 | 19%             |

<div style=\"page-break-after: always\"></div>

| Non-platinum, Non-CHOP   | Pralatrexate   |   12 |   121.0 | 1.17   | 33%   |
|--------------------------|----------------|------|---------|--------|-------|
| Multi-agent Chemotherapy | -1             |   12 |    87.5 |        | 42%   |
| Stem Cell Transplant     | Pralatrexate   |    9 |   324   | 2.38   | 56%   |
| Stem Cell Transplant     | -1             |    9 |   274   |        | 56%   |

## · Responses to Pralatrexate in Patients Who Progressed Following CHOP or ICE

Table 25 Responses to Pralatrexate in Patients Who Received First-line CHOP or Any Prior ICE

|                          | Investigator Assessment   | Investigator Assessment     | Investigator Assessment                     | Central Review       | Central Review                              |
|--------------------------|---------------------------|-----------------------------|---------------------------------------------|----------------------|---------------------------------------------|
| Prior Treatment          | ORR to Prior Treatment    | ORR to Pralatrexate         | Median Duration of Response to Pralatrexate | ORR to Pralatrexate  | Median Duration of Response to Pralatrexate |
| First-line CHOP (n = 16) | 75% (37.5% CR, 37.5% PR)  | 38% (25% CR, 6% CRu, 6% PR) | 12.5 months                                 | 44% (19% CR 25% PR)  | NE                                          |
| Any Prior ICE (n = 20)   | 25% (15% CR, 10% PR)      | 40% (25% CR, 15% PR)        | 16.2 months                                 | 40% (15% CR, 25% PR) | 13.1 months                                 |

NE = not estimable due to insufficient PD events

Four  patients  who  responded  to  second-line  pralatrexate  following  CHOP  (n=2)  or  ICE  (n=2) proceeded to SCT (and were thus censored for duration of response).

## · Decreased Risk of Death in Patients Who Responded to Pralatrexate

Landmark  and  time-dependent  covariate  analyses  were  applied,  adjusted  for  the  following  baseline factors that could be potentially predictive chosen by clinicians: age (&lt; 60 vs. age  60), extranodal growth (yes vs no), ECOG performance status (0,1 vs. 2), and number of prior therapies (&lt; 3,  3).

Table 26 Summary of Analyses of Survival by Tumour Response, Adjusting For Baseline Factors

| Evaluation Method   | Statistical Method       | No. Patients in Analysis (Responders)   | HR (95% CI)       |
|---------------------|--------------------------|-----------------------------------------|-------------------|
| Per central review  | Landmark at cycle 1 a    | 93 (20)                                 | 0.80 (0.38, 1.68) |
|                     | Time-dependent covariate | 109 (32)                                | 0.60 (0.32, 1.14) |
| Per investigator    | Landmark at cycle 1 a    | 91 (32)                                 | 0.49 (0.26, 0.93) |
|                     | Time-dependent covariate | 109 (43)                                | 0.39 (0.22, 0.71) |

The only baseline factor statistically significant at the 0.05 level was ECOG performance status, which was statistically significant in both methods. Extranodal growth was found to be marginally significant with either method.

<div style=\"page-break-after: always\"></div>

## · Historic Controls/Registry Data

Data from three registries, one from Europe and two from the US, were provided.

## o European registry

This Registry has provided data on all PTCL patients diagnosed between 1997 and 2007. One hundred and four patients have been identified as having a diagnosis with histological subtypes of PTCL that were included in the PDX-008 study; the OS from diagnosis in this patient group showed a median of just 10 months, with a 5-year OS rate of 34.9%.

Fifty-five patients (53%) had a progression event, including 24 who progressed or died during initial therapy, 14 who progressed from PR or SD following initial therapy, and 14 who relapsed after a CR. A further 3 patients died while still in CR.

The median OS after failure of treatment was less than 1 month, with a 12-month survival of 10.7%. The  majority  of  these  patients  would  not  have  been  eligible  for  inclusion  in  PDX-008,  as  4  weeks needed to have lapsed between prior chemotherapy and pralatrexate initiation.

- o US registries

Data  was  obtained  a  US  registry  and  compared  to  the  outcomes  in  PDX-008.  Fifty  patients  were identified  for  inclusion  in  this  dataset  as  follows:  Histologies  consistent  with  the  inclusion  criteria  of PDX-008, and patients with at least 2 therapies. In comparison to the PDX-008 population, the registry dataset population was younger and less heavily pretreated. There was a 66% response rate to the most recent therapy and an 88% response rate to any therapy by investigator assessment.

The median OS (censored at 24.1 months) for the registry patients was 8.7 months (95% CI, 7.2-not estimable), with a range of 0.4-144.0 months; the median OS for the PDX-008 study was 14.5 months (95% CI, 10.6- 22.5), with a range of 1.0-24.1* months.

Comparisons  between  pralatrexate  and  a  concurrent  second  database  of  comparable  patients  with PTCL were performed.  Data on 70 patients treated between June 1997 and July 2011 was used for analysis.

The median OS (censored at 24.1 months) for the registry patients was 6.1 months (95% CI, 4.0 11.0; the median OS for the PDX-008 study was 14.5 months (95% CI, 10.6- 22.5

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  study  supporting  the  present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 28 Summary of Efficacy for trial PDX-008

| Title : A Multi-center, Phase 2, Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma   | Title : A Multi-center, Phase 2, Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma   | Title : A Multi-center, Phase 2, Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                               | PDX-008                                                                                                                                                                                                                        | PDX-008                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                         | Open-label, non-randomized, multi-center                                                                                                                                                                                       | Open-label, non-randomized, multi-center                                                                                                                                                                                       |
|                                                                                                                                                                                                                                | Duration of main phase:                                                                                                                                                                                                        | 24 August 2006 - 17 August 2009                                                                                                                                                                                                |
| Hypothesis                                                                                                                                                                                                                     | Not applicable                                                                                                                                                                                                                 | Not applicable                                                                                                                                                                                                                 |
| Treatments group                                                                                                                                                                                                               | Pralatrexate, 6 weekly doses of pralatrexate IV (30mg/m2/week) over 3-5 minutes, followed by 1 week rest                                                                                                                       | Pralatrexate, 6 weekly doses of pralatrexate IV (30mg/m2/week) over 3-5 minutes, followed by 1 week rest                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                | Response rate                                                      |              | Response rate was defined as number of responders (CR+CRu+PR) and assessed by independent central review                                                                                                  |      |          |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|
|                                                 | Secondary endpoint                                                                                                                                                                                                                                              | Duration of response                                               |              | Number of days between the date of first tumour response assessment of objective response (including CR, CRu, and PR) to the time of the first tumour response assessment of PD or death due to any cause |      |          |
|                                                 | Secondary endpoint                                                                                                                                                                                                                                              | PFS                                                                |              |                                                                                                                                                                                                           |      |          |
|                                                 | Secondary endpoint                                                                                                                                                                                                                                              | OS                                                                 |              |                                                                                                                                                                                                           |      |          |
| Database lock                                   | 17 August 2009                                                                                                                                                                                                                                                  |                                                                    |              |                                                                                                                                                                                                           |      |          |
| Results and Analysis                            |                                                                                                                                                                                                                                                                 |                                                                    |              |                                                                                                                                                                                                           |      |          |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                |                                                                    |              |                                                                                                                                                                                                           |      |          |
| Analysis population and time point description  | Efficacy analysis set consists of all evaluable patients (n = 109); a patient was considered evaluable if he/she received at least 1 dose of pralatrexate and had a diagnosis of eligible PTCL histopathological subtype confirmed by central pathology review. |                                                                    |              |                                                                                                                                                                                                           |      |          |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                 |                                                                    | Pralatrexate |                                                                                                                                                                                                           |      |          |
|                                                 | Number of subject                                                                                                                                                                                                                                               |                                                                    | 109          |                                                                                                                                                                                                           |      |          |
|                                                 | Response rate                                                                                                                                                                                                                                                   |                                                                    |              | Central review of IWC                                                                                                                                                                                     |      |          |
|                                                 |                                                                                                                                                                                                                                                                 |                                                                    |              | n                                                                                                                                                                                                         | (%)  | (95% CI) |
|                                                 |                                                                                                                                                                                                                                                                 | CR+CRu+PR                                                          |              | 32                                                                                                                                                                                                        | (29) | (21, 39) |
|                                                 |                                                                                                                                                                                                                                                                 | CR                                                                 |              | 11                                                                                                                                                                                                        | (10) |          |
|                                                 |                                                                                                                                                                                                                                                                 | CRu                                                                |              | 1                                                                                                                                                                                                         | (1)  |          |
|                                                 |                                                                                                                                                                                                                                                                 | PR                                                                 |              | 20                                                                                                                                                                                                        | (18) |          |
|                                                 |                                                                                                                                                                                                                                                                 | Investigator Review                                                |              |                                                                                                                                                                                                           |      |          |
|                                                 | n                                                                                                                                                                                                                                                               |                                                                    |              | Local                                                                                                                                                                                                     | (%)  | (95% CI) |
|                                                 |                                                                                                                                                                                                                                                                 | CR+CRu+PR                                                          |              | 43                                                                                                                                                                                                        | (39) | (30, 49) |
|                                                 |                                                                                                                                                                                                                                                                 | CR                                                                 |              | 17                                                                                                                                                                                                        | (16) |          |
|                                                 |                                                                                                                                                                                                                                                                 | CRu                                                                |              | 3                                                                                                                                                                                                         | (3)  |          |
|                                                 |                                                                                                                                                                                                                                                                 | PR                                                                 |              | 23                                                                                                                                                                                                        | (21) |          |
|                                                 | Duration of response                                                                                                                                                                                                                                            | Median 10.1 mos, range 1*-673 days (95% CI, 3.4 mos-not estimable) |              |                                                                                                                                                                                                           |      |          |
|                                                 | PFS                                                                                                                                                                                                                                                             | Median 3.5 mos, range 1*-726 days (95% CI, 1.7-4.8 mos)            |              |                                                                                                                                                                                                           |      |          |
|                                                 | OS                                                                                                                                                                                                                                                              | Median 14.5 mos, range 1.0*-24.1 mos (95% CI, 10.6-22.5 mos)       |              |                                                                                                                                                                                                           |      |          |

## Analysis performed across trials (pooled analyses and meta-analysis)

Efficacy  data  across  studies  were  not  provided  as  pooled  analyses  due  to  the  differences  in tumour types, doses and schedules of administration of pralatrexate, and methods for efficacy assessments.

## Clinical studies in special populations

No clinical  study  in  children  or  other  special  populations  has  been  performed.  Patients with  renal  or hepatic impairment were not eligible for the PDX-008 study.

<div style=\"page-break-after: always\"></div>

## Supportive studies

## PDX-02-078

PDX-02-078 was a non-randomised, open-label Phase I/II study in patients with relapsed or refractory aggressive  NHL  or  HL.  The  primary  objectives  were  to  determine  the  efficacy  of  pralatrexate, determine impact of PK on AEs and drug elimination, and optimize a weekly schedule of pralatrexate with vitamin B12 and folic acid supplementation. Seventy-two patients were treated in the study. In the initial version of the study protocol, the starting dose of pralatrexate was 135 mg/m 2  administered every other week with intra-patient dose escalation. A higher than anticipated incidence of Grade 3 or 4  stomatitis  occurred  at  this  dose  in  patients.  In  addition,  many  patients  with  palpable  disease experienced marked reductions in their disease by day 7, which grew back to baseline levels by day 15, suggesting cytokinetic failures. The protocol was then amended to become a Phase 1/2 study with an inter-patient dose-escalation scheme starting at 30 mg/m 2  weekly for 3 weeks of a 4-week cycle with subsequent increases in number of consecutive doses and dose amount. An amendment to the protocol included addition of vitamin B12 and folic acid supplementation. When dose-limiting toxicities (DLTs) occurred at the dose of 45 mg/m 2  for 6 weeks of a 7-week cycle, the maximum tolerated dose (MTD) was determined to be 30 mg/m 2 /week for 6 weeks on a 7-week cycle.

Of the 39 evaluable patients, 13 patients had a response (6 CRs, 1 CRu, and 6 PRs) by investigator assessment (RR 33%), 15 had SD, and 11 had PD. Of the 13 patients who responded, 12 patients had T-cell lymphoma and 1 had B-cell lymphoma. Overall, there were 36 patients in PDX-02-078 with T-cell lymphoma, of whom 20 were evaluable per the protocol (must have completed 2 cycles of therapy) resulting in a response rate in T-cell lymphoma of 60%, based on investigator assessment. The median duration of response for the 13 responding patients was 5 months, with a range of  1-18 months. However, the presentation and discussion of data was difficult to follow, and the real number of true responders fulfilling the criteria for evaluation is not entirely clear to the CHMP. It appears that 7/15 recruited patients, with histological entities included in the pivotal PDX-008 study and treated with the same dose regimen, responded to the treatment.

## Study PDX-010

Study PDX-010 is an ongoing Phase I, open-label, multi-centre study of single agent pralatrexate in patients  with relapsed  or  refractory  cutaneous  T-cell  lymphoma  (CTCL).  The  objectives  of  the  study are to determine an effective and well-tolerated dose and schedule of single-agent pralatrexate with vitamin  B12  and  folic  acid  supplementation  that  can  be  administered  safely  and  to characterize  the safety profile of pralatrexate in this group of patients. The 15 mg/m 2  dose given for 3 of 4 weeks was determined as the optimal dose/schedule and has been expanded with up to a total of 20 evaluable patients enrolled at this dose/schedule. Enrolment was completed after the data cut-off with a total of 54  treated  patients, including  23  enrolled  in  the  expanded  cohort  treated  with  pralatrexate  at 15 mg/m 2  for 3 of 4 weeks.

Interim efficacy analyses showed that the overall response rate per investigator assessment using the modified severity-weighted assessment tool (mSWAT) was 40% (19/47 patients). Two patients had a best response of CR, 17 had PR, 18 had SD, 7 had PD, 3 patients did not have a response assessment prior to study treatment discontinuation, and response was pending for 1 patient. The 19 responders were heavily pretreated, with a median of 6 (range 3-18) prior treatment regimens and a median of 4 (range  1-11)  prior  systemic  regimens.  The  overall  response  rate for  the  22  patients  treated  at  the determined recommended dosing regimen for CTCL patients (15 mg/m2 given weekly for 3/4 weeks) was 43%, with all 10 of the responding patients experiencing PR. In the 35 patients treated at the dose intensity of 15 mg/m2 given weekly for 3/4 weeks or higher, the overall response rate was 51% (18/35), with 17 PRs and 1 CR.

<div style=\"page-break-after: always\"></div>

## Study PDX-009

PDX-009 is a Phase I/IIa, open-label, multi-centre study of pralatrexate and gemcitabine administered on  sequential  days,  or  the  same  day  depending  on  cohort,  with  vitamin  B12  and folic  acid supplementation to patients with relapsed or refractory lymphoproliferative malignancies. The data for PDX-009 were analyzed separately based on the phase of the study. In the phase 1 portion  of  the study, 3 to 6 patients in sequential cohorts were enrolled into each treatment group until the MTD was determined.  Eight  of  34  evaluable  patients  in this  phase  of  the  study  had  a  response  (24%),  all  of whom  had  PRs.  Six  additional  patients (18%)  had  SD.  One  patient  was  considered  evaluable  but withdrew consent. The overall disease control rate (CR + CRu + PR + SD) for the phase 1 portion of the  study  was 41%.  The  median  time  to  PD  for  the  patients  in  the  phase  1  part  of  the  study  was 51 days (range 1-379 days). According to the study report there were 8 evaluable patients with PTCL in this cohort, with 6 PDs and 2 PRs (by investigator).

Patients  are  currently  being  randomized  in  the  phase  2a  component  of  the  study  to  receive either sequential dosing (pralatrexate 10 mg/m2  and  gemcitabine  400  mg/m 2 ) or  same-day dosing (pralatrexate  15  mg/m2 and gemcitabine 600 mg/m 2 ) to confirm the tolerability of the combination dose regimen and to obtain preliminary efficacy data to support later phase clinical trials. As of the data cut-off of 17 February 2010 for this ongoing study, 62 patients had been treated and had data available.

Of 27 evaluable patients in the phase 2a component of the study, 5 patients (19%) have achieved a response including 2 CRs and 3 PRs. These responses have been observed in both dosing schedules: 2 of 14 evaluable patients in the sequential-day dosing group and 3 of 13 patients in the same-day dosing group. Four patients (15%) in the phase 2a component had SD. The overall disease control rate for  the  phase  2a  portion  of  the  study to  date  was  33%.  As  enrolment  in  this  phase  of  the  study  is ongoing,  time-to-event  analyses have  not  yet  been  performed.  According  to  the  study  report  there were  8  evaluable  patients  with  PTCL  in  this  cohort,  with  4  PDs,  2  SDs,  and  2  patients  apparently unevaluable by IWC but with a metabolic response by PET (by investigator).

## Proposed confirmatory study

The Applicant proposed to perform as a specific obligation a randomised study with pralatrexate versus single-agent systemic treatment of physician's choice. The Applicant considers it unlikely that patients in  the  post-approval  study  will  be  those  considered  to  be  eligible  for  transplant  in  the  second-line relapsed setting and suggests a choice of commercially available, single-agent chemotherapeutics and biologicals as comparator.

The  Applicant  has  performed  an  international  feasibility  survey  and  an  analysis  of  the  competitive landscape and concluded that the proposed confirmatory study with its presently suggested design and a 3 years recruitment period including EU as well as non-EU sites would be feasible.

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The main efficacy results are derived from the pivotal PDX-008 study (n=109 evaluable patients), with some support from the preceding phase I/II dose-finding PDX-02-078 study (n=15 evaluable patients with PTCL as defined in the PDX-008 study and treated with the same dose regimen).

Contrary to the CHMP/EMA advice, forwarded to the Sponsor in the setting of a protocol assistance, the pivotal study was designed as a single-arm trial with response rate constituting the primary endpoint.

<div style=\"page-break-after: always\"></div>

As will be discussed below, lack of a randomised controlled study, in the absence of dramatic activity, hampers a conclusive assessment of the benefit-risk balance.

According  to  the  Applicant,  reasons  for  choosing  a  single-arm  approach  included  the  rarity  of  the studied  disorders  and  the  lack  of  treatment  consensus  in  the  refractory/relapse  setting,  that  is,  an obvious control arm. The Applicant furthermore stated that '..., the observation of objective responses -  particularly  durable  responses  -  is  generally  accepted  as  a  clinically  meaningful  endpoint  by haematologists  and  oncologists,  and  this  endpoint  can  be  robustly  assessed  in  non-comparative studies'.    Although  the  facts  regarding  the  rarity  of  the  disease(s)  and  the  lack  of  a  treatment consensus in refractory/relapsing PTCL are acknowledged, the clinical benefit of objective response per se has not been established in this clinical setting and in the absence of dramatic activity, the clinical benefit cannot be considered established. Additionally, a single arm design does not allow estimation of clinical benefit in terms of clinical benefit endpoints such as PFS or OS.

## Efficacy data and additional analyses

The response rate in PDX-008 study was 29%. Only 15% of patients in the efficacy set obtained a confirmed response duration of ≥ 14 weeks. The significance of PFS and OS is not possible to assess with this study design.

The intra-individual analyses comparing efficacy of pralatrexate with that of previous therapies were non-prespecified.  These  analyses  are  associated  with  the  corresponding  pitfalls,  e.g.  historical comparisons,  investigator-derived  PFS  data  and  the  risk  of  underestimated  response  duration  of previous therapy.

The  presented  historical  registry  data  are  of  general  interest  but  of  limited  value  for  a  direct comparison with data obtained with pralatrexate. The validity of the historical control as a comparator for PDX-008 is questioned by CHMP. It is not clear how selection bias was avoided and therefore, the historical comparison presented considered not acceptable.

The preliminary results of studies PDX-010 and PDX-009 did not add any substantial information to the assessment of pralatrexate's efficacy within the proposed indication. Study PDX-010 is a Phase I study of  patients  with  CTCL,  a  very  different  patient  group  than  those  with  PTCL.  In  study  PDX-009, 16 evaluable PTCL patients show 10 PDs, 2 SDs, 2PRs, and 2 patients unevaluable by IWC but with a metabolic response by PET (by investigator).

## Additional expert consultation

Following the CHMP request, a Scientific Advisory Group meeting was convened on 1 December 2011 to  provide  advice  on  the  following  list  of  questions  adopted  by  the  CHMP  at  its  November  2011 meeting.

1. The SAG is asked to describe how impressive they view the efficacy data to be (based on response rate, duration of response, PFS, OS) in light of the methodological limitations of the study, in particular the absence of a randomised control group.

Pralatrexate has shown antitumor activity in patients with relapsed PTCL. Based on indirect comparisons, the activity in terms of response rate appears to be in the same range of other singleagent or combination regimens which are currently used in this setting, although the efficacy of such treatment options cannot be considered established according to conventional scientific or regulatory standards. The antitumor activity observed for pralatrexate cannot be considered impressive or otherwise outstanding, and based on this the activity it is not possible to establish the clinical efficacy of this agent in the proposed indication.

<div style=\"page-break-after: always\"></div>

There are serious concerns from the point of view of external validity in view of the design of the pivotal study, especially the non-randomised design of the study. Such design does not allow establishing the efficacy of pralatrexate in terms of relevant clinical benefit endpoints such as PFS or OS in this population. Overall, the clinical benefit cannot be considered established and therefore the benefit cannot be considered to outweigh the risks.

## 2. Does the SAG consider the proposed confirmatory study feasible in the EU after the medicinal product would have obtained a marketing authorisation in the EU?

Overall, the proposed trial is feasible (before or after a marketing authorisation). From an ethical point of view there are in principle no major issues, due to the fact that benefits have not been established.

Due to the rare disease, an underpowered study may be the only possible option. Such trial could still generate useful data, particularly in terms of PFS or OS, and to assess the proportion of patients that can undergo BMT (as a secondary endpoint). The feasibility of the study in terms of recruitment will also be affected also by practical issues (e.g., treatment options made available for the control arm).

Due to the long expected time lag between progression and death, PFS seems to be a more sensitive endpoint and this could allow a cross-over option after progression if this is deemed necessary. However, if the trial aims to detect a difference in terms of OS then cross-over is likely to be a problem.

## 3. Does the SAG consider the results of the ongoing PDX-017 study of value and supportive/confirmatory in terms of efficacy for the current indication applied for?

This trial is in a different indication and would not contribute useful information to support the proposed indication.

## 4. Referring to Q2 and Q3 is there another patient group which is considered relevant for the indication applied for where a controlled study would be considered feasible to conduct.

The proposed study is considered feasible (see answer to Q2). No other patient group was identified.

## 5. The SAG is asked to discuss the severity of the side effects, in particular regarding mucositis and other skin reactions, and whether these can be managed in clinical practice.

Overall the toxicity is considered to be significant, in particular concerning mucositis, skin reactions. Although in many cases such toxicity can be managed, as there is vast experience on managing similar toxicity with other agents such as methotrexate, drug-related deaths associated with pralatrexate have been observed. In the absence of established benefits, even if mostly manageable, the toxicity remains a concern.

Patients with existing cutaneous involvement are likely to be at a higher risk of cutaneous toxicity. In addition,  there  are  too  few  data  in  patients  with  'third  space'  distribution  of  the  drug  and  these uncertainties should be part of a risk minimisation plan.

## 2.5.4. Conclusions on the clinical efficacy

Pralatrexate  showed  antitumor  activity  in  terms  of  response  rate.  However,  the  extent  to  which antitumor  activity  reflects  clinical  benefit  is  unknown.  Therefore,  the  clinical  efficacy  of  this  agent cannot be considered established in the proposed indication.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## Patient exposure

Based  on  the  data  cut-off  (31  January  2011)  of  the  last  update  submitted  by  the  Applicant,  the clinical study safety database included data on 689 patients who were treated with pralatrexate across all  clinical  studies,  of  which  141  patients  with  relapsed/refractory  PTCL  who  received  single-agent pralatrexate (PDX-008  =  111  patients;  PDX-02-078  =  30  patients).  In  addition,  post-marketing experience  in  the  USA  is  estimated  include  1,157  to  2,025  patients.  Overall,  the  total  exposure  of pralatrexate is approximately 1,298 to 2,166 patients in the requested indication.

In  study  PDX-008  the  protocol  allowed  for  dose  omission  or  dose  reduction  to  20  mg/m 2 /week if  a patient  experienced  protocol-defined  Adverse  Events.  Dose  reduction  below  20  mg/m 2 was  not allowed. 76 patients (68%) remained at the target dose for the duration of treatment. The pralatrexate dose was reduced from 30 mg/m 2  to 20 mg/m 2  for 35 patients (32%).

The majority of patients received 1-3 cycles of treatment. The median total dose administered over the course  of  treatment  was  208 mg/m 2 (range  27-2109  mg/m 2 )  and  the  mean  was  384  mg/m 2 .  The median duration of treatment was 70 days and the mean was 121 days (range 1-696 days) for all treated  patients  The  median  number  of  pralatrexate  doses  administered  to  patients  was  7 and  the mean was 14 (range 1-74 doses).

Concerning  long  term  treatment,  nineteen  patients  (17%)  were  treated  with  pralatrexate  for ≥ 6 months and 10 patients (9%) were treated for ≥ 1 year.

## Adverse events

The  safety  of  pralatrexate  was  evaluated  in  111 peripheral  T-cell  lymphoma  (PTCL)  patients  in  one single-arm  pivotal  clinical  study,  PDX-008,  in  which  patients  received  30 mg/m 2 once  weekly  for 6 weeks in 7-week cycles.

The most common adverse drug reactions reported in the PDX-008 study were mucosal inflammation (68% of patients), thrombocytopenia (40%), nausea (33%) and anaemia (32%). Neutropenia of any grade occurred in 24% of patients.

The  most  common  AEs ≥ grade  3  were  thrombocytopenia,  mucosal  inflammation,  neutropenia, anaemia and leucopoenia (32%, 22%, 22%, 16% and 8%, respectively). Other common Grade 3 and 4  adverse  reactions  included  skin  ulcer,  infection,  anorexia,  dyspnoea,  vomiting,  nausea,  pain,  and fatigue.

The median time to onset of AEs ≥ Grade 3 was 15 days for thrombocytopenia, 19 days for mucosal inflammation, and 22 days for neutropenia. The median duration of AEs ≥ Grade 3 was 16 days for thrombocytopenia, 13 days for mucosal inflammation, and 8 days for neutropenia.

In  the  pivotal  study  the  median  onset  of ≥ grade  3  mucosal  inflammation,  thrombocytopenia  and neutropenia was between day 15-19 and the median duration was 8-16 days.

Bleeding  complications  coincident  with  the  low  platelet  counts  were  generally  mild  in  severity  and predominantly  presented  clinically  as  epistaxis.  Infection  complications  coincident  with  the  low neutrophil counts were mostly Grade 1-2 in severity.

<div style=\"page-break-after: always\"></div>

Table 29 Treatment-Related Adverse Events by System Organ Class and Preferred Terms. All Grades population 1 - pivotal study, all treated patients

|                                                 | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   | PDX-008 (N=111)   |
|-------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                                                 | Grade 1           | Grade 1           |                   |                   | Grade 3           | Grade 3           | Grade 4           | Grade 4           | Total             | Total             |
| System Organ Class Preferred Term               | n                 | (%)               | n                 | (%)               | n                 | (%)               | n                 | (%)               | n (%)             |                   |
| ALL                                             | 11                | (10)              | 24                | (22)              | 42                | (38)              | 29                | (26)              | 106 (95)          |                   |
| GASTROINTESTINALDISORDERS                       | 22                | (20)              | 42                | (38)              | 22                | (20)              | 4                 | (4)               | 90 (81)           |                   |
| STOMATITIS                                      | 20                | (18)              | 32                | (29)              | 18                | (16)              | 4                 | (4)               | 74 (67)           |                   |
| NAUSEA                                          | 22                | (20)              | 12                | (11)              | 4                 | (4)               | 0                 | (0)               | 38 (34)           |                   |
| CONSTIPATION                                    | 17                | (15)              | 6                 | (5)               | 0                 | (0)               | 0                 | (0)               | 23 (21)           |                   |
| VOMITING                                        | 15                | (14)              | 6                 | (5)               | 2                 | (2)               | 0                 | (0)               | 23 (21)           |                   |
| DIARRHOEA                                       | 12                | (11)              | 6                 | (5)               | 1                 | (1)               | 0                 | (0)               | 19 (17)           |                   |
| ABDOMINALPAINUPPER                              | 4                 | (4)               | 2                 | (2)               | 0                 | (0)               | 0                 | (0)               | 6 (5)             |                   |
| APHTHOUS STOMATITIS                             | 5                 | (5)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 5 (5)             |                   |
| GASTROOESOPHAGEALREFLUXDISEASE                  | 4                 | (4)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 5 (5)             |                   |
| ORAL PAIN                                       | 5                 | (5)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 5 (5)             |                   |
| ABDOMINALDISCOMFORT                             | 3                 | (3)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 3 (3)             |                   |
| ABDOMINAL PAIN                                  | 2                 | (2)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 3 (3)             |                   |
| DRY MOUTH                                       | 3                 | (3)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 3 (3)             |                   |
| DYSPEPSIA                                       | 3                 | (3)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 3 (3)             |                   |
| HAEMORRHOIDS                                    | 2                 | (2)               | 0                 | (0)               | 1                 | (1)               | 0                 | (0)               | 3 (3)             |                   |
| FLATULENCE                                      | 2                 | (2)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 2 (2)             |                   |
| GASTRITIS                                       | 1                 | (1)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 2 (2)             |                   |
| LIP DRY                                         | 2                 | (2)               | 0                 | (0)               | 0                 |                   | 0                 | (0)               | 2 (2)             |                   |
| OESOPHAGITIS                                    | 0                 | (0)               | 0                 | (0)               | 1                 | (0) (1)           | 1                 | (1)               | 2 (2)             |                   |
| ANAL INFLAMMATION                               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| CHEILITIS                                       | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| CHEILOSIS                                       | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| DYSPHAGIA                                       | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| GINGIVAL OEDEMA                                 | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| GINGIVALPAIN                                    | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1) 1           |                   |
| HAEMORRHOIDALHAEMORRHAGE                        | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | (1)               |                   |
| HYPOAESTHESIAORAL                               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1) 1           |                   |
| LIP DISORDER                                    | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | (1)               |                   |
| LIP PAIN                                        | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1) 1           |                   |
| LIP ULCERATION                                  | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | (1)               |                   |
| MOUTH ULCERATION                                | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| ODYNOPHAGIA                                     | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| OESOPHAGEALPAIN                                 | 0                 | (0)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | (1) 1             |                   |
| ORAL DISORDER                                   | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | (1)               |                   |
| ORAL MUCOSAL ERYTHEMA                           | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| PANCREATITIS                                    | 0                 | (0)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| PARAESTHESIAORAL                                | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1) (1)         |                   |
| PERIANAL ERYTHEMA                               | 0                 | (0)               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 1                 |                   |
| RECTALHAEMORRHAGE                               | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1) (1)         |                   |
| TONGUEDISCOLOURATION                            | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1                 |                   |
| TONGUEULCERATION                                | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| TOOTHACHE                                       | 1                 | (1)               | 0                 | (0)               | 0                 | (0)               | 0                 | (0)               | 1 (1)             |                   |
| GENERALDISORDERSANDADMINISTRATIONSITECONDITIONS |                   |                   |                   | (17)              | 10                | (6)               | 2                 | (2)               | 60 (54)           |                   |
|                                                 | 29                | (26)              | 19                |                   |                   |                   | 1                 |                   |                   |                   |
| FATIGUE PYREXIA                                 | 17 17             | (15) (15)         | 11 4              | (10) (4)          | 5 0               | (5)               | (0) 0             | (1) (0)           | 34 (31) 21 (19)   |                   |

<div style=\"page-break-after: always\"></div>

| OEDEMA PERIPHERAL                           | 13          | (12)    | 7 (6)   | 0            | (0)     | 0           | 20 (18)     |
|---------------------------------------------|-------------|---------|---------|--------------|---------|-------------|-------------|
| MUCOSALINFLAMMATION                         | 2 (2)       | 4       | (4)     | 2            | (2)     | (0) 1 (1)   | 9 (8)       |
| ASTHENIA                                    | 2 (2)       | 3       | (3)     | 1            | (1)     | 0 (0)       | 9 (5)       |
| FACE OEDEMA                                 | 3 (3) 2     | 1 0     | (1)     | 1            | (1)     | 0 (0)       | 5 (5) 4     |
| PAIN AXILLARY PAIN                          | (2) 2 (2)   | 0       | (0) (0) | 2 0          | (2) (0) | 0 (0)       | (4) 2 (2)   |
| CHEST PAIN                                  |             | 2       |         | 0            | 0 0     | (0)         | 2           |
| CHILLS                                      | 0 (0) 2     | 0       | (2) (0) | 0            | (0) (0) | (0) (0)     | (2) 2       |
| INFLUENZA LIKE ILLNESS                      | (2)         | 1       | (1)     | 0            | 0 0     | (0)         | (2) 2 (2)   |
| LOCALISED OEDEMA                            | 1 (1) 2 (2) | 0       | (0)     | 0            | (0) (0) | (0)         | 2 (2)       |
| EARLYSATIETY                                | 1 (1)       | 0       | (0)     | 0            | 0 (0) 0 | (0)         | 1 (1)       |
| INFUSIONRELATEDREACTION                     | 1 (1)       | 0       | (0)     | 0            | (0) 0   | (0)         | 1 (1)       |
| LOCAL SWELLING                              | 1 (1)       | 0       | (0)     | 0            | (0) 0   | (0)         | 1 (1)       |
| MUCOSALDRYNESS                              | 1 (1)       | 0       | (0)     | 0            | (0) 0   | (0)         | 1 (1)       |
| RESPIRATORY，THORACICANDMEDIASTINALDISORDERS |             |         |         |              | (5)     |             |             |
|                                             | 40 (36)     | 8       | (7)     | 5            | 1       | (1)         | 54 (49)     |
| EPISTAXIS                                   | 24 (22)     | 2       | (2)     | 0            | (0) 0 0 | (0)         | 26 (23)     |
| DYSPNOEA                                    | 8 (7)       | 0       | (0)     | 3            | (3) (1) | (0)         | 11 (10)     |
| PHARYNGOLARYNGEALPAIN                       | 8 (7)       | 1       | (1)     | 1            | 0       | (0)         | 10 (9)      |
| COUGH                                       | 8 (7)       | 0       | (0)     | 0            | (0)     | 0 (0) 0     | 8 (7)       |
| DYSPHONIA                                   | 5 (5)       | 0       | (0)     | 0            | (0)     | (0)         | 5 (5)       |
| PHARYNGEAL INFLAMMATION                     | (1)         | 2       | (2)     | 1            | (1)     | 0 (0)       | 4 (4)       |
| DRY THROAT                                  | 1 2 (2)     | 0       | (0)     | 0            | (0)     | 0 (0)       | 2 (2)       |
| PLEURAL EFFUSION                            | 2 (2)       | 0       | (0)     | 0            | (0)     | 0 (0)       | 2 (2)       |
| PNEUMONITIS                                 | 0           |         |         |              |         |             |             |
|                                             | (0)         | 2       | (2)     | 0            | (0)     | 0 (0)       | 2 (2)       |
| PRODUCTIVECOUGH                             | (2)         | 0       | (0)     | 0            | (0)     | 0 (0)       | 2 (2)       |
| HICCUPS                                     | 2 1 (1)     | 0       | (0)     | 0            | (0)     | 0 (0)       | (1)         |
| HYPOXIA                                     | 0 (0)       |         | (1)     | 0            |         | 0           | 1 1 (1)     |
| LUNG CONSOLIDATION                          | (1)         | 1 0     | (0)     | 0            | (0)     | (0) (0)     | 1 (1)       |
| NASALCONGESTION                             | 1 1 (1)     | 0       | (0)     | 0            | (0) (0) | 0 0         | 1 (1)       |
| PLEURITIC PAIN                              | 0 (0)       | 1       | (1)     | 0            |         | (0) 0 (0)   | (1)         |
| PULMONARYCONGESTION                         | 0 (0)       | 1       | (1)     | 0            | (0) (0) | 0 (0)       | 1 (1)       |
| PULMONARYEMBOLISM                           | 0 (0)       | 0       | (0)     | 0            | (0)     | 1           | 1 (1)       |
| REFLUXLARYNGITIS                            | 0 (0)       | 1       | (1)     | 0            |         | (1) 0 (0)   | 1 (1)       |
| RHINORRHOEA                                 | 1 (1)       | 0       | (0)     | 0 0          | (0) (0) | (0)         | 1 (1)       |
|                                             | 1           |         |         | (0)          | 0       |             | 1           |
| TACHYPNOEA THROATTIGHTNESS                  | (1) 1 (1)   | 0 0     | (0) (0) | (0)          | 0 0     | (0) (0)     | (1) 1 (1)   |
|                                             |             |         |         | 0            |         |             |             |
| BLOODANDLYMPHATICSYSTEMDISORDERS            | 3 (3)       | 9       | (8)     | 22           | (20) 19 | (17)        | 53 (48)     |
| THROMBOCYTOPENIA                            | 0 (0)       | 5       | (5)     | 13           | 15      | (14)        | 33 (30)     |
| ANAEMIA                                     | 1 (1)       | 15      | (14)    | (12) 13 (12) | 1       | (1)         | 30 (27)     |
| NEUTROPENIA                                 | 0 (0)       | 3       | (3)     | 12           | (11)    | 7 (6) 3     | 22 (20)     |
| LEUKOPENIA                                  | 1 (1)       | 0       | (0)     | 1            | (1) (4) | (3)         | 5 (5)       |
| FEBRILE NEUTROPENIA                         | 0 (0)       | 0       | (0)     | 4            | 0 0     | (0)         | 4 (4)       |
| LYMPHOPENIA                                 | 1 (1)       | 0       | (0)     | 1            | (1) (1) | (0)         | 2 (2) 2     |
| PANCYTOPENIA                                | 0 (0)       | 0       | (0)     | 1 0          | 1       | (1)         | (2)         |
| HAEMOLYTICANAEMIA                           | 0 (0)       | 1       | (1)     | (0) (0)      | 0       | (0)         | 1 (1)       |
| LYMPH NODE PAIN                             | 1 (1)       | 0       | (0)     | 0            | 0       | (0) (0)     | 1 (1)       |
| SPLENOMEGALY                                | 1 (1)       | 0       | (0)     | 0            | (0)     | 0           | 1 (1)       |
| SKINANDSUBCUTANEOUSTISSUEDISORDERS          | 23 (21)     | 11      | (10)    | 6            | (5)     | 0 (0)       | 40 (36)     |
| RASH                                        | 10 (9)      | 2       | (2)     | 0 (0)        | 0       | (0)         | 12 (11)     |
| PRURITUS                                    | 4 (4)       | 3       | (3)     | 1 (1) 2      | 0       | (0)         | 8 (7)       |
| SKIN ULCER                                  | 2 (2)       | 2       | (2)     | (2)          | 0       | (0)         | 9 (5)       |
| ALOPECIA                                    | 4 (4)       | 0       | (0)     | 0            | (0) (0) | 0 (0) 0     | 4 (4)       |
| BLISTER                                     | 2 (2)       | 2       | (2)     | 0 1          |         | (0)         | 4 (4)       |
| SKIN LESION                                 | 1 (1)       | 2       | (2)     | (1)          | 0       | (0)         | 4 (4)       |
| DRY SKIN                                    | 3 (3)       | 0       | (0)     | 0            | (0)     | 0 (0)       | (3)         |
|                                             | 3 (3)       |         |         |              | (0)     | 0           | 3 3         |
| ERYTHEMA                                    |             | 0       | (0)     | 0            |         | (0)         | (3) 3 (3)   |
| PERIORBITALOEDEMA                           | 1 (1)       | 2       | (2)     | (0)          | 0       | (0)         |             |
| PETECHIAE                                   | 3 (3)       | 0       | (0)     | 0            | (0)     | 0           | 3 (3)       |
| URTICARIA                                   | (2)         | 0       |         | 0 1          |         | (0) (0)     |             |
| RASHGENERALISED                             | 2 2 (2)     | 0       | (0) (0) | 0            | (1) (0) | 0 0 (0)     | 3 (3) 2 (2) |
| ECCHYMOSIS                                  | 1 (1)       | 0       | (0)     | 0 0          | (0)     | 0           | 1 (1)       |
| GENERALISEDERYTHEMA                         | 1 (1)       | 0       | (0)     | (0)          | 0       | (0) (0)     | 1 (1)       |
| NIGHT SWEATS                                | 1 (1)       | 0       | (0)     | 0 (0)        |         | 0 (0)       | 1 (1)       |
| PAIN OF SKIN                                | 0 (0)       | 1       | (1) (1) | 0 (0) 0 (0)  | 0 0     | (0) (0)     | 1 (1) 1 (1) |
| PENILEULCERATION RASHERYTHEMATOUS           | 0 (0) 0 (0) | 1 0     | (0)     | 1 (1)        |         | 0           | 1 (1)       |
| RASH MACULAR                                | 1           | (1) 0   | (0)     | 0 0          | (0)     | (0) 0       | 1 (1)       |
| RASH MACULO-PAPULAR RASH PAPULAR            | 1 (1) 1     | 0 (1) 0 | (0) (0) | (0) 0 (0)    | 0 0     | (0) (0) (0) | 1 (1) 1 (1) |

<div style=\"page-break-after: always\"></div>

| RASH PRURITIC                                         | 0     | (0)      | 0                 | (0)     | 1 (1)     | 0     | (0)         | 1 (1)               |             |
|-------------------------------------------------------|-------|----------|-------------------|---------|-----------|-------|-------------|---------------------|-------------|
| SCAB                                                  | 1     | (1)      | 0                 | (0) (0) | 0 0       | (0) 0 | (0)         | 1 (1)               |             |
| SKIN DISORDER SKIN EXFOLIATION                        | 1 0   | (1) (0)  | 0 1               | (1)     | (0) 0 (0) | 0 0   | (0) (0)     | 1 (1) 1 (1)         |             |
| SKIN HAEMORRHAGE                                      | 1     | (1)      | 0                 | (0)     | 0 (0)     | 0     | (0)         | 1 (1)               |             |
| SKIN TOXICITY                                         | 0     | (0)      | 1                 | (1) 0   | (0)       | 0     | (0)         | 1 (1)               |             |
| INFECTIONSANDINFESTATIONS                             | 9     | (8)      | (17)              | 9       | (8)       | 2     | (2)         | 39                  |             |
| SINUSITIS                                             | 1     | (1)      | 19 5              | 0       | (0)       | 0     | (0)         | (35) 6 (5)          |             |
| FOLLICULITIS                                          | 4     | (4)      | (5) 0 (0)         | 1       | (1)       | 0     | (0)         | 5 (5)               |             |
| ORAL HERPES                                           | 5     | (5)      | 0                 | (0) 0   | (0)       | 0     | (0)         | 5 (5)               |             |
| CANDIDIASIS                                           | 2     | (2)      | 1 (1)             | 1       | (1)       | 0     | (0)         | 4 (4) 4             |             |
| ORALCANDIDIASIS                                       | 4     | (4)      | 0 (0) (1)         | 0       | (0)       | 0 0   | (0) (0)     | (4) 4               |             |
| UPPERRESPIRATORYTRACTINFECTION                        | 2     | (2)      | 1 3               | 1       | (1)       | 0     | (0)         | (4) 4               |             |
| URINARYTRACTINFECTION                                 | 0     | (0)      | (3)               | 1       | (1)       | 0     |             | (4)                 |             |
| HERPESZOSTER                                          | 1     | (1)      | 0 (0)             | 2       | (2)       | 0     | (0)         | 3 (3)               |             |
| LOCALISEDINFECTION                                    | 0     | (0)      | 3 (3) 2           | 0       | (0)       |       | (0)         | 3 (3)               |             |
| PNEUMONIA                                             | 0     | (0)      | (2)               | 1       | (1)       | 0     | (0)         | 3 (3)               |             |
| SEPSIS                                                | 0     | (0)      | 0 (0)             | 1       | (1)       | 2 0   | (2)         | 3 (3)               |             |
| BRONCHITIS                                            | 0     | (0)      | 2 (2)             | 0       | (0)       | 0     | (0)         | 2 (2)               |             |
| CELLULITIS                                            | 0     | (0)      | 2 (2)             | 0       | (0)       |       | (0)         | 2 (2)               |             |
| INFECTION                                             | 0     | (0)      | 1 (1)             | 1       | (1)       | 0     | (0)         | 2 (2)               |             |
| SUBCUTANEOUSABSCESS                                   | 0     | (0)      | 2 (2)             | 0       | (0)       | 0     | (0)         | 2 (2)               |             |
| ABSCESS                                               | 0     | (0)      | 1 (1)             | 0       | (0)       | 0     | (0)         | 1 (1)               |             |
| BACTERIALINFECTION                                    | 0     | (0)      | 1 (1)             | 0       | (0)       | 0     | (0)         | 1 (1)               |             |
| CHRONICSINUSITIS                                      | 1 (1) |          | 0 (0)             | 0       | (0)       | 0 0   | (0)         | (1) (1)             |             |
| CLOSTRIDIUMDIFFICILE COLITIS CYTOMEGALOVIRUSCOLITIS   | 0     | (0)      | 0 (0) 0 (0)       | 1       | (1) (1)   | 0     | (0) (0)     | 1 1 (1)             |             |
| FUNGAL INFECTION                                      | 0     | (0)      | 1                 | 1       | (0)       | 0     |             | 1                   |             |
| FUNGALSKIN INFECTION                                  | 0     | (0) (0)  | (1) 1             | 0 0     | (0)       | 0     | (0)         | (1) 1               |             |
| HERPES SIMPLEX                                        | 0 1   | (1)      | (1) 0 (0)         | 0       | (0)       | 0     | (0) (0)     | (1) 1 (1)           |             |
| HERPESVIRUSINFECTION                                  | 1     | (1)      | 0 (0)             | 0       | (0)       | 0     | (0)         | 1 (1)               |             |
| LUNG INFECTION                                        | 1     | (1)      | 0 (0)             | 0       | (0)       | 0     | (0)         | 1 (1) (1)           |             |
| NAIL INFECTION                                        | 0     | (0)      | 1 (1)             | 0       | (0)       | 0     | (0)         | 1                   |             |
| NASOPHARYNGITIS                                       | 1     | (1)      | 0 (0)             | 0       | (0)       | 0     | (0)         | 1 (1) 1             |             |
| OESOPHAGEALCANDIDIASIS                                | 0     | (0)      | 1 (1)             | 0       | (0)       | 0     | (0)         | (1) 1               |             |
| PHARYNGITIS                                           | 1     | (1)      | 0 (0)             | 0       | (0)       | 0     | (0)         | (1) 1               |             |
| PILONIDAL CYST                                        | 0     | (0)      | 1 (1) (1)         | 0       | (0)       | 0     | (0)         | (1)                 |             |
| SINUSITISBACTERIAL                                    | 0     | (0)      | 1 1               | 0       | (0)       | 0     | (0)         | 1 (1)               |             |
| STAPHYLOCOCCALINFECTION                               | 0     | (0)      | (1)               | 0       | (0)       | 0     | (0)         | 1 (1)               |             |
| TOOTH INFECTION                                       |       | (1)      | (0)               |         | (0)       | 0     | (0)         | 1 (1)               |             |
| VULVOVAGINALMYCOTICINFECTION                          | 1 1   | (1)      | 0 0 (0)           | 0 0     | (0)       | 0     | (0)         | 1 (1)               |             |
| INVESTIGATIONS PLATELET COUNT DECREASED               | 6 1   | (5) (1)  | 11 (10) 3 (3)     | 12 4    | (11) (4)  | 7 4 0 | (6) (4)     | 36 (32) 12 (11)     |             |
| HAEMOGLOBINDECREASED                                  |       | (2)      | 3 3               | 3       | (3)       | 1 1   | (1)         | 10 9 (8) 7          |             |
| ALANINEAMINOTRANSFERASEINCREASED                      | 3     | (3)      | (3) (3)           | 4       | (4)       | (1)   | (0)         | (9)                 |             |
| WHITEBLOODCELLCOUNTDECREASED NEUTROPHILCOUNTDECREASED | 2 1 0 | (1)      | 2 (2) 1           | 3 4     | (3) (4)   | 1     | (1)         | (6) 6 (5)           |             |
| WEIGHTDECREASED                                       | 4     | (0) (4)  | (1) 2 1           | 0 2     | (0)       | 0 0   | (0)         | 6 (5) 5             |             |
| ASPARTATEAMINOTRANSFERASEINCREASED                    | 2     | (2)      | (2) (1) 1         |         | (2)       |       | (0)         | (5)                 |             |
| ALANINEAMINOTRANSFERASE                               | 0     | (0)      | 2                 | 2       | (2)       | 0     | (0)         | 3 (3)               |             |
| ASPARTATEAMINOTRANSFERASE                             | 0     | (0) (1)  | (1) (2)           | 1       | (1)       | 0     | (0)         | 3 (3) 2             |             |
| BLOODALKALINEPHOSPHATASE INCREASED                    | 1     |          | 1 (1)             | 0       | (0)       | 0 0   | (0) (0)     | (2) 2               |             |
| BLOOD BILIRUBININCREASED                              | 1     | (1)      | 1 (1) 0           | 0       | (0)       | 0     |             | (2) 1 (1)           |             |
| BLOODCREATINE INCREASED                               | 1     | (1) (0)  | (0) 1             | 0       | (0)       |       |             | 1 (1) 1             |             |
| BLOOD CREATININE                                      | 0     |          | (1)               | 0       | (0)       |       | (0) (0) (0) | 1                   |             |
| BLOOD GLUCOSE INCREASED                               | 1     | (1)      | 0 1               | 0 0     |           | 0 0 0 |             | 1                   |             |
|                                                       | 0 1   |          | (0)               |         | (0)       |       |             | (1) (1) 1           |             |
| BLOODPHOSPHORUSINCREASED BLOODPOTASSIUMDECREASED      |       | (0)      | (1) 0             |         | (0)       |       | (0)         | (1)                 |             |
| BLOODURICACIDINCREASED                                | 1     | (1) (1)  | (0) 0 (0)         | 0 0     | (0) (0)   | 0 0   | (0)         | (1) 1               |             |
|                                                       | 0     |          | 1 (1)             | 0       | (0)       |       | (0) (0) (0) | 1                   |             |
| EJECTIONFRACTIONDECREASED                             |       |          |                   |         |           |       |             |                     |             |
| LIVERFUNCTIONTESTABNORMAL                             | 0     | (0)      | 1                 | 0       | (0)       | 0 0   |             |                     |             |
|                                                       |       | (0)      | (1)               |         |           |       |             | (1) (1) 27 (24) (9) |             |
| METABOLISMANDNUTRITIONDISORDERS HYPOKALAEMIA          | 17 8  | (15) (7) | 6 (5) 2 (2) 0 (0) | 4 0 0   | (4) (0)   | 0 0   | (0) (0) (0) | 10 7 (6)            |             |
| DECREASEDAPPETITE ANOREXIA HYPOMAGNESAEMIA            | 7 3   | (6) (3)  | 1 (1) 0 (0)       | 2 0     | (0) (2)   | 0 0 0 | (0)         | 6 5                 |             |
| DEHYDRATION                                           | 5 0   | (5) (0)  |                   | 1       | (0) (1)   |       | (0) (0)     | (5) (5) (3)         | (5) (5) (3) |
|                                                       |       |          | 2 (2)             |         |           | 0     |             | 3 2                 |             |
| HYPERKALAEMIA                                         |       |          | (1)               | 0       | (0)       |       | (0)         |                     |             |
|                                                       | 1     | (1)      | 1                 | 0       |           | 0 0   |             | (2) (2)             |             |
| HYPERURICAEMIA                                        | 1     |          |                   |         | (0)       |       | (0)         | 2                   |             |
|                                                       |       | (1)      | 1 (1)             |         |           |       |             |                     |             |

<div style=\"page-break-after: always\"></div>

| HYPOPHOSPHATAEMIA                            | 1             | (1)        | 0           | (0)     | 1       | (1)     | 0       | 2       | (2)        | (2)        | (2)            | (2)      |
|----------------------------------------------|---------------|------------|-------------|---------|---------|---------|---------|---------|------------|------------|----------------|----------|
| CELL DEATH                                   | 0             | (0)        | 0           | (0) (0) | 1       | (1) 0   | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| HYPERCALCAEMIA                               | 1             | (1)        | 0           | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| HYPERGLYCAEMIA                               | 1             | (1)        | 0           | (0)     | 0 (0)   | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| HYPOGLYCAEMIA                                | 1             | (1)        | 0 (0)       | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| MUSCULOSKELETALANDCONNECTIVE TISSUEDISORDERS | 11            | (10)       | 13 (12) (4) | 3       | (3)     | 0       | (0)     | 27      | (24) (8)   | (24) (8)   | (24) (8)       | (24) (8) |
| PAIN INEXTREMITY                             | 5             | (5) (5)    | 4 1         | 0       | (0)     | 0       | (0)     | 9 6     | (5)        | (5)        | (5)            | (5)      |
| MUSCLE SPASMS MYALGIA                        | 5 5           |            | (1) (0)     | 0 1     | (0) (1) | 0 0     | (0) (0) | 6       | (5)        | (5)        | (5)            | (5)      |
| ARTHRALGIA                                   | 1             | (5) (1)    | 0 4         | (4) 0   | (0)     | 0       | (0)     | 5       | (5)        | (5)        | (5)            | (5)      |
| BACK PAIN                                    | 1             | (1)        | 2 (2)       | 1       | (1)     | 0       | (0)     | 4       | (4)        | (4)        | (4)            | (4)      |
| MUSCULOSKELETALPAIN                          | 1             | (1)        | 2 (2) (3)   | 0       | (0)     | 0       | (0)     | 3       | (3)        | (3)        | (3)            | (3)      |
| NECK PAIN                                    | 0             | (0)        | 3           | 0       | (0)     | 0       | (0)     | 3       | (3)        | (3)        | (3)            | (3)      |
| COSTOCHONDRITIS                              | 0             | (0)        | 0 (0)       | 1       | (1)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| JOINTSTIFFNESS                               | 1             | (1)        | 0 (0)       | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| JOINT SWELLING                               | 1             | (1)        | 0 (0) 0     | 0 0     | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| MUSCULOSKELETALCHESTPAIN                     | 1             | (1)        | (0)         |         | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| MUSCULOSKELETALDISCOMFORT                    | 1             | (1)        | 0 (0)       | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| MUSCULOSKELETALSTIFFNESS                     | 0             | (0)        |             |         | (0)     | 0       | (0)     | 1       |            |            |                |          |
|                                              |               | 1          | (1)         | 0       |         |         |         |         | (1)        | (1)        | (1)            | (1)      |
| NERVOUSSYSTEMDISORDERS HEADACHE              | 15 (14) 6 (5) | 5 2        | (2)         | (5) 2 0 | (2) (0) | 0 0     | (0) (0) | 22 8    | (7)        | (7)        | (7)            | (7)      |
| DIZZINESS                                    | 5             | (5)        | 0 (0)       | 1       | (1)     | 0       | (0)     | 6       | (5)        | (5)        | (5)            | (5)      |
| PARAESTHESIA                                 | 2             | (2) 3      | (3)         | 0       | (0)     | 0       | (0)     | 5       | (5)        | (5)        | (5)            | (5)      |
| HYPOAESTHESIA                                | 2 (2)         | 0          | (0)         | 0       | (0)     | 0       | (0)     | 2       | (2)        | (2)        | (2)            | (2)      |
| NEUROPATHYPERIPHERAL                         | 2             | (2) 0      | (0)         | 0       | (0)     | 0       | (0)     | 2       | (2)        | (2)        | (2)            | (2)      |
| DYSGEUSIA                                    | 1             | 0 0        | (0)         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| FORMICATION                                  | 1             | (1) (1)    | (0)         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| MEMORY IMPAIRMENT                            | 0             | (0) 1      | (1)         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| NEURALGIA                                    | 0             | 1 0        | (1)         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| PERIPHERALSENSORYNEUROPATHY                  | 0             | (0) (0)    | (0)         | 1       | (1)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| SENSORYLOSS                                  | 1             |            | (0)         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| SYNCOPE                                      | (1) 0 (0)     | 0 0        | (0)         | 1       | (1)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| EYEDISORDERS                                 | 18            | (16) 6 (5) | 0 (0) 0     | 0 (0) 0 | (0) (0) | 0 0     | (0)     | 18      | (16) 6 (5) | (16) 6 (5) | EYE IRRITATION | (0)      |
| OCULARHYPERAEMIA                             | 5             | (5) (4)    | 0 (0) (0)   | 0 0     | (0)     | 0       | (0) (0) | 5 4     | (5) (4)    | (5) (4)    | (5) (4)        | (5) (4)  |
| LACRIMATIONINCREASED CONJUNCTIVALHYPERAEMIA  | 4             |            | 0           |         | (0)     | 0       |         |         |            |            |                |          |
|                                              | 2             | (2)        | 0 (0)       | 0       | (0)     | 0 0     | (0)     | 2 2     | (2)        | (2)        | (2)            | (2)      |
| VISION BLURRED                               | 2             | (2)        | 0 (0)       | 0 0     | (0)     | 0       | (0)     | 1       | (2)        | (2)        | (2)            | (2)      |
| CONJUNCTIVITIS                               | 1             | (1)        | 0 (0)       | 0       | (0)     |         | (0)     |         | (1)        | (1)        | (1)            | (1)      |
| DRY EYE                                      | 1             | (1)        | 0 (0) (0)   | 0       | (0)     | 0       | (0) (0) | 1       | (1)        | (1)        | (1)            | (1)      |
| ERYTHEMA OF EYELID EYE PRURITUS              | 1             | (1)        | 0 0         | 0       | (0)     | 0 0     | (0)     | 1       | (1) (1)    | (1) (1)    | (1) (1)        | (1) (1)  |
|                                              | 1             | (1)        | (0) 0       | 0       | (0) (0) | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| EYELID OEDEMA                                | 1             | (1)        | (0) 0       | 0       |         | 0       | (0)     | 1       |            |            |                |          |
| EYELIDPTOSIS EYELIDSPRURITUS                 | 1 1           | (1)        | (0) (0)     | 0       | (0) (0) | 0       | (0)     | 1       | (1) (1)    | (1) (1)    | (1) (1)        | (1) (1)  |
| PHOTOPSIA                                    | 1             | (1)        | 0 0         | 0       | (0)     | 0       | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
|                                              |               | (1) (1)    | (0) 0       |         | (0)     |         | (0)     | 1       | (1)        | (1)        | (1)            | (1)      |
| SCLERAL HYPERAEMIA                           | 1             |            | (0)         | 0       | (0)     | 0 0     |         | 1       |            |            |                |          |
| UVEITIS                                      | 1             |            | (0)         | 0       |         |         | (0)     | 1       |            |            |                |          |
| VISUALACUITYREDUCED                          | 1             | (1) (1)    | (0)         | 0       |         | 0       |         |         | (1) (1)    | (1) (1)    | (1) (1)        | (1) (1)  |
|                                              |               |            | 0 0         |         | (0)     |         | (0)     |         | (5)        | (5)        | (5)            | (5)      |
| PSYCHIATRICDISORDERS ANXIETY                 | 4 1           | (4) (1)    | 2 (2) 1 (1) | 0 0     | (0) (0) | 0 0     | (0) (0) | 6 2 2   | (2)        | (2)        | (2)            | (2)      |
| INSOMNIA                                     | 1 1           | (1) (1)    | 1 (1) 0     | 0       | (0)     | 0       | (0) (0) | 1 1     | (2) (1)    | (2) (1)    | (2) (1)        | (2) (1)  |
| AGITATION                                    | 1             |            | (0) 0       | 0       | (0)     | 0 0     | (0)     |         |            |            |                |          |
| CONFUSIONALSTATE                             |               | (1)        | (0)         | 0       | (0) (0) |         |         | 1       | (1) (1)    | (1) (1)    | (1) (1)        | (1) (1)  |
| DELUSION                                     | 1             | (1)        | 0 (0)       | 0       |         | 0       |         |         |            |            |                |          |
| DEPRESSION                                   | 1             | (1)        | 0 (0)       | 0       | (0)     | 0       | (0) (0) | 1       | (1)        | (1)        | (1)            | (1)      |
| EARANDLABYRINTHDISORDERS                     | 4             | (4)        | 1 (1)       | 0       | (0)     | 0 0     | (0) (0) | 5 2     | (5)        | (5)        | (5)            | (5)      |
| TINNITUS                                     | 2             | (2)        | 0 (0)       | 0       | (0)     |         | (0)     | 1       | (2)        | (2)        | (2)            | (2)      |
| DEAFNESS HYPOACUSIS                          | 1 0           | (1) (0)    | 0 (0) 1 (1) | 0 0     | (0) (0) | 0 0     | (0)     | 1 1     | (1) (1)    | (1) (1)    | (1) (1)        | (1) (1)  |
| VERTIGO                                      | 1             | (1)        | 0 (0)       | 0       | (0)     | 0       | (0)     |         | (1)        | (1)        | (1)            | (1)      |
| INJURY，POISONINGANDPROCEDURALCOMPLICATIONS   | 4             | (4)        | 1 (1)       | 0       |         | (0)     | (0)     | 5 2     | (5)        | (5)        | (5)            | (5)      |
| CONTUSION                                    | 2             | (2)        | 0 (0)       | 0       | (0)     | 0 0     | (0) (0) | 1       | (2) (1)    | (2) (1)    | (2) (1)        | (2) (1)  |
| EXCORIATION                                  | 0             | (0)        | (1)         | 0       | (0)     | 0       |         | 1       |            |            |                |          |
| MUSCLE STRAIN                                | 1             | (1)        |             | 0       | (0)     |         | (0)     |         |            |            |                |          |
|                                              | 1             |            |             | 0       |         | 0       |         | 1       |            |            |                |          |
|                                              |               |            |             |         |         | 0       | (0)     |         |            |            |                |          |
|                                              |               |            | 0           |         |         |         |         |         |            |            |                |          |
|                                              |               |            |             | (0)     |         |         |         |         |            |            |                |          |
| PROCEDURALNAUSEA                             |               |            |             |         |         |         |         |         |            |            |                |          |
|                                              |               |            |             |         | (0)     |         |         |         |            |            |                |          |
|                                              | 1 0 (0)       | 1 0 (0)    | 1 0 (0)     | 1 0 (0) | 1 0 (0) | 1 0 (0) | 1 0 (0) | 1 0 (0) | 1 0 (0)    | 1 0 (0)    | 1 0 (0)        | 1 0 (0)  |
|                                              | (1)           |            |             |         |         |         |         |         |            |            |                |          |
|                                              |               |            |             |         |         |         |         |         |            |            | (1)            | (1)      |
|                                              | (1)           | (1)        | (1)         | (1)     | (1)     | (1)     | (1)     | (1)     | (1)        | (1)        | (1)            | (1)      |

<div style=\"page-break-after: always\"></div>

| CARDIACDISORDERS                                                   |   3 | (3)   |   0 | (0)   | 0     | (0)     | 1 (1)   | 4   | (4)   |
|--------------------------------------------------------------------|-----|-------|-----|-------|-------|---------|---------|-----|-------|
| TACHYCARDIA                                                        |   2 | (2)   |   0 | (0)   | 0     | (0)     | 0 (0)   | 2   | (2)   |
| CARDIO-RESPIRATORYARREST                                           |   0 | (0)   |   0 | (0)   | 0     | 1       | (1)     | 1   | (1)   |
| CARDIOMEGALY                                                       |   1 | (1)   |   0 | (0)   | 0     | (0) (0) | 0 (0)   | 1   | (1)   |
| SUPRAVENTRICULARTACHYCARDIA                                        |   0 | (0)   |   0 | (0)   | 1 (1) | 0       | (0)     |     | (1)   |
| REPRODUCTIVESYSTEMANDBREASTDISORDERS                               |   3 | (3)   |   1 | (1)   | 0 (0) | 0       | (0)     | 4   | (4)   |
| BALANOPOSTHITIS                                                    |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| GENITAL RASH                                                       |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| GENITALULCERATION                                                  |   0 | (0)   |   1 | (1)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| VULVOVAGINALPRURITUS                                               |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| VASCULARDISORDERS                                                  |   1 | (1)   |   1 | (1)   | 0 (0) | 1       | (1)     | 3   | (3)   |
| HYPOTENSION                                                        |   1 | (1)   |   0 | (0)   | 0 (0) | 1       | (1)     | 2   | (2)   |
| JUGULAR VEIN THROMBOSIS                                            |   0 | (0)   |   1 | (1)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| SUBCLAVIANVEINTHROMBOSIS                                           |   0 | (0)   |   1 | (1)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| HEPATOBILIARYDISORDERS                                             |   0 | (0)   |   2 | (2)   | 0 (0) | 0       | (0)     | 2   | (2)   |
| HYPERBILIRUBINAEMIA                                                |   0 | (0)   |   2 | (2)   | 0 (0) | 0       | (0)     | 2   | (2)   |
| CHOLANGITIS                                                        |   0 | (0)   |   1 | (1)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| HEPATOSPLENOMEGALY                                                 |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| RENALANDURINARYDISORDERS                                           |   1 | (1)   |   0 | (0)   | 1 (1) | 0       | (0)     | 2   | (2)   |
| RENAL FAILURE                                                      |   0 | (0)   |   0 | (0)   | 1 (1) | 0       | (0)     | 1   | (1)   |
| URINARY HESITATION                                                 |   1 | (1)   |   0 | (0)   | 0     | (0)     | 0 (0)   | 1   | (1)   |
| CONGENITAL，FAMILIALAND GENETIC DISORDERS                           |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| PHIMOSIS                                                           |   1 | (1)   |   0 | (0)   | 0 (0) | 0       | (0)     | 1   | (1)   |
| NEOPLASMS BENIGN,MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) |   0 | (0)   |   0 | (0)   | 1 (1) | 0       | (0)     | 1   | (1)   |
| TUMOURLYSIS SYNDROME                                               |   0 | (0)   |   0 | (0)   | 1 (1) | 0       | (0)     | 1   | (1)   |

## Serious adverse event/deaths/other significant events

## Serious adverse events

SAEs that occurred in ≥ 2% of patients in the PDX-008 clinical trial are presented in descending order and by grade (all grades and ≥ Grade 3) in the table below.

Table 30 PDX-008: SAEs ≥ 2% incidence

|                                | PDX-008 (N =111)   | PDX-008 (N =111)   | PDX-008 (N =111)   | PDX-008 (N =111)   |
|--------------------------------|--------------------|--------------------|--------------------|--------------------|
|                                | All Grades         | All Grades         | ≥ Grade 3          | ≥ Grade 3          |
| SeriousAdverseEvents           |                    | (%)                |                    | (%)                |
| Pyrexia                        | 8                  | (7)                | 1                  | (1)                |
| Mucosal inflammation (grouped) | 6                  | (5)                | 6                  | (5)                |
| Febrile neutropenia            | 5                  | (5)                | 5                  | (5)                |
| Sepsis                         | 5                  | (5)                | 4                  | (4)                |
| Dehydration                    | 4                  | (4)                | 2                  | (2)                |
| Dyspnoea                       | 4                  | (4)                | 4                  | (4)                |
| Herpes zoster                  | 3                  | (3)                | 3                  | (3)                |
| Neutropenia (grouped)          | 3                  | (3)                | 2                  | (2)                |
| Pneumonia                      | 3                  | (3)                | 2                  | (2)                |
| Thrombocytopenia (grouped)     | 3                  | (3)                | 3                  | (3)                |
| Abdominal pain                 | 2                  | (2)                | 1                  | (1)                |
| Cerebral infarction            | 2                  | (2)                | 2                  | (2)                |
| Fatigue                        | 2                  | (2)                | 2                  | (2)                |
| Hypotension                    | 2                  | (2)                | 2                  | (2)                |
| Renal failure acute            | 2                  | (2)                | 2                  | (2)                |
| Skin ulcer                     | 2                  | (2)                | 0                  | (0)                |
| Urinary tract infection        | 2                  | (2)                | 2                  | (2)                |

Folotyn

<div style=\"page-break-after: always\"></div>

The most common treatment-related SAEs reported in the PDX-008 study were mucosal inflammation and  pyrexia  (both  5%),  and  febrile  neutropenia  (4%).  Treatment-related  SAEs  of  grade  4  were reported due to thrombocytopenia (3%), mucosal inflammation and sepsis (both 2%).

In all studies (n=574), treatment-related SAEs of any grade were reported in 117 patients (20%); the most  commonly  reported  were  mucosal  inflammation  (9%),  febrile  neutropenia,  pyrexia,  and thrombocytopenia  (all  2%).  Tumour  lysis  syndrome  occurred  in  4  patients  in  the  clinical  trials  of pralatrexate, whereof 3 patients with PTCL.

## Deaths

In the pivotal study there were 8 deaths (7%), during the study or within 30 days of treatment. Seven deaths were due to disease progression and one (&lt;1%) due to cardiopulmonary arrest.

In  the  entire  safety  population,  6  deaths  were  considered  to  be  at  least  possibly  related  to  study treatment, including 3 in patients with PTCL: Two related to neutropenia and one due to whole body desquamation.

## Serious dermatological reactions

Among the 689 patients who received at least 1 dose of pralatrexate across all clinical studies, 346 patients  (50%)  experienced  at  least  1  AE  regardless  of  causality  within  the  skin  and  subcutaneous tissue disorders SOC. The most common of these dermatological AEs include alopecia (12%), pruritus (7%), and rash (7%).

Six  cases  in  both  clinical  study  and  post-approval  environments  resulted  in  a  fatal  outcome.  These severe events generally occurred after the first dose in patients with extensive skin disease and were generally associated with other adverse events including mucositis, neutropenia, and/or infection and included extensive skin involvement with both lymphoma and the subsequent dermatological reaction. These dermatological events included skin exfoliation, ulceration, and toxic epidermal necrolysis.

Twenty seven patients (4%) reported a grade 3-5 AE in the skin and subcutaneous tissue disorders SOC; grade 3-5 treatment-related dermatological AEs occurred in 23 patients overall (3%), those that occurred in &gt; 1 patient included pain of skin, pruritus, and skin ulcer in 3 patients each (&lt; 1%), and exfoliative rash, palmar-plantar erythrodysaesthesia syndrome, skin lesion, and toxic skin eruption in 2 patients  each  (&lt;  1%).    Fifteen  patients  across  all  studies  reported  dermatological  SAEs  and  an additional  2  patients  reported  nonserious  dermatological  AEs  that  were  discussed  in  the  context  of nondermatological SAEs. Thus, 17 patients in a total of 689 patients across all studies were considered as  having  experienced  important  dermatological  reactions  which  corresponds  to  an  incidence  of approximately 2.5%.

In  PDX-008,  7  patients  (6%)  reported  Grade  3  events  and  no  patients  reported  Grade  4-5 dermatological  AEs.  Grade  3  treatment-related  dermatological  AEs  occurred  in  6  patients  (5%), including 2 patients with skin ulcer, 1 patient with erythematous rash and pruritic rash, and 1 patient each with pruritus, skin lesion, and urticaria. Two patients (2%) reported dermatological SAEs; both were hospitalisations for skin ulcer management (one was a Grade 1 treatment-related report and the other was a Grade 2 non-treatment-related reported).

## Thromboembolic cases

Five thromboembolic SAEs were reported in PDX-008. All 5 SAEs were Grade 3-4 in severity, and 4 of 5 were assessed by the investigator as not related to pralatrexate. The SAE of pulmonary embolus was assessed by the investigator as possibly related to pralatrexate.

<div style=\"page-break-after: always\"></div>

Based  on  the  information  provided,  1 patient  had  complete  SAE  resolution,  1 patient's  condition improved, and the other 3 patients were discharged. One patient had a cerebral infarction that was treated  with  aspirin,  resulting  in  resolution  of  all  symptoms,  and  one  patient  had  a  subclavian thrombosis that was treated with heparin and warfarin, and the condition subsequently improved and the patient was discharged.

Two patients were reported as continuing on pralatrexate treatment, 2 patients were noted as having pralatrexate  discontinued,  and  1  patient  had  been  previously  discontinued  from  pralatrexate  for progression of disease (PD). This patient received the last dose of pralatrexate 22 days prior to SAE onset,  was  permanently  discontinued  from  the  study  8  days  prior  to  SAE  onset,  and  had  received subsequent therapy for the lymphoma (gemcitabine) 2 days prior to SAE onset.

## Respiratory disorders

The SAEs of special interest involving respiratory disorders identified from the PDX-008 study included dyspnoea, exertional dyspnoea, and pneumonitis. There were 6 SAEs identified occurring in 5 patients, including  4  events  of  dyspnoea,  all ≥ grade  3,  considered  not  related  to  pralatrexate,  1  event  of exertional  dyspnoea  considered  possibly  related  to  pralatrexate  but  likely  due  to  lymphomatous infiltration of the lung, and 1 event of pneumonitis with suspicion of hypersensitivity aetiology. There were no reported findings of peripheral blood eosinophilia in any of these patients associated with the SAEs of dyspnoea, exertional dyspnoea, or pneumonitis.

However, there were insufficient  data  provided  in  the  reporting  of  the  SAEs  to  thoroughly  evaluate specific diagnostic criteria for acute or chronic interstitial pneumonitis.

## Renal Failure

There were 2 renal failure serious adverse events (SAEs) of special interest identified from the pivotal study PDX-008. Both cases were Grade 3-4 in severity and were assessed by the investigator as not related  to  pralatrexate.  One  case  resulted  in  death  and  the  other  resulted  in  discontinuation  of pralatrexate  treatment  due  to  disease  progression  (PD).  In  neither  case  was  there  any  evidence  of acute renal failure due to a renal toxic effect of pralatrexate.

## Laboratory findings

## Haematology

In the PDX-008 study, clinically significantly reduced (defined as those ≥ grade 2 and represented a shift  of ≥ 1  grade  from  the  baseline  value)  neutrophil  and  platelet  counts  were  reported  for 49 (44%) and  53  (48%) patients,  respectively.  In  total,  21  patients  (19%)  had  Grade  3  neutrophil counts and 10 patients (9%) had Grade 4 counts; 17 patients (15%) had Grade 3 platelet counts and 25 patients (23%) had Grade 4 counts.

Five patients (5%) had platelet counts at some point during the study of &lt; 10,000 μ L. Two of these 5 patients discontinued study treatment due to thrombocytopenia. Two patients had their dose reduced to  20  mg/m 2 ,  yet  continued  to  experience  Grade  3-4  thrombocytopenia, 1  patient  had  his  dose reduced to 20 mg/m 2   and  never  experienced  &gt;  Grade  2 thrombocytopenia  with  subsequent  dosing, and  1  patient  discontinued  study  treatment  due  to PD  during  the  thrombocytopenia  occurrence. Clinically significantly reduced haemoglobin levels were reported in 41% of the patients.

Overall, the frequency of decreased blood cell counts was higher in patients with lymphoproliferative malignancies than in patients with solid tumours.

## Clinical chemistry

<div style=\"page-break-after: always\"></div>

The clinical chemistry abnormality profile suggests a hepatotoxic potential of pralatrexate. The most frequent was  increased aspartate aminotransferase (AST) in 19 patients (17%)  and  alanine aminotransferase  (ALT)  in  18  patients  (16%).  In  total,  7  patients  (6%)  had  Grade  3  ALT  values. However, no grade 4 liver enzyme abnormalities were reported in the PDX-008 study. AST changes were  very  similar.  In  total,  3  patients  (3%)  had  Grade  3  bilirubin  values  and  1  patient  (1%)  had Grade 4.

Elevated creatinine levels were reported in all studies, but at low frequencies. In total, 2 patients (2%) had Grade 3 creatinine values and 1 patient (1%) had Grade 4. Hypocalcaemia was reported in 23% of the combined PDX-02-078 and PDX-010 safety population.

## Cardiology

A clinical QTc assessment was completed in a subgroup of 14 evaluable patients who received pralatrexate doses of 190 or 230 mg/m 2  every 2 weeks over 3-5 minutes or over 1 hour in the completed  Phase  1  clinical  trial  of  patients  with  previously  treated  NSCLC  (PDX-007).  The information provided did not raise any major cardiac safety concerns.

## Safety in special populations

Safety of pralatrexate has not been evaluated in patients with hepatic impairment or moderate and severe renal impairment.

In relation to age, patients over 65 years experienced more mucosal inflammation (85% vs. 62%) and epistaxis (38% vs. 20%) than patients below 65 years.

Female  patients  experienced  more  thrombocytopenia  (57%  vs.  33%)  and  anaemia  (46%  vs.  29%) than male patients.

No study data of pralatrexate are available in pregnant women or in subjects under 18 years old.

## Safety related to drug-drug interactions and other interactions

No  formal  clinical  assessments  of  pharmacokinetic  drug-drug  interactions  between pralatrexate  and other medicinal products have been conducted.

In a phase 1 study with pralatrexate, co-administration of increasing doses of probenecid resulted in delayed clearance of pralatrexate and a commensurate increase in exposure.

Due to the  substantial  contribution  of  renal  excretion  (approximately  34%;  PDX-008)  to  the overall clearance of pralatrexate, concomitant administration of medicinal products that are subject to substantial renal clearance (e.g. NSAIDs, trimethoprim/sulfamethoxazole) could potentially result in delayed clearance of pralatrexate .

## Discontinuation due to adverse events

Twenty-six patients (23%) withdrew from pralatrexate treatment due to an AE as listed in PDX-008, Table  30.  The  timing  of  the patients'  withdrawals  due  to  AEs  varied.  Four  patients  withdrew  after 1 dose of pralatrexate. However, 12 patients did not withdraw due to AEs until after cycle 1, including 4  patients  who  remained  on  treatment  for  &gt;  6  months  prior  to  withdrawal . Most  reasons  for discontinuation correspond to the most common severe toxicities seen in the safety population.

<div style=\"page-break-after: always\"></div>

Table 31 PDX-008: AEs responsible for treatment withdrawal

| Adverse Event Term Listed    |   TotalNumberofPatients | Relationship toPralatrexate   |
|------------------------------|-------------------------|-------------------------------|
| Mucosalinflammation          |                       7 | Related (all)                 |
| Thrombocytopenia             |                       4 | Related (all)                 |
| Neutropenia                  |                       2 | Related (both)                |
| CMV colitis                  |                       1 | Related                       |
| Renal failure                |                       1 | Not related                   |
| Pyrexia                      |                       1 | Related                       |
| Liver function test abnormal |                       1 | Related                       |
| Bile duct cancer             |                       1 | Not related                   |
| Cardiopulmonary arrest       |                       1 | Related                       |
| Nausea                       |                       1 | Related                       |
| Pain                         |                       1 | Related                       |
| Pulmonary embolism           |                       1 | Related                       |
| Pneumonia                    |                       1 | Not related                   |
| Pneumonitis                  |                       1 | Related                       |
| Urticaria                    |                       1 | Related                       |
| Thrombosis                   |                       1 | Not related                   |

## Post marketing experience

Pralatrexate  has  been  commercially  available  in  the  US  since  accelerated approval  was  granted  on 24 September 2009 for the treatment of relapsed or refractory PTCL. Based on product distribution data, the potential exposure in the post-marketing setting is estimated to be 1,157 to 2,025 patients. Review  of Post-Marketed Safety Surveillance data from the last 2 years demonstrated  that spontaneously reported AEs  in the post-marketing  setting were  consistent with or related to events reported in clinical studies.

## 2.6.1. Discussion on clinical safety

The safety database presented in this application included data on 689 patients who were treated with pralatrexate  across  all  clinical  studies,  of  which  141  patients  with  relapsed/refractory  PTCL  who received single-agent pralatrexate (PDX-008 = 111 patients; PDX-02-078 = 30 patients). In addition, post-marketing experience in the USA is estimated include 1,157 to 2,025 patients. Overall, the total exposure of pralatrexate is approximately 1,298 to 2,166 patients in the requested indication. Although the presented safety discussion lack the solidity of randomised data it is considered that that the safety database,  including  the  experience  from  performed  studies  as  well  as  the  postmarketing  setting,  is reasonably sufficient to allow to determine the toxicity profile..

The overall frequency of adverse events was high. Most reported side effects of pralatrexate, including bone marrow suppression and mucositis, are class-specific and thereby expected. Although generally manageable, erious events and also deaths related to these terms occurred. In this setting of possible long-term treatment, the prevalence of mucosal inflammation, even at low grades, should be noted.

Across all studies covered, treatment-related SAEs occurred in 20% of patients. The most commonly reported  terms  were,  in  decreasing  order,  mucosal  inflammation,  febrile  neutropenia,  pyrexia,  and thrombocytopenia. These terms were also the most commonly reported in the PDX-008 study, where treatment-related SAEs occurred in 25% of patients; treatment-related SAEs of grade 4 consisted of thrombocytopenia, mucosal inflammation and sepsis.

<div style=\"page-break-after: always\"></div>

Pralatrexate treatment is associated with the risk of development of tumour lysis syndrome. Routine prophylaxis should be applied.

As of 31 January 2011, 17 cases with serious dermatological reactions in a total of 689 patients across all  studies  were  reported,  corresponding  to  an  incidence  of  approximately  2.5%;  within  the  total experience  6  deaths  have  been  reported.  Interpretation  of  the  incidence  figures  is  difficult  without controlled data for comparison. These dermatological events included skin exfoliation, ulceration, and toxic  epidermal  necrolysis.  Twenty  seven  patients  (4%)  reported  a  grade  3-5  AE  in  the  skin  and subcutaneous  tissue  disorders  SOC;  grade  3-5  treatment-related  dermatological  AEs  occurred  in 23 patients overall (3%). Clinical findings suggest exaggerated cutaneous responses to minor trauma and impaired cutaneous wound healing, and epithelial tropism with pralatrexate is possible. Notably, a toxic  skin  effect  was  also  observed  in  patients  with  non-small  cell  lung  cancer  and  transitional  cell carcinoma,  presumably  without  any  skin  involvement  of  the  disease.  An  epithelial  tropism  with pralatrexate is possible.

Extensive skin disease and heavy pre-treatment with chemotherapy and/or radiation were identified as risk  factors  for  development  of  severe  dermatological reactions, The fact  that severe  dermatological reactions occur early in treatment, generally after the first dose (as for 5 of the 6 reported deaths), is problematic as no prodrome can be used for treatment decisions. Further vigilance is mandated and in the event of a future approval educational material for healthcare workers concerning prevention of serious dermatological reactions should be considered. Treatment with pralatrexate is associated with a risk of serious and fatal dermatological reactions that currently cannot be fully predicted or avoided. Interpretation of the incidence figures is difficult without controlled data for comparison.

Five  thromboembolic  SAEs  were  reported  in  PDX-008.  Four  of  the  cases  were  grade  3  and  not considered related to study drug. The last case, a SAE of pulmonary embolus grade 4, was assessed by the investigator as possibly related to pralatrexate. It is  acknowledged  the  pathogenesis  of thromboembolic  events  in  cancer  patients  are  complex.  In  consequence  the  interpretation  of  the reason for its occurrence in the individual patient is difficult. No definitely association of an increased likelihood of thromboembolism following administration of pralatrexate has been observed.

The  observed  hepatotoxicity  was  generally  manageable.  However,  as  development  of  more  severe hepatotoxicity  from  pralatrexate  would  limit  also  other  treatment  options  for  the  patient,  it  is considered  important  to  evaluate  the  possibility  to  prospectively  identify  patients  that  might  be  of increased risk for hepatotoxicity. It is acknowledged that due to the limited safety data from patients with pre-existing hepatic impairment it cannot presently be evaluated whether such patients have a greater  risk  to  develop  hepatotoxicity,  or  more  severe  hepatotoxicity,  upon  pralatrexate  treatment than patients with pre-treatment normal hepatic function.

Elimination of the related compound methotrexate is known to be prolonged in patients with ascites or pleural effusion and it is recommended to drain ascites and pleural effusion in advance of treatment. The  effect  of  third  space  compartment  fluid  accumulation  of  pralatrexate  (e.g.,  pleural  effusions, ascites,  significant  peripheral  oedema)  is  unknown.  In  patients  with  clinically  significant  third  space fluid,  consideration  should  be  given  to  draining  the  effusion  prior  to  initiation  of  treatment  with pralatrexate.

Further key information on renal clearance of pralatrexate and the impact of renal impairment on the pharmacokinetic  and  safety  profiles  of  pralatrexate  will  be  forthcoming  from  2  ongoing  clinical pharmacology studies (Study PDX-016 and Study PDX-019).

<div style=\"page-break-after: always\"></div>

## 2.6.2. Conclusions on the clinical safety

The  overall  frequency  of  pralatrexate-related  AEs  was  high.  Most  reported  side  effects  were  classspecific,  expected,  and  manageable.  A  high  prevalence  of  mucositis  was  noted.  Deaths  related  to treatment with pralatrexate were reported.

Treatment with pralatrexate is associated with a risk of serious and fatal dermatological reactions that currently cannot be fully predicted or avoided.

Although the presented safety discussion lack  the  solidity  of  randomised  data  the  CHMP  considered that  the  present  safety  data  base,  including  the  experience  from  performed  studies  as  well  as  the postmarketing setting, is reasonably sufficient to allow to characterise the toxicity profile.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  Applicant  fulfils  the legislative requirements provided that a deficiency was rectified.

## Risk Management Plan

The Applicant submitted a risk management plan.

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to conclude on risk minimisation activities at this time.

## 2.8. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the Applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

The  single  arm  pivotal  PDX-008  study  is  considered  to  have  been  well-conducted,  with  enrolled patients  reflecting  the  heterogeneity  of  PTCL  entities  encountered  in  clinical  practise,  and  with  the individual diagnoses and response assessments centrally reviewed.

In this study, treatment of patients with relapsed or refractory PTCL with single pralatrexate induced a response (CR, CRu, or PR) in 32 of 109 (29%) evaluable study subjects. Response to pralatrexate was of relatively rapid onset, with 63% of responders observed to respond within 1 cycle of treatment as assessed by central review.

Responses were noted also in patients  resistant  to  any  previous  therapy  and  in  patients  previously treated with methotrexate.

Median PFS was 106 days (95% CI, 51-146) according to central review, while 121 days (95% CI, 77148) based on response assessed by investigator (43/109, 39%).

<div style=\"page-break-after: always\"></div>

OS was 14.5 months (95% CI, 10.6-22.5) with a range of 1.0-24.1 months.

Median duration of response (confirmed and unconfirmed) was 306 days (95% CI, 103-not estimable) or  10.1  months, with  a  range  of  1-673  days.  Forty-four  percent  of  the  responding  (confirmed  and unconfirmed) patients had a duration of response in excess of 6 months.

Not  predefined  analyses  are  presented  that  indicate  that  pralatrexate  induces  longer  PFS  and,  in certain  analyses,  higher  response  rate  than  the  corresponding  estimates,  including  TTP,  seen  in previous lymphoma treatment/s. These analyses are, however, associated with the weaknesses of all retrospective analyses and historical comparisons.

## Uncertainty in the knowledge about the beneficial effects

The choice of study design (single arm) as well as primary endpoint (response rate) severely hampers the interpretation of the significance of the results obtained in the PDX-008 study. It has to be pointed out, that CHMP, for this reason in the protocol assistance given clearly stated that neither the design nor the primary endpoint was acceptable for a registration study.

The first major problem is the interpretation of the study results in terms of magnitude. In the absence of generally accepted treatment recommendations and published reports of randomised studies in the setting  of  relapsed/refractory  PTCL,  there  is  no  reference  point  to  rely  upon  in  the  judgement  of response. Results in previously published single-arm studies with other agents are also of very limited value,  due  mainly  to  small  study  populations  with  often  non-comparable  entities  of  T/NK-cell lymphoma.  Similarly,  registry  data  are  for  obvious  reasons  of  limited  help  and  cannot  be  used  for direct  comparisons.  The  presented  historical  control  comparison  is  not  acceptable  as  evidence  of relevant  efficacy.  Therefore,  without  a  comparator  arm,  the  magnitude  of  response  achieved  with pralatrexate in the PDX-008 study cannot be critically assessed. The observed response rate cannot be considered as dramatic activity.

The second major problem relates to the interpretation of the clinical benefit of the primary endpoint, the response rate. It is actually not known whether or to what extent a response in this setting of PTCL translates into clinical benefit. Furthermore, accepted markers of clinical benefit as PFS and OS, both secondary endpoints in the pivotal study, are not possible to interpret in a single-arm design.

## Risks

## Unfavourable effects

Based  on  the  data  cut-offs  of  the  120-Day  Safety  Update,  the  clinical study  safety  database comprises 141 patients with relapsed/refractory PTCL who received single-agent pralatrexate (PDX-008 =  111  patients;  PDX-02-078  =  30  patients).  Combined  with  patients  in  the postmarketing setting (N = 1157 to 2025), the total exposure of pralatrexate is approximately 1298 to 2166 patients in the requested indication. Although the presented safety discussion lack the solidity of randomised data the CHMP considered that the present safety data base, including the experience from performed studies as well as the postmarketing setting, is reasonably sufficient to allow to characterise the toxicity profile. Mucosal inflammation (68% of patients in PDX-008) and bone marrow suppression are  class-related  toxicities  and  were  commonly  reported.  Although  severe  reactions  occurred  and  in some  cases  led  to  treatment  discontinuation  in  the  PDX-008  study,  these  toxicities  are  considered generally manageable at institutions familiar with lymphoma chemotherapy. The number and severity of neutropenia-related infections do not raise any major concern.

<div style=\"page-break-after: always\"></div>

The clinical chemistry abnormality profile suggests a hepatotoxic potential of pralatrexate. However, no grade  4  liver  enzyme  abnormalities  were  reported  in  the  PDX-008  study.  Elevated  creatinine  levels were reported in all studies, but at low frequencies.

In  the  entire  safety  population,  6  deaths  were  considered  to  be  at  least  possibly  related  to  study treatment, whereof 3 in patients with PTCL: Two related to neutropenia and one due to whole body desquamation.

Tumour  lysis  syndrome  was  reported  in  one  patient  with  CTCL  and  three  patients  with  PTCL, emphasising the importance of preventive measures.

Seventeen serious cases, including cases associated with death, of dermatological reactions in a total of 689 patients across all studies correspond to an incidence of approximately 2.5%. Treatment with pralatrexate is associated with a risk of serious and fatal dermatological reactions that currently cannot be fully predicted or avoided.

## Uncertainty in the knowledge about the unfavourable effects

Safety of pralatrexate has not been evaluated in patients with hepatic or moderate and severe renal impairment.

The  incidence  of  serious  dermatological  reactions  may  be  high,  but  interpretation  of  the  figures  is difficult without controlled data for comparison.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Tumour response is not a clinical benefit endpoint per se and cannot be considered as an established surrogate endpoint for important clinical benefit endpoints such as PFS and OS.

The overall frequency of pralatrexate-related AEs was high. A high prevalence of mucositis was noted. Deaths  related  to  treatment  with  pralatrexate  were  reported.  Serious  dermatological  reactions, including cases associated with death, were observed.

## Benefit-risk balance

Tumour  response  is  not  a  clinical  benefit  endpoint  and  cannot  be  considered  as  an  established surrogate  endpoint  for  important  clinical  benefit  endpoints.  Therefore,  the  benefits  have  not  been established.  In  the  absence  of  established  benefits,  a  positive  benefit-risk  balance  cannot  be considered established.

## Discussion on the benefit-risk balance

The overall benefit-risk balance of Folotyn in the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) (nodal, other extranodal and leukaemic/disseminated) is negative.

Due to the uncontrolled design of the pivotal study, evidence of efficacy is lacking in terms of relevant clinical benefit endpoints such as OS and PFS. The baseline-controlled studies presented do not include a  concurrently  randomized  control  group.  In  the  absence  of  dramatic  activity,  such  studies  have important  methodological  limitations  due  to  untestable  assumptions.  Thus,  the  evidence  of  efficacy presented was not considered sufficient to establish a clinical benefit.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Folotyn in the treatment of adult patients  with  peripheral  T-cell  lymphoma  (nodal,  extranodal  and  leukaemic/disseminated)  who  have progressed after at least one prior therapy, the CHMP considers by majority decision that the efficacy of the above mentioned medicinal product is not sufficiently demonstrated, and, therefore recommends the  refusal  of  the  granting  of  the  conditional  Marketing  Authorisation  for  the  above  mentioned medicinal product. The CHMP considers that:

-  In  the  absence  of  established  benefits,  a  positive  benefit-risk  balance  cannot  be  considered established.

Furthermore,  the  CHMP,  in  light  of  the  negative  recommendation,  is  of  the  opinion  that  it  is  not appropriate to conclude on the new active substance status at this time.

Divergent position to the majority recommendation is appended to this report.

## 5. Re-examination of the CHMP opinion of 19 April 2012

Following the CHMP conclusion that Folotyn was not approvable for the treatment of adult patients with peripheral  T-cell  lymphoma  (nodal,  extranodal  and  leukaemic/disseminated)  who  have  progressed after at least one prior therapy, as in the absence of established benefits a positive benefit-risk balance could not be considered established, the Applicant submitted detailed grounds for the re-examination of the grounds for refusal.

## Detailed grounds for re-examination submitted by the Applicant

Following  a  request  from  the  Applicant  at  the  time  of  the  re-examination,  the  CHMP  convened  a Scientific Advisory Group (SAG) inviting the experts to provide their views on the CHMP grounds for refusal, taking into account the Applicant's response.

The  Applicant  presented  in  writing  and  at  an  oral  explanation  the  grounds  that  the  adopted  CHMP Opinion  may  not  have  considered  the  data  fully  in  the  proper  clinical  context  for  the  purpose  of assessing the clinical benefits of pralatrexate in an orphan disease setting where there is hitherto no authorised treatment available.  Further analyses were provided by the Applicant to support the clinical efficacy of pralatrexate in the proposed indication.

The  Applicant  outlined  the  following  detailed  grounds  to  be  taken  into  account  during  the  reexamination.

Ground 1 - The magnitude of clinical efficacy of pralatrexate in the treatment of patients with PTCL who have progressed after at least one prior therapy (relapsed/refractory PTCL) can be assessed based on  the  data  provided.  These  data  provide  sufficient  evidence  to  support  the  clinical  efficacy  of pralatrexate on the following basis:

-  Features  of  the  unique  mechanism  of  action  of  pralatrexate  have  demonstrated  preferential activity in T-cell lymphomas.

<div style=\"page-break-after: always\"></div>

-  Clinical efficacy in relapsed/refractory PTCL has been demonstrated in both the pivotal study, PDX-008 and the supportive Phase 1/2 study PDX-02-078.
-  The  clinical  efficacy  of  pralatrexate  is  demonstrated  in  PDX-008  through  the  response  rate (29%  and  39%  by  central  review  and  investigator,  respectively,  with  a  median  duration  of response of 12.6 months and a median duration of CR/CRu of 44.2 months), durable responses (59% and 47% of responders with &gt; 6 and &gt; 12 months of response duration, respectively), and clinical benefits achieved through those responses, including the improved outcomes for patients  in  comparison  to  their  most  immediate  prior  therapy,  using  patients  as  their  own controls.
-  The  magnitude  of  the  clinical efficacy benefit of pralatrexate is  further  confirmed  by comparisons  to  historical  database  and  matched-control  analyses,  in  which  pralatrexate demonstrated an improved overall survival (OS) outcome (hazard ratio of 0.39 [95% CI: 0.26, 0.60] and median OS of 19.0 months for pralatrexate vs. 5.8 months for matched controls). Given that the natural course of the disease is well-known and characterised, this approach should be considered appropriate to inform the assessment of clinical efficacy.

Ground  2 -  PTCL  is  an  orphan  disease  with  a  very  aggressive  clinical  course,  and  there  are  no therapies in the EU approved specifically for this indication; thus, pralatrexate addresses a significant unmet medical need.

Ground  3 -  Immediate  patient  access  on  the  public  health  grounds  outweighs  the  risk  inherent  in scientific uncertainties surrounding the benefit assessment.

According  to  the  Applicant,  the  approach  taken  to  conclude  a  positive  benefit-risk  balance  for pralatrexate  is  consistent  with  the  established  principles  set  out  in  the  applicable  CHMP  guidelines, especially the 'Guideline on the Evaluation of Anticancer Medicinal Products in Man', and the 'Guideline on Clinical Trials in Small Populations.'

## Additional expert consultation

1.  The SAG is asked to describe how impressive they view the efficacy data to be (based on response rate, duration of response, PFS, OS) in light of the methodological limitations of  the  study,  in  particular  the  absence  of  a  randomised  control  group,  but  taking  into account the novel mechanism of action and observed responses in patients who were non-responders.

## The SAG is also asked to comment on whether the observed duration of responses are considered to be exceptional in this disease setting.

The SAG considered the additional analyses presented, the mechanism of action, and the observed responses in patients assessed as non responders to prior regimens. The duration of response in selected  responders  was  considered  promising.  However,  the  SAG  maintained  its  view  that although pralatrexate has shown antitumour activity in patients with relapsed PTCL, the activity in terms  of  response  rate  appears  to  be  in  the  same  range  of  other  single-agent  or  combination regimens which are currently used in this setting, although the efficacy of such treatment options cannot be considered established according to conventional scientific or regulatory standards.

<div style=\"page-break-after: always\"></div>

The SAG maintained its view that there are serious concerns from the point of view of external validity  in  view  of  the  design  of  the  pivotal  study,  especially  the  non-randomised  design  of  the study.  Such  design  does  not  allow  establishing  the  efficacy  of  pralatrexate  in  terms  of  relevant clinical  benefit  endpoints  such  as  PFS  or  OS.  Overall,  the  clinical  benefit  cannot  be  considered established and therefore the benefit cannot be considered to outweigh the risks.

## 2.  Do  the  case  matched  controls  offer  an  opportunity  to  place  the  observed  effect  of pralatrexate  into  clinical  context  and  can  the  magnitude  of  effect  be  considered sufficient to conclude that clinically relevant efficacy has been established?

The matched case control did not add convincing data to allow placing the observed effect into clinical  context  in  terms  of  clinically  relevant  endpoints,  mainly  due  to  possible  bias  in  patient selection  in  this  heterogeneous  disease.  Similarly,  the  magnitude  of  effect  was  not  considered sufficient in view of the possible biases. Although the matched controls analyses can be considered useful  as  hypothesis  generating,  the  data  are  not  sufficient  to  establish  the  clinical  efficacy  of pralatrexate in the target indication.

## 3.  Do the data from the Phase I study provide significant independent corroboration of an effect?

The  phase  I  data  showed  hints  of  antitumour  activity  but  the  magnitude  was  not  considered exceptional. These data in their own right were not sufficient to provide independent corroboration of an effect of pralatrexate in the target indication.

## 4.  Does the SAG consider that the proposal to demonstrate a 50% improvement in Overall Survival in the confirmatory study is a realistically achievable goal?

If  not,  does  the  SAG  consider  the  results  of  the  ongoing  PDX-017  study  of  value  and supportive/confirmatory in terms of efficacy for the current indication applied for, or is there another patient group which is considered relevant for the indication applied for where a controlled study would be considered feasible to conduct?

The proposed trial looks for an improvement of median OS of 61% (from 9 to 14.5 months). The expected magnitude of improvement does not seem to be a realistic goal given the available data on antitumour activity.

The  results  of  the  PDX-017  study  may  be  of  limited  value  for  the  current  application,  due  to important differences in terms of line of therapy, patient selection, and treatment schedule. This study is not expected to be of sufficient support or to confirm the efficacy in the target indication.

A controlled study in the target indication is considered feasible and best way to establish clinical efficacy.  Considering  the  design  and  size  of  the  study,  different  possible  approaches  (including different primary endpoints to OS) should be considered. A collaborative study and prospectively planned meta-analysis should also be considered. Scientific Advice is recommended.

## Overall conclusion on grounds for re-examination

The CHMP assessed all the detailed grounds for re-examination and argumentations presented by the Applicant and considered the views of the Scientific Advisory Group.

Regarding Ground 1, the CHMP maintained the view that without a comparator arm, the magnitude of response  cannot  be  critically  assessed.  The  observed  activity  in  terms  of  response  rate  cannot  be considered dramatic and it is not known whether or to what extent a response might translate into clinical benefit for this patient group.

<div style=\"page-break-after: always\"></div>

The  Applicant  presented  an  analysis  where  pralatrexate  appears  to  reverse  the  trend  of  decreasing response  to  successive  lines  of  chemotherapy  and  decreasing  median  PFS.  However,  this  type  of comparison cannot be considered as convincing to establish efficacy as it relies on strong assumptions, similar to a historical comparison.

The Applicant has provided a matched historical controlled analysis, with comparisons made against OS data. The criteria specified represent key prognostic factors, but there are multiple other potential differences between a clinical trial population, who must satisfy a range of inclusion / exclusion criteria, and  those  historical  databases  which  will  include  a  broader  set  of  patients.  Inclusion  criteria  for  a clinical  trial  might  include  a  certain  life  expectancy  and  performance status; exclusion criteria might include presence of other active concurrent malignancies, cardiac problems or uncontrolled hypertension, concurrent HIV etc. Any bias introduced by these underlying differences would not be addressed in the primary analysis or either sensitivity analysis.

The Applicant has used medical review to determine the comparability of the matched groupings but the potential for bias remains, as important dissimilarity of treatment and control groups cannot be excluded. For example, it is not possible to determine whether the subjects were treated in a similar setting  and  manner  (potential  differences  in  compliance,  concomitant  and  supportive  treatments, adequacy of dose and treatment duration, stage or severity of disease) and thus whether the matches were comparable except for the interventions under consideration.

Overall, externally controlled trials tend to overestimate the effect of test therapies and, despite the magnitude of the effect described, the interpretation that pralatrexate improved OS in comparison to matched historical controls can be considered as hypothesis generating only because of the multiple potential biases which cannot be excluded convincingly.

With respect to Ground 2, the CHMP acknowledged that PTCL is an orphan disease with an aggressive clinical course and a poor prognosis. There are currently no approved therapies in the EU specifically for the claimed indication and there is an unmet medical need. Therefore, the committee agreed that there  is  a  need  for  new  therapies  with  established  efficacy  in  this  disease.  However,  the  submitted clinical  data  for  Folotyn  are  not  considered  to  be  sufficient  to  inform  a  favourable  benefit-risk assessment. Even if there is currently no consensus on standard therapy for PTCL, the data submitted do not allow drawing any conclusion on the efficacy of Folotyn. Therefore, concerning the arguments presented by the Applicant for Ground 3 the CHMP considered that because the benefits have not been demonstrated the need for immediate access is not justified.

In conclusion, following assessment of the analyses provided in response to the grounds for refusal, the submitted data are still considered insufficient to establish the efficacy of Folotyn in patients with peripheral  T-cell  lymphoma  (nodal,  extranodal  and  leukaemic/disseminated)  who  have  progressed after  at  least  one  prior  therapy.  Therefore,  the  CHMP  has  maintained  its  previous  position  that  the efficacy has not been established.

## 6. Recommendations following re-examination

Based on the arguments of the Applicant and all the supporting data on quality, safety and efficacy for Folotyn  in  the  treatment  of  adult  patients  with  peripheral  T-cell  lymphoma  (nodal,  extranodal  and leukaemic/disseminated) who have progressed after at least one prior therapy, the CHMP re-examined its initial opinion and in its final opinion concluded by majority decision that the efficacy of the above mentioned medicinal product is not sufficiently demonstrated, and, therefore recommends the refusal

<div style=\"page-break-after: always\"></div>

of the granting of the conditional Marketing Authorisation for the above mentioned medicinal product. The CHMP considers that:

-  In  the  absence  of  established  benefits,  a  positive  benefit-risk  balance  cannot  be  considered established.

Furthermore,  the  CHMP,  in  light  of  the  negative  recommendation,  is  of  the  opinion  that  it  is  not appropriate to conclude on the new active substance status at this time.

Divergent position to the majority recommendation is appended to this report.

## REFERENCES

Branda R.F. (1981): Transport of 5-methyltetrahydrofolic acid in erythrocytes from various mammalian species. J Nutr 111, 618-23.

Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., GrilloLopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N.L., Armitage J.O., Carter W., Hoppe R. &amp; Canellos G.P. (1999): Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17, 1244-53.

Izbicka E., Diaz A., Streeper R., Wick M., Campos D., SteVen R. &amp; Saunders M. (2009): Distinct mechanistic activity proWle of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 64(5), 993-9.

Khokhar N.Z., She Y., Rusch V.W. &amp; Sirotnak F.M. (2001): Experimental therapeutics with a new 10deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 7, 3199-205.

Nottebrock H. &amp; Then R. (1977): Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol 26(22), 2175-9.

Serova M., Bieche I., Koumaravel J., Vidaud M., Pronk B., Cvitkovic E., Faivre S. &amp; Raymond E. (2009): Cytotoxicity of pralatrexate, a novel synthetic antifolate, in human cancer cell lines [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1686.

Sirotnak F.M., DeGraw J.I., Colwell W.T. &amp; Piper J.R. (1998): A new analogue of 10-eazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42, 313-8.

Toner L.E., Vrhovac R., Smith E.A., Gardner J., Heaney M., Gonen M., Teruya-Feldstein J., Sirotnak F. &amp; O'Connor O.A. (2006): The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 12, 924-932.

Vose J., Armitage J. &amp; Weisenburger D. (2008): International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26, 4124-30.

Wang E.S., O'Connor O., She Y., Zelenetz A.D., Sirotnak F.M. &amp; Moore M.A.S. (2003): Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression. Leuk &amp; Lymph 44 (6), 1027-35.

<div style=\"page-break-after: always\"></div>

## APPENDIX 1 DIVERGENT POSITIONS

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION EXPRESSED BY CHMP MEMBERS

In  general,  the  factual  presentation  of  the  efficacy  and  safety  data  for  Folotyn  for  the  treatment  of relapsed or refractory PTCL as reflected in the Day 180 JAR is agreed with. However, another and more positive  conclusion  on  the  benefit-risk  balance  may  be  reached  when  looking  at  the  possibility  of  a conditional approval.

## Unmet medical need and PTCL is a life-threatening disease

It has long been recognised that the majority of PTCLs have an inferior prognosis compared with their B-cell  counterparts.  The  standard  therapy  for  PTCLs  is  CHOP  (cyclophosphamide,  doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines. With the  exception  of  anaplastic  lymphoma  kinase-positive  anaplastic  large  cell  lymphoma  (ALK+  ALCL), the cure rate for PTCLs with CHOP is low with a long-term survival of only 10% to 30%. It has been suggested  that  anthracyclines  may  not  be  effective  in  PTCL  due  to  inherent  overexpression  of  Pglycoprotein (Pgp) which is known to contribute to anthracycline resistance.

As stated in the ASH (American Society of Haematology) Education Book p.514-25, December 2011, several  experts  question  the  adequacy  of  regimens  building  on  a  CHOP  backbone  in  the  first-line setting since neither the shortening of the treatment interval from CHOP21 to CHOP14 or the addition of etoposide to CHOP have improved OS. The addition of alemtuzumab to CHOP has increased toxicity without  improving  the  prognosis.  The  inclusion  of  HD-Chemotherapy  +  HSCT  as  consolidation  has resulted in conflicting results in terms of cure rate.

First-line combinations that bypass the Pgp efflux pump are now being investigated. Pralatrexate may have an interesting mechanism of action in that respect.

In conclusion first-line therapy for PTCL appears to be inadequate in terms of long-term disease-free survival.

If  the  first-line  therapy is inadequate and exhausts most of the available classical cytostatics in that setting, the treatment results of second-line or later line therapy are so dismal that the US National Comprehensive  Cancer  Network  (NCCN)  Guideline  for  relapsed/refractory  PTCL  (2009)  states  that clinical trials are the preferred option in both first and second relapse.

Thus,  the  high  medical  need  for  new  medicines  for  the  treatment  of  patients  with  PTCL  cannot  be questioned.

## Positive Risk/Benefit Balance

In contrast to the CHMP Scientific Advisory Group for Oncology, it is the opinion of the divergent CHMP members that an ORR of about 30% (and 11% in CR/CRu) for a single agent in patients with PTCL is comparable  to  the  activity  of  other  classical  approved  cytostatics  when  used  as  single  agents.  The 11% CR patients had a median duration of response of 44 months and some of these patients may be candidates  for  curative  high-dose  therapy  with  haematopoietic  stem  cell  support.    Moreover, pralatrexate  has  a  new  mechanism  of  action  that  most  probably  makes  it  suitable  for  use  in combination  with  other  anticancer  agents.  The  apparent  selective  activity  in  T-cell  lymphomas (O.A. O'Connor et al. J Clin Oncol 2009; 27:4357-64) is also of clinical interest.

It is not to be expected that any new single agent therapy will dramatically change the prognosis in advanced aggressive non-Hodgkin's lymphoma where 4-5 drug combinations have been standard of care for more than 30 years.

A median duration of response of 10.5 months and a median overall survival of 14.5 months for the 109 patients included in the phase II trial PDX-008 are strong indicators of clinical benefit even if it is fully acknowledged that additional [comparative] data are still required.

<div style=\"page-break-after: always\"></div>

The safety profile of pralatrexate, although not trivial, is sufficiently well described from the submitted clinical trials as well as the post-marketing experience outside the EU to allow a benefit/risk judgment.

Therefore,  in  the  opinion  of  the  divergent  CHMP  members  the  benefits  to  public  health  of  making pralatrexate immediately available on the market outweigh the risk inherent in the fact that additional data are still required.

## Conditional Marketing authorisation

In accordance with Regulation (EC) No 726/2004, conditional marketing authorisations will be valid for one year on a renewable basis. In the case of the conditional marketing authorisation, authorisation is granted  before  all  data  are  available.  The  applicant  at  the  CHMP  oral  explanation  and  at  the  CHMP Scientific Advisory Group for Oncology hearing confirmed that the PDX-3501 randomised, controlled in relapsed/refractory  PTCL  comparative  trial  planned  for  initiation  by  Q2  2012  would  be  feasible.  The divergent CHMP members are of the opinion that this trial together with other trials in the ongoing clinical  development  programme  for  pralatrexate  will  provide  the  required  additional  data  within  a reasonable period of time taking into consideration the orphan indication.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Jens Heisterberg

Catherine Moraiti

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

David Lyons

Agnes Gyurasics

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Dalibor Valik

Alar Irs

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Natalja Karpova

Pieter Neels

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Romaldas Ma č iulaitis

Outi Mäki-Ikola